

EXHIBIT 7

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0001	Handwritten Journal, [REDACTED]	1/15/2007	SRPT-VYDS-0163133	SRPT-VYDS-0163301	
PTX0002	Handwritten Journal, [REDACTED]	5/16/2004	SRPT-VYDS-0156085	SRPT-VYDS-0156292	
PTX0003	Email thread between Steve Wilton, Frank Bennett, Frank Rigo, Sue Fletcher, Abbie Adams, Stacy Jordan, sent June 1, 2, 7, 2011	6/7/2011	WILTON0017728	WIL TON0017732	
PTX0004	Handwritten Journal, [REDACTED] (last entry not redacted is Thursday, 28th February 08)	6/29/2007	SRPT-VYDS-0162960	SRPT-VYDS-0163132	
PTX0005	Email thread between Steve Wilton, Frank Bennett, Frank Rigo, Sue Fletcher, Abbie Adams, in vitro data, sent 6/1/2011	6/1/2011	WILTON0017758	WIL TON0017761	
PTX0006	Email forwarded by Steve Wilton to Sue Fletcher and Abbie Adams with [REDACTED], December 23, 2008	12/23/2008	WILTON0017692	WILTON0017695	
PTX0007	Email from A. Fall to S. Wilton Subject: Results, sent 12/7/2005	12/7/2005	WILTON0012329	WILTON0012329	
PTX0008	Handwritten Journal, [REDACTED]	4/23/2008	SRPT-VYDS-0161650	SRPT-VYDS-0161826	
PTX0009	Email message from Abbie Adams to Steve Wilton attaching [REDACTED]	4/21/2009	WILTON0004949	WILTON0004952	
PTX0010	Email message (with annotated attachment) from Abbie Adams to Steve Wilton attaching [REDACTED] April 21, 2009	4/21/2009	WILTON0004950	WILTON0004950	

No. 1:21-cv-1015-JLH (D. Del.)

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0011	" [REDACTED] (metadata date created 7/13/2005, date modified 7/13/2005)	7/13/2005	WILTON0015532	WILTON0015619	
PTX0012	Principal Investigator: Stephen D. Wilton PhD, " [REDACTED]" (metadata date created 7/25/2008, date modified 8/28/2008)	8/28/2008	WILTON0016126	WIL TON0016162	
PTX0013	Requests for sequences with varying umole amounts	9/5/2008	WILTON0016164	WILTON0016166	
PTX0014	Handwritten Journal, " [REDACTED]"	3/19/2009	SRPT-VYDS-0160640	SRPT-VYDS-0160819	
PTX0015	Handwritten Journal, " [REDACTED]"	11/3/2009	SRPT-VYDS-0161337	SRPT-VYDS-0161480	
PTX0016	Email message from Abbie Adams to Steve Wilton " [REDACTED]" [REDACTED], April 22, 2010	4/22/2010	WILTON0018576	WILTON0018579	
PTX0017	Handwritten Journal, " [REDACTED]"	4/1/2010	SRPT-VYDS-0159054	SRPT-VYDS-0159206	
PTX0018	Email messages between Abbie Adams and Steve Wilton regarding " [REDACTED]"	6/28/2010	WILTON0017861	WILTON0017864	
PTX0019	Email messages between Abbie Adams and Steve Wilton regarding " [REDACTED]" [REDACTED] June 28, 2010	6/28/2010	WILTON0017524	WILTON0017527	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0020	Email messages between Abbie Adams and Steve Wilton regarding "[REDACTED]", January 16, 2012	1/16/2012	WILTON0018025	WILTON0018028	
PTX0021	Email thread between Laine Cowan and Chris Garabedian, Diane Frank, Rick Bestwick, Peter Sazani, F. Muntoni, G. Dickson, Ed Kaye, Wendy Cort, Kate Haviland, Juliet Ellis Subject: "[REDACTED]" [REDACTED] Sept. 20 & 28, 2012	9/28/2012	FRANK00000211	FRANK00000212	
PTX0022	Sarepta Therapeutics, nucleofection run titled "[REDACTED]" [REDACTED] Presentation Deck	1/31/2013	BESTWICK00000013	BESTWICK00000016	
PTX0023	Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s Subpoena to Produce Documents, Information, or Objects or to Permit Inspection of Premises in a Civil Action to Richard Bestwick , Nippon Shinyaku Co., Ltd. V. Sarepta Therapeutics, Inc., No. 21-1015 (D. Del. May 31, 2023)	5/31/2023	NONE	NONE	
PTX0024	"Declaration of Richard K. Bestwick, Ph.D., Under 37 C.F.R. § 1.132", Application No. 11/570,691, June 15, 2010	6/15/2010	NONE	NONE	
PTX0025	"Application Data Sheet 37 CFR 1.76" for Improved Exon Skipping Compositions for Treating Muscular Dystrophy, December 20, 2012	12/20/2012	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0026	Email thread between Laine Cowan, Chris Garabedian, Ed Kaye, Peter Sazani, Diane Frank, Rick Bestwick Subject: "[REDACTED]", August 23, 2012	8/23/2012	SRPT-VYDS-0213846	SRPT-VYDS-0213847	
PTX0027	Email thread between Diane Frank, Laine Cowan, Rick Bestwick, George Dickson, Linda Popplewell, F. Muntoni, Juliet Ellis, Joanna Cox, Subject: "[REDACTED]" September 28, 2012	9/28/2012	SRPT-VYDS-0213938	SRPT-VYDS-0213940	
PTX0028	Email thread between Diane Frank, Laine Cowman, Rick Bestwick, Subject: "[REDACTED]", October 15 & 16, 2012	10/16/2012	SRPT-VYDS-0213988	SRPT-VYDS-0213988	
PTX0029	Email thread between Diane Frank, Rick Bestwick, Laine Cowan, Jessica Stromme, Tom Holt, Jayant Aphale, Bao Cai, Lori Houle-Custer, Ankur Desai, Stacey Bailey, Subject "[REDACTED]" March 4 & 6, 2013	3/6/2013	SRPT-VYDS-0215451	SRPT-VYDS-0215452	
PTX0030	WIPO International Publication Number WO 2014/153240 A2	9/25/2014	NONE	NONE	
PTX0031	"Declaration of Fred Schnell, Under 37 § C.F.R. 1.132," Application No. 14/776,533, December 11, 2018	12/11/2018	NONE	NONE	
PTX0032	U.S. Patent App. Publication No. US 2010/0168212 A1	7/1/2010	NS00063279	NS00063313	
PTX0033	Images: [REDACTED]	6/13/2008	WILTON0002435	WILTON0002435	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0034	Printout of online submission of "NHMRC Research Grant Application, Application Summary, Version 63" for Application ID 572579, dated 11 Jan 2008	1/11/2008	FLETCHER0000226	FLETCHER0000309	
PTX0035	Handwritten Journal, "Laboratory Notebook, [REDACTED]" cover and pages 1-117	1/18/2005	SRPT-VYDS-0158885	SRPT-VYDS-0159001	
PTX0036	Email from Steve Wilton to Frank Bennett et. All Subject: in vitro data, sent 6/1/2011	6/1/2011	WILTON0017773	WIL TON0017775	
PTX0037	Email from A. Fall to S. Wilton Subject: Paper, sent 12/6/2005	12/6/2005	WILTON0012317	WIL TON0012326	
PTX0038	Steve Wilton & Sue Fletcher, [REDACTED] [REDACTED] Centre for Neuromuscular & Neurological Disorders	6/4/2009	FLETCHER0000346	FLETCHER0000350	
PTX0039	REMOVED DOCUMENT FROM LIST (DUPLICATE)	12/23/2008	WILTON0017692	WIL TON0017695	
PTX0040	Chalermchai Mitrpant et al., "Rational Design of Antisense Oligomers to Induce Dystrophin Exon Skipping," 17.8 Molecular Therapy Org. 1418-1426 (Aug. 2009)	3/17/2009	NONE	NONE	
PTX0041	Grant Application, Title of Project "Antisense oligonucleotide suppression of DMD" signed 27/2/03	2/27/2003	FLETCHER0000043	FLETCHER0000088	
PTX0042	Grant Progress Report, Title of Project "Antisense oligonucleotide suppression of DMD" Grant Number 1 R01 NS044146-02	9/30/2007	FLETCHER0000027	FLETCHER0000034	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0043	Nippon Shinyaku Co., Ltd. and NS Pharma, Inc.'s Notice to Take Depositions (Brian Forsa and Steve Wilton), Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics Inc., No. 21-1015 (ECF No. 223) (D. Del. June 12, 2023)	6/12/2023	NONE	NONE	
PTX0044	LinkedIn Web Biography of Brian Forsa - Executive Director, Chief of Staff to Chief Commercial officer at Sarepta Therapeutics (viewed on June 7, 2023 1:38 PM)	6/7/2023	NONE	NONE	
PTX0045	Metadata Log of Sarepta Documents (prepared by Morgan Lewis and viewed on June 14, 2023)	6/14/2023	NONE	NONE	
PTX0046	[REDACTED] (metadata date modified 9/10/2019)	9/10/2019	SRPT-VYDS-0210679	SRPT-VYDS-0210695	
PTX0047	Excel document named "Microsoft_Excel_Worksheet.xlsx" Excel workbook (native format)	9/10/2019	SRPT-VYDS-0210696	SRPT-VYDS-0210696	
PTX0048	[REDACTED] Brian Forsa & Alexandra Annis, Sarepta Therapeutics Presentation Deck (metadata date modified 7/9/2020)	7/9/2020	SRPT-VYDS-0210727	SRPT-VYDS-0210791	
PTX0049	Excel workbook (native format) attachment Forsa Dep Ex 007, worksheet entitled "[REDACTED]" (metadata date modified 7/8/2020)	7/8/2020	SRPT-VYDS-0210792	SRPT-VYDS-0210792	
PTX0050	[REDACTED] Sarepta Therapeutics Presentation Deck	6/8/2021	SRPT-VYDS-0209787	SRPT-VYDS-0209791	
PTX0051	Email from Alana Copeland to Brian Forsa Subject "RE: [REDACTED]" [REDACTED] Sent 3/9/2020	3/9/2020	SRPT-VYDS-0209352	SRPT-VYDS-0209353	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0052	"Viltolarsen Launch Themes, Updates as of August 26, 2020" Sarepta Therapeutics Presentation Deck	8/26/2020	SRPT-VYDS-0209514	SRPT-VYDS-0209557	
PTX0053	[REDACTED] SKIP-NMD Grant# 305370" Report	4/22/2013	SRPT-VYDS-0201524	SRPT-VYDS-0201588	
PTX0054	Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s Subpoena to Produce Documents, Information, or Objects or to Permit Inspection of Premises in a Civil Action to Diane Frank , Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics, Inc., No. 21-1015 (D. Del. May 30, 2023)	5/30/2023	NONE	NONE	
PTX0055	LinkedIn Web Profile for Diane Frank, Consultant (captured on August 16, 2023)	8/16/2023	NONE	NONE	
PTX0056	Email message from Diane Frank to Chris Garabedian (cc to Rick Bestwick) Subject: "[REDACTED]" July 11, 2012	7/11/2012	SRPT-VYDS-0214705	SRPT-VYDS-0214707	
PTX0057	Email thread between Diane Frank and Sue Fletcher, Subject "RE: Travel to Perth!" August 28, 2012	8/28/2012	SRPT-VYDS-0213849	SRPT-VYDS-0213850	
PTX0058	Email thread between Diane Frank, Dwight Weller, Peter Sazani, Ryszard Kole, Adrienne Ste. Marie, Ed Kaye, Subject: "Partner Description Form 19Sep11" September 21, 2011	9/21/2011	FRANK00000028	FRANK00000030	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0059	Email thread between Adrienne Ste. Marie, Chris Garabedian, Effie Toshav, Ryszard Kole, Diane Frank, Peter Sazani, Dwight Weller, Ed Kaye, Juliet Ellis, Kate Bushby, Volker Straub, G. Dickson, Thomas Voit, Eugenio Mercuri, Steven Laval, Graham Clark, Gennaro Capasso, Sandrine Testaz, Francesco Muntoni, Jenny Morgan, Subject: "[REDACTED] [REDACTED] October 4,	10/4/2011	FRANK00000015	FRANK00000025	
PTX0060	Email thread between Laine Cowan, Diane Frank, Peter Sazani, Ed Kaye Subject: [REDACTED] January 30, 2012	1/30/2012	FRANK00000001	FRANK00000005	
PTX0061	Email message from Diane Frank to Rick Bestwick, Subject: [REDACTED] July 2, 2012	7/2/2012	SRPT-VYDS-0214525	SRPT-VYDS-0214525	
PTX0062	Email message from Diane Frank to Rick Bestwick, Subject: [REDACTED] August 1, 2012	8/1/2012	SRPT-VYDS-0215457	SRPT-VYDS-0215457	
PTX0063	Email message from Laine Cowan to Jessica Stromme (cc Diane Frank), Subject: [REDACTED] [REDACTED] August 13, 2012	8/13/2012	FRANK00000070	FRANK00000070	
PTX0064	Email message from Rick Bestwick to Stacey Bailey, Shara Webb (cc Chris Garabedian, Peter Sazani, Diane Frank, Laine Cowan, Bao Cai, Gunnar Hanson) Subject: [REDACTED] [REDACTED] with attachment [REDACTED]	8/23/2012	FRANK00000114	FRANK00000115	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0065	Email thread between Ed Kaye, Diane Frank, Peter Sazani, Chris Garabedian, Laine Cowan, Rick Bestwick, Subject [REDACTED] [REDACTED] September 26, 2019	9/26/2012	FRANK00000204	FRANK00000205	
PTX0066	Excel document [REDACTED] [REDACTED] to email message sent 9/13/2012; [REDACTED]	9/13/2012	FRANK00000152	FRANK00000152	
PTX0067	Email thread between Rick Bestwick, G. Dickson, Laine Cowan, Diane Frank, Linda Popplewell, Francesco Muntoni, Juliet Ellis, Joanna Coz, Subject [REDACTED] [REDACTED] September 28 - October 4, 2012	10/4/2012	FRANK00000228	FRANK00000230	
PTX0068	Email thread between G. Dickson, Rick Bestwick, Laine Cowan, Diane Frank, Francesco Muntoni, Linda Popplewell, Joanna Cox, Subject: [REDACTED] [REDACTED] September 28 - October 5, 2012	10/5/2012	FRANK00000234	FRANK00000236	
PTX0069	Email message from Diane Frank to Chris Garabedian, Kate Haviland (cc Wendy Cort), Subject: [REDACTED] [REDACTED] October 29, 2012	10/29/2012	SRPT-VYDS-0214031	SRPT-VYDS-0214032	
PTX0070	Email message from Diane Frank to Laine Cowan, Ed Kaye, Subject [REDACTED] [REDACTED] November 17, 2012	11/17/2012	SRPT-VYDS-0213827	SRPT-VYDS-0213828	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0071	Email chain between Penelope Smith, Linda Poppewell, Diane Frank, Karen Anthony, Juliet Ellis, Laine Cowan, Peter Sazani, Francesco Muntoni, Anita Le-Heron, Virginia Arechavala, Ed Kaye, Jenny Morgan, George Dickson, Subject: [REDACTED] and [REDACTED] January 15-17, February 1, 3, 10, 18, 19, 2013	2/19/2013	SRPT-VYDS-0215355	SRPT-VYDS-0215362	
PTX0072	Email message from Diane Frank to Dan Mourich, Fred Schnell, Brian Leppert, Rick Bestwick, Emily Naughton, Subject [REDACTED] February 26, 2013	2/26/2013	SRPT-VYDS-0215407	SRPT-VYDS-0215425	
PTX0073	Sarepta's Notice of Rule 30(b)(1) Deposition of Gardner Gendron , Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics Inc., No. 21-1015 (D. Del. July 6, 2023)	7/6/2023	NONE	NONE	
PTX0074	LinkedIn Web Biography of Gardner Gendron, US Head Commercial at NS Pharma, Inc., as of July 11, 2023	7/11/2023	NONE	NONE	
PTX0075	NS Pharma Organizational Chart, dated July 25, 2022	7/25/2022	NS00036975	NS00036985	
PTX0076	"Viltepso performance (11/09-11/13) and activity status (11/02-11/06) report, 2020.11.13, NS Pharma, Inc." (English)	11/13/2020	NS00036995	NS00036998	
PTX0077	"Viltepso performance (11/09-11/13) and activity status (11/02-11/06) report, 2020.11.13, NS Pharma, Inc." (Japanese followed by certified English translation)	11/13/2020	NS00036995	NS00036998	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0078	"Viltepso Results (12/21-12/25) and Activity Status (12/14-12/18) Report, 12.25.2020, NS Pharma, Inc." (English)	12/25/2020	NS00037036	NS00037041	
PTX0079	"Viltepso Results (12/21-12/25) and Activity Status (12/14-12/18) Report, 12.25.2020, NS Pharma, Inc." (Japanese followed by certified English translation)	12/25/2020	NS00037036	NS00037041	
PTX0080	Native Excel Workbook, two worksheets: "Forecast Model, Calendar Year Summary" (metadata date created and date modified 12/9/2022)	12/9/2022	NS00074042	NS00074042	
PTX0081	Native Excel Workbook, five worksheets: "ASP SUMMARY, ASP REPORT, BUCKETS, PERIOD, NDCS" period 2021-06	6/1/2021	NS00036993	NS00036993	
PTX0082	Native Excel Workbook, three worksheets: "Commerical_20, Commerical_21, Commercial_22"	9/30/2022	NS00036994	NS00036994	
PTX0083	Native Excel Workbook, four worksheets: "Commerical_20, Commerical_21, Commercial_22, Commercial_23" (metadata date created 11/2/2020, date modified 6/9/2023, date printed 11/10/2020)	6/9/2023	NS00091316	NS00091316	
PTX0084	NS Pharma Memo to Mr. Yoshihiko Makita, "Preliminary Royalty Rate of Viltepso for Fiscal Year 2023" date, April 11, 2023	4/11/2023	NS00091312	NS00091312	
PTX0085	Printout of Native Workbook "[REDACTED] [REDACTED] access programs ex-U.S. and outside of Japan" with headings [REDACTED] and "[REDACTED]" (metadata date created 6/1/2023, date modified 6/10/2023, date printed 6/6/2023)	6/10/2023	NS00091313	NS00091313	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0086	"On the [REDACTED] for [REDACTED] of drugs not [REDACTED] and the [REDACTED] handling (updated version), August 22, 2022, International Business Division, Nippon Shinyaku Co., Ltd." presentation deck	8/22/2022	NS00090751	NS00090753	
PTX0087	"On the [REDACTED] for [REDACTED] of drugs not [REDACTED] and the [REDACTED] handling (updated version), August 22, 2022, International Business Division, Nippon Shinyaku Co., Ltd." presentation deck (Japanese followed by certified English translation)	8/22/2022	NS00090751	NS00090753	
PTX0088	"NS Pharma 2022 Fiscal Year Sales Forecast Attainment, 5 Dec 2022" presentation deck	12/5/2022	NS00074025	NS00074033	
PTX0089	Email message from Gardner Gendron to Jonathan Cabral, Subject: "FW: Commercial Pricing Recommendation 04.27.2020.pptx", sent April 27, 2020	4/27/2020	NS00096857	NS000096857	
PTX0090	NS Pharma "[REDACTED] Committee, April 16, 2020" presentation deck	4/16/2020	NS00096858	NS000096881	
PTX0091	"[REDACTED] Committee Policy" NS Pharma, Inc., issue date and effective date: April 8, 2020	4/8/2020	NS00097081	NS00097090	
PTX0092	"Commercial [REDACTED] Agreement" between Nippon Shinyaku Co., Ltd and [REDACTED] Inc., effective date July 17, 2019	7/17/2019	NS00073479	NS00073508	
PTX0093	"[REDACTED] and [REDACTED] Agreement" between NS Pharma, Inc. and Nippon Shinyaku Co., Ltd., effective date August 25, 2020 (signed 08/28/2020)	8/25/2020	NS00074895	NS00074931	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0094	"[REDACTED] and [REDACTED] [REDACTED]" between NS Pharma Inc. and [REDACTED] LLC, effective date August 1, 2020 (signed 1/28/2021)	8/1/2020	NS00075034	NS00075075	
PTX0095	"[REDACTED] Agreement" between NS Pharma, Inc. and Nippon Shinyaku Co., Ltd., effective date February 4, 2020 (signed 2/5/2020)	2/4/2020	NS00074956	NS00074975	
PTX0096	"[REDACTED] Addendum" between [REDACTED] [REDACTED] and NS Pharma, Inc., effective date August 10, 2020 (signed 8/10/2020)	8/10/2020	NS00074976	NS00074985	
PTX0097	"[REDACTED] and [REDACTED] Agreement" between NS Pharma, Inc. and Nippon Shinyaku Co., Ltd., effective date August 1, 2020 (signed 8/5/2020)	8/1/2020	NS00074987	NS00075032	
PTX0098	"Exhibit A, Traditional [REDACTED] [REDACTED] Between NS Pharma, Inc. ("Client") And [REDACTED] [REDACTED], effective date 02.04.2020 (signed 8/19/2020)	2/4/2020	NS00074933	NS00074955	
PTX0099	"[REDACTED]" between NS Pharma, Inc. and Nippon Shinyaku Co., Ltd., effective as of August 1, 2020 (signed 8/10/2020)	8/1/2020	NS00075079	NS00075120	
PTX0100	"[REDACTED] Agreement" between NS Pharma, Inc. and Nippon Shinyaku Co., Ltd., effective as of June 22, 2020 (signed 8/7/2020)	6/22/2020	NS00075122	NS00075161	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0101	NS Pharma, "Duchenne's Muscular Dystrophy (DMD) [REDACTED] August 2021, [REDACTED] presentation deck (metadata parent date 8/31/2022)	8/31/2022	NS00074369	NS00074463	
PTX0102	Email message [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] Subject: [REDACTED] [1/4 - 1/8/2021] Sent	1/11/2021	NS00097297	NS00097298	
PTX0103	"[REDACTED] Department, 12/21 - 12/23/2020" (metadata parent date 1/11/2021)	1/11/2021	NS00097299	NS00097301	
PTX0104	Email message from [REDACTED] [REDACTED] [REDACTED] Subject: "[REDACTED]" sent 4/25/2021	4/25/2021	NS00096000	NS00096000	
PTX0105	"[REDACTED]" (email parent date 4/25/2021)	4/25/2021	NS00096001	NS00096004	
PTX0106	NS Pharma, "[REDACTED] September 2022" presentation deck (metadata parent date 9/14/2022)	9/14/2022	NS00041924	NS00042003	
PTX0107	NS Pharma, "[REDACTED] 08.02.2022" presentation deck	8/2/2022	NS00057814	NS00057855	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0108	NS Pharma, " [REDACTED] " presentation deck (metadata date created 6/24/2020, date modified 9/9/2020)	9/9/2020	NS00058001	NS00058030	
PTX0109	Email thread [REDACTED] [REDACTED] [REDACTED], June 10, 15, 16, 24, 25, 2021 (Sent 6/25/2021)	6/25/2021	NS00095398	NS00095402	
PTX0110	NS Pharma, " [REDACTED] Prepared by [REDACTED] presentation deck (metadata date created 10/1/2019, date modified 6/26/2021)	6/26/2021	NS00095403	NS00095446	
PTX0111	Native Excel Worksheet entitled " [REDACTED] and "Sheet1" Fiscal Year April 2022-March 2023 (metadata date created 2/9/2022, date modified 12/9/2022)	12/9/2022	NS00074040	NS00074040	
PTX0112	Email message [REDACTED] Subject: [REDACTED] with attachments Sent 12/2/2022	12/2/2022	NS00096010	NS00096010	
PTX0113	NS Pharma, [REDACTED] April 16, 2020 presentation deck (metadata date created 4/17/2020 date modified 4/17/2020)	4/17/2020	NS00096011	NS00096030	
PTX0114	NS Pharma, [REDACTED] Updated 03/24/20 presentation deck (metadata date created 10/1/2019, date modified 3/25/2020)	3/25/2020	NS00096031	NS00096049	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0115	"NS Pharma, [REDACTED] Updated 03/34/20," presentation deck (metadata date created 10/1/2019, date modified 3/25/2020)	3/25/2020	NS00096050	NS00096060	
PTX0116	"[REDACTED] February 4, 2020," presentation deck (metadata date created 10/1/2019, date modified 2/5/2020)	2/5/2020	NS00096061	NS00096086	
PTX0117	"[REDACTED] Last Updated: August 12, 2020"	8/12/2020	NS00096087	NS00096092	
PTX0118	"NS Pharma, [REDACTED] presentation deck (metadata date created 10/1/2019, date modified 5/29/2020)	5/29/2020	NS00096093	NS00096163	
PTX0119	Declaration of Michelle L. Hastings, PH.D., Exhibit 43, Joint Appendix to Claim Construction Brief, executed on February 6, 2023	2/6/2023	NONE	NONE	
PTX0120	Anthony J. Hinrich, et al., "Therapeutic correction of ApoER2 splicing in Alzheimer's disease mice using antisense oligonucleotides," 8(4) EMBO Mol. Med. 328-345 (Apr. 2016) Neuromuscular Disorders 102-110 (Feb. 2010) ePublished date Feb. 22, 2016	2/22/2016	NONE	NONE	
PTX0121	Frederic F. Depreux et al., "Antisense oligonucleotides delivered to the amniotic cavity in utero modulate gene expression in the postnatal mouse," 44(20) Nucleic Acids Research 9519-9529 (Nov. 16, 2016) published online September 28, 2016	9/28/2016	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0122	Jennifer L. Chang et al., "Targeting Amyloid-B Precursor Protein, APP, Splicing with Antisense Oligonucleotides Reduces Toxic Amyloid-B Production," 26(6) J. of Molecular Therapy 1539-1551 (June 5, 2018) published Mar. 6, 2018	3/6/2018	NONE	NONE	
PTX0123	Jessica L. Centa et al., "Therapeutic efficacy of antisense oligonucleotides in mouse models of CLN3 Batten disease," 26 J. Nature Med. 1444-1451 (Sept. 2020) published July 27, 2020	6/27/2020	NONE	NONE	
PTX0124	Wren E. Michaels et al., "Open reading frame correction using splice-switching antisense oligonucleotides for the treatment of cystic fibrosis," 119(3) Proceedings of the Nat'l Acad. of Scienc. (accepted Dec. 3, 2021, published January 10, 2022)	1/10/2022	NONE	NONE	
PTX0125	Wren E. Michaels et al., "Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells," 48(13) Nucleic Acids Research 7454-7467 (July 27, 2020) published June 10, 2020	6/10/2020	NONE	NONE	
PTX0126	Numbers 936-20-M-0596, 936-20-M-0597, 936-20-M-0598, Final report, " approved November 5, 2021	11/5/2021	NS00153927	NS00153962	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0127	Number 936-21-M-0641, Final Report, "[REDACTED] approved March 15, 2022	3/15/2022	NS00153963	NS00153997	
PTX0128	"[REDACTED] Number 936-21-M-0643, Final Report, "[REDACTED] Study completion date: May 17, 2023	5/17/2023	NS00102924	NS00102987	
PTX0129	"[REDACTED] Number 936-21-M-0644, Final Report, "[REDACTED] Study completion date: May 17, 2023	5/17/2023	NS00102988	NS00103060	
PTX0130	"[REDACTED] Number 936-22-M-0661, Final Report, "[REDACTED] Study completion date: May 17, 2023	5/17/2023	NS00103061	NS00103110	
PTX0131	U.S. Patent No. 9,840,706 B2	12/12/2017	NONE	NONE	
PTX0132	U.S. Patent App. Publication No. US 2023/0097387 A1	3/30/2023	NONE	NONE	
PTX0133	U.S. Patent No. 10,144,931 B2	12/4/2018	NS00154462	NS00154520	
PTX0134	WIPO International Publication No. WO 2020/089325 A1	5/7/2020	NS00156405	NS00156562	
PTX0135	Excerpts from Application No. 14/852,264 ('948 FH): "First Preliminary Amendment Under 37 C.F.R. § 1.115" & "Amendment in Response to Non-Final Office Action Under 37 C.F.R. § 1.111"	9/11/2015	SRPT-VYDS-0057510 SRPT-VYDS-0058515	SRPT-VYDS-0057510 SRPT-VYDS-0058529	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0136	Excerpts from Application No. 14/852,264 ('948 FH): "Transmittal for Power of Attorney to One or More Registered Practitioners" & "Amendment in Response to Non-Final Office Action Under 37 C.F.R. § 1.111"	2/17/2015	SRPT-VYDS-0072805 SRPT-VYDS-0073821	SRPT-VYDS-0072805 SRPT-VYDS-0073834	
PTX0137	Excerpts from Application No. 14/852,264 ('948 FH): "First Preliminary Amendment Under 37 C.F.R. § 1.115" & "Amendment in Response to Non-Final Office Action Under 37 C.F.R. § 1.111"	2/18/2016	SRPT-VYDS-0074084 SRPT-VYDS-0075111	SRPT-VYDS-0074084 SRPT-VYDS-0075125	
PTX0138	Excerpts from Application No. 15/420,823, "Amendment and Reply Under 37. C.F.R. § 1.111," "Office communication" (11/07/2018) & "Office communication" (1/3/2020)	8/6/2018	NONE	NONE	
PTX0139	Nippon Shinyaku Co. Ltd.'s Final Invalidity Contentions, dated July 11, 2023	7/11/2023	NONE	NONE	
PTX0140	U.S. Patent App. Publication No. US 2007/0082861 A1	4/12/2007	SRPT-VYDS-0008113	SRPT-VYDS-0008287	
PTX0141	U.S. Patent No. 9,353,371 B2	5/31/2016	NONE	NONE	
PTX0142	Seth Robey & Frank S. David, "Drug launch curves in the modern era," 16 Nature Reviews Drug Discovery 13-14 (Dec. 2, 2016)	12/2/2016	SRPT-VYDS-0236527	SRPT-VYDS-0236528	
PTX0143	Patient Information Sheet [REDACTED], as of March 10, 2023	3/10/2023	SRPT-VYDS-0213542	SRPT-VYDS-0213543	
PTX0144	[REDACTED] Agreement between Nippon Shinyaku Co., Ltd., and NS Pharma, Inc., entered into April 1, 2020 (English)	4/1/2020	NS00036893	NS00036908	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0145	Second Amended Complaint for Breach of Contract, Declaratory Judgement of Patent Invalidity, and Patent Infringement (D.I. 86), Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics, Inc., No. 21-1015 (D. Del. Jan. 14, 2022)	1/14/2022	NONE	NONE	
PTX0146	"License Agreement" between Sarepta Therapeutics, Inc. and Sarepta International C.V. and BioMarin Nederlands BV and BioMarin Technologies BV, executed July 17, 2017	7/17/2017	SRPT-VYDS-0207092	SRPT-VYDS-0207177	
PTX0147	"Commercial Supply Agreement" between Sarepta Therapeutics, Inc. and [REDACTED], dated May 18, 2017	5/18/2017	SRPT-VYDS-0213333	SRPT-VYDS-0213380	
PTX0148	"Third Amendment to Commercial Supply Agreement" between [REDACTED] dated June 22, 2020	6/22/2020	SRPT-VYDS-0213383	SRPT-VYDS-0213392	
PTX0149	"Fifth Amendment to Commercial Supply Agreement" between [REDACTED] dated April 14, 2021	4/14/2021	SRPT-VYDS-0213330	SRPT-VYDS-0213332	
PTX0150	"Technology Transfer, Validation and Commercial Fill/Finish Services Agreement" between [REDACTED] entered into June 9, 2021	6/9/2021	SRPT-VYDS-0220040	SRPT-VYDS-0220067	
PTX0151	"Packaging and Supply Agreement" between [REDACTED] and [REDACTED], effective June 24, 2020	6/24/2020	SRPT-VYDS-0219963	SRPT-VYDS-0219990	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0152	"Fourth Amendment to Commercial Outsourcing Services Agreement" between [REDACTED] and [REDACTED] effective September 28, 2021	9/28/2021	SRPT-VYDS-0219884	SRPT-VYDS-0219891	
PTX0153	"Second Amendment to Distribution Services Agreement" between [REDACTED] and [REDACTED] dated July 1, 2020	7/1/2020	SRPT-VYDS-0213445	SRPT-VYDS-0213450	
PTX0154	Sarepta's Responses and Objections to NS's Second Set of Interrogatories (Nos. 14-21), April 3, 2023	4/3/2023	NONE	NONE	
PTX0155	FDA filing regarding "3.2.S.1. General Information [Golodirsen, [REDACTED] Inc.], 2. Structure [Golodirsen, [REDACTED] Inc.]" (metadata date modified 8/27/2018)	8/27/2018	SRPT-VYDS-0007049	SRPT-VYDS-0007050	
PTX0156	3.2.S.2. Manufacture [Golodirsen, [REDACTED] Americas, Inc] (metadata date modified 12/16/2020)	12/16/2020	SRPT-VYDS-0007051	SRPT-VYDS-0007088	
PTX0157	PL Harding et al., "The Influence of Antisense Oligonucleotide Length on Dystrophin Exon Skipping," 15:1 Molecular Therapy 157-166 (Jan. 2007)	8/24/2006	NONE	NONE	
PTX0158	[REDACTED] V2.0 (11.2020) (metadata dated created 12/17/2019; date modified 4/19/2022)	11/1/2020	SRPT-VYDS-0211555	SRPT-VYDS-0211623	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0159	Press Release, "Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study for ELEVIDYS Gene Therapy Duchenne Muscular Dystrophy" 10/30/23 4:01 PM EDT	10/30/2023	NONE	NONE	
PTX0160	Eric Sagonowsky, "Sarepta's Elevidys fails on primary endpoint, but executives see path to wider DMD approval anyway" (Fierce Pharma Oct. 30, 2023)	10/30/2023	NONE	NONE	
PTX0161	"Horizontal Merger Guidelines," U.S. Department of Justice and the Federal Trade Commission, Issued: August 19, 2010	8/19/2010	NONE	NONE	
PTX0162	"Clinical Development Success Rates and Contributing Factors 2011-2020," Biotechnology Innovation Organization, PharmaIntelligence Informa, Quantitative Life Sciences, February 2021	2/1/2021	NONE	NONE	
PTX0163	Email thread between Matthew Gall and Masaya Toda, Subject: "[REDACTED] September 19, 22, 26 and October 2, 2017	10/2/2017	SRPT-VYDS-0222811	SRPT-VYDS-0222813	
PTX0164	Sarepta's Notice of Rule 30(b)(1) Deposition of Leslie Magnus , Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics Inc., No. 21-1015 (D. Del. July 14, 2023)	7/14/2023	NONE	NONE	
PTX0165	Highlights of Prescribing Information for Viltipso (viltolarsen injection) for intravenous use, revised 8/2020, dated 08/12/2020	8/12/2020	NS00035358	NS00035369	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0166	Accelerated Approval Letter from the FDA U.S. Food & Drug Administration to Nippon Shinyaku Co., Ltd. Regarding Viltepso (viltolarsen) injection NDA 212154, dated 08/12/2020	8/12/2020	NS00035370	NS00035379	
PTX0167	"Center for Drug Evaluation and Research, Application Number: 212154Orig1s000, Administrative and Correspondence Documents" Meeting Minutes dated 10/24/2018	10/24/2018	NS00035380	NS00035403	
PTX0168	"Center for Drug Evaluation and Research, Application Number: 212154Orig1s000, Product Quality Review(s)" Executive Summary dated 06/15/2020	6/15/2020	NS00035404	NS00035428	
PTX0169	"Center for Drug Evaluation and Research, Application Number: 212154Orig1s000, Clinical Pharmacology Review(s)" dated 6/15 and 6/16/2020	6/16/2020	NS00035429	NS00035450	
PTX0170	"Center for Drug Evaluation and Research, Application Number: 212154Orig1s000, Clinical Review(s)" dated 5/13 and 5/14/2020	5/14/2020	NS00035451	NS00035579	
PTX0171	"Center for Drug Evaluation and Research, Application Number: 212154Orig1s000, Proprietary Name Review(s)" dated 01/06 and 01/07/2020	1/7/2020	NS00035580	NS00035605	
PTX0172	"Center for Drug Evaluation and Research, Application Number: 212154Orig1s000, Other Review(s)" dated 3/17/2020	3/17/2020	NS00035610	NS00035667	
PTX0173	"Center for Drug Evaluation and Research, Application Number: 212154Orig1s000, Non-Clinical Review(s)" dated 07/16/2020	7/16/2020	NS00035668	NS00035716	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0174	"Center for Drug Evaluation and Research, Application Number: 212154Orig1s000, Risk Assessment and Risk Mitigation Review(s)" dated 08/04/2020	8/4/2020	NS00035717	NS00035726	
PTX0175	"Center for Drug Evaluation and Research, Application Number: 212154Orig1s000, Summary Review" dated 08/12/2020	8/12/2020	NS00035727	NS00035754	
PTX0176	"Center for Drug Evaluation and Research, Approval Package for: Application Number: 212154Orig1s000" dated 08/12/2020	8/12/2020	NS00035755	NS00035767	
PTX0177	"Summaries" of NDA 212154, Section "2.2 Introduction to Summary" (metadata created date 9/28/2019, modified date 9/28/2019)	9/28/2019	NS00035826	NS00035826	
PTX0178	"Summaries" of NDA 212154, Section "2.3 Quality Overall Summary" (metadata created date 9/28/2019, modified date 9/28/2019)	9/28/2019	NS00035827	NS00035827	
PTX0179	"Quality Overall Summary" of NDA 212154, Section "2.3P.1 Description and Composition of the Drug Product" (metadata created date 9/28/2019, modified date 9/28/2019)	9/28/2019	NS00035828	NS00035828	
PTX0180	"Investigator's Brochure, Viltolarsen (NS-065/NCNP-01)" Edition: ver. 9.0, Release Date: May 13, 2022	5/13/2022	NS00041039	NS00041264	
PTX0181	"NS-065/NCNP-01, Clinical Study Report" Version 1, July 30, 2018	7/30/2018	NS00052639	NS00052759	
PTX0182	"Clinical Study Report: NS-065/NCNP-01-201" May 30, 2019	5/30/2019	NS00052760	NS00052938	
PTX0183	"Summaries" of NDA 212154, Section "2.5 Clinical Overview," Nippon Shinyaku Co., Ltd. (metadata date created 9/28/2019, date modified 9/27/2019)	9/28/2019	NS00065426	NS00065468	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0184	"Quality Overall Summary" of NDA 212154, Section "2.3.P.2 Pharmaceutical Development" (metadata date created 9/28/2019, date modified 9/28/2019)	9/28/2019	NS00065541	NS00065553	
PTX0185	"2.7 Clinical Summary" of NDA 212154, Section "2.7.3 Summary of Clinical Efficacy Duchenne Muscular Dystrophy," Nippon Shinyaku Co., Ltd. (metadata date created 9/28/2019, date modified 9/28/2019)	9/28/2019	NS00066000	NS00066108	
PTX0186	Craig M. McDonald, et al., "Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study," The Lancet (Nov. 22, 2017)	11/22/2017	NS00057198	NS00057239	
PTX0187	"Ninth Development Safety Update Report for Active Substance(s): Viltolarsen (NS-065/NCNP-01), Development International Birth Date (DIBD): 14-May-2013" signed 6/29/2023	6/29/2023	NS00137710	NS00137980	
PTX0188	NS Pharma, Inc., Study NS-065/NCNP-01-201 Statistical Analysis Plan, IND#: 127,474, "Statistical Analysis Plan" signed 3/6/2019 (metadata date created 3/3/2018, date modified 3/7/2018)	3/7/2018	NS00104178	NS00104228	
PTX0189	NS Pharma, Inc., Study NS-065/NCNP-01-210 NH SAP 2019-02-28, IND#:127,474, "Natural History/Historical Control Statistical Analysis Plan" NH SAP DATE: 2019-02-28, FINAL V2.0 (metadata date created 3/5/2019, date modified 3/6/2019)	3/6/2019	NS00104229	NS00104365	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0190	Email message from Shimpei Sonohara to Adam Latts, Stephen Sudovar, Stacey Helfant (cc to Gardner Gendron, Jonathan Cabral, Randy McGonigal, Denise Quigley, Stephanie Soto, Leslie Magnus, Nancy Park), Subject: FAQ, with attachment "[REDACTED].docx" sent January 17, 2020	1/17/2020	NS00097387	NS00097387	
PTX0191	"19 June 2019, Viltolarsen (NS-065/NCNP-01) FAQ," attachment to email message from Shimpei Sonohara to Adam Latts, Stephen Sudovar, Stacey Helfant (cc tom Gardner Gendron, Jonathan Cabral, Randy McGonigal, Denise Quigley, Stephanie Soto, Leslie Magnus, Nancy Park) dated 19 June 2019	6/19/2019	NS00097388	NS00097400	
PTX0192	"Q&A for [REDACTED] dated Nov 18, 2020	11/18/2020	NS00113604	NS00113607	
PTX0193	Presentation entitled "Cure Duchenne" by "Leslie Magnus, MD" (metadata parent date 9/29/2021, date created 2/5/2019, date modified 9/29/2021)	9/29/2021	NS00056021	NS00056029	
PTX0194	Email message from Jonathan Cabral to Leslie Magnus (cc to Gardner Gendron, William Finneran, Erica Scott) Subject: Clinical [REDACTED] Analytics, August 2, 2021	8/2/2021	NS00095359	NS00095359	
PTX0195	"IPD Analytics, New Drug Review, Viltepso (viltolarsen)" IPD Analytics Published date August 2020 (metadata date created 8/31/2020, date modified 8/31/2020)	8/31/2020	NS00095360	NS00095368	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0196	Email thread between Leslie Magnus and Eric Hoffman, forwarded to Gardner Gendron, Leslie magnus, Stephen Sudovar, Randy McGonigal, Jonathan Cabral, and Stacey Helfant, Subject "FW: Question about [REDACTED]", sent 10/6/2020	10/6/2020	NS00096224	NS00096227	
PTX0197	Email message forwarded from Yuko Horiuchi to Leslie Magnus attaching "files we used yesterday in the meeting with Gardner [Gendron]." Sent 4/24/2019	4/24/2019	NS00103489	NS00103489	
PTX0198	Native Excel file, [REDACTED] Report 1038173, for the period 3/15/2019 - 3/21/2019 (metadata date created 3/22/2019, date modified 4/13/2019)	4/19/2019	NS00103747	NS00103747	
PTX0199	Email message from Leslie Magnus to Ogilvy Team: Craig Gelband, Cristina Mayer, Jillian Dietzold (cc to Michael Melucci) Subject: [REDACTED] planning sent 9/12/2019	9/12/2019	NS00113347	NS00113347	
PTX0200	Email message from Leslie Magnus to Ogilvy Team attachment: "[REDACTED] slides, "[REDACTED] slides, "[REDACTED] slides, "[REDACTED] slides, "[REDACTED] slides, "[REDACTED] slides (metadata date created 5/24/2019, date modified 5/31/2019)	5/31/2019	NS00113348	NS00113372	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0201	Email message from Leslie Magnus to Taishi Yamashita, Tatsuya Horiguchi (cc to Takeshi Seita) Subject: "Question about [REDACTED] [REDACTED]" with Taishi Yamashita's response sent 7/22/2020	7/22/2020	NS00115569	NS00115570	
PTX0202	Email message from Leslie Magnus (no recipient information), Subject: "Branded Webinar Deck" sent 7/29/2020	7/29/2020	NS00123362	NS00123362	
PTX0203	Presentation entitled "Viltepso: A New FDA-Approved Treatment for Patients with Duchenne Muscular Dystrophy (DMD) Amenable to Exon 53 Skipping" (metadata date created 1/17/2013, date modified	7/28/2020	NS00123363	NS00123388	
PTX0204	Email message from Robert Crozier to Leslie Magnus, Subject: "-202 protocol" sent 9/10/2021	9/10/2021	NS00127168	NS00127168	
PTX0205	"NS Pharma [REDACTED] Meeting" minutes (metadata date created 7/8/2020, date modified 7/8/2020)	7/8/2020	NS00099140	NS00099141	
PTX0206	"NS Pharma [REDACTED] Meeting" minutes (metadata date created 7/21/2020, date modified 7/21/2020)	7/21/2020	NS00099144	NS00099146	
PTX0207	University of Western Australia v. Academisch Ziekenhuis Leiden, "Decision - Motions - 37 CFR § 41.1225(a) (Substitute)" (PTAB May 12, 2016)	5/12/2016	NONE	NONE	
PTX0208	U.S. Patent App. No. 15/274,772	6/30/2017	NONE	NONE	
PTX0209	"Preliminary Amendment and Request to Provoke an Interference," Application No. 13/902,376, dated May 31, 2013	5/31/2013	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0210	"Amendment in Response to Non-Final Office Action Under 37 C.F.R. § 1.111," Application No. 13/902,376, dated March 21, 2014	3/21/2014	NONE	NONE	
PTX0211	"Amendment in Response to Non-Final Office Action Under 37 C.F.R. § 1.111," Application No. 14/316,609 dated January 21, 2015	1/21/2015	NONE	NONE	
PTX0212	Steve D. Wilton & Susan Fletcher, Editorial, "Antisense oligonucleotides in the treatment of Duchenne muscular dystrophy: Where are we now?," 15 Neuromuscular Disorders 399-402 (2005)	3/16/2005	NONE	NONE	
PTX0213	"NS Pharma Duchenne Muscular Dystrophy (DMD) [REDACTED] March 31, 2023" presentation deck (metadata date created 3/30/2020, date modified 3/31/2022)	3/31/2022	NS00042807	NS00042857	
PTX0214	Exhibit A, "Mutual Confidentiality Agreement, Effective Date: June 1, 2020" between Nippon Shinyaku Co., Ltd., and Sarepta Therapeutics, Inc.	6/1/2020	NONE	NONE	
PTX0215	Sarepta's Notice of Rule 30(b)(1) Deposition of Angela Melia , Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics Inc., No. 21-1015 (D. Del. July 6, 2023)	7/6/2023	NONE	NONE	
PTX0216	"Eighth Development Safety Update Report for Active Substance(s): Viltolarsen (NS-065/NCNP-01), Development International Birth Date (DIBD): 14-May-2013," Date of DSUR: 28-Jun-2022, signed June 29, 2022	6/29/2022	NS00039216	NS00039501	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0217	Full prescribing information for "Viltepso (viltolarsen) injection, An exon-skipping treatment option for DMD patients with an exon 52 deletion" Revised 3/2021 (metadata date created 10/6/2021, date modified	10/6/2021	NS00041423	NS00041436	
PTX0218	"Viltepso™ (viltolarsen) injection FDA Approval Webinars: Key Messages, Questions & Answers, Last Updated: August 12, 2020"	8/12/2020	NS00059349	NS00059355	
PTX0219	Study "A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys with Duchenne Muscular Dystrophy (DMD)" Study Number NS-065/NCNP-01-202, Final Date 10 August 2022; Ver. 1.1	8/10/2022	NS00039681	NS00039840	
PTX0220	NCT04060199, "Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)," ClinicalTrials.gov, Last Update Posted July 2, 2021, Sponsor NS Pharma, Inc.	7/2/2021	NS00046479	NS00046486	
PTX0221	Hirofumi Komaki et al., "A Japanese Phase I/II study of NS-065/NCNP-01 (Viltolarsen), Exon53 skipping drug, in patients with Duchenne muscular dystrophy - A does-finding study poster presentation" (metadata date created 9/29/2018, date modified 4/8/2019)	4/8/2019	NS00125617	NS00125617	
PTX0222	Susan Fletcher et al., Editorial, "Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide," 8 J. Gene Medicine 207-216 (Nov. 14, 2005)	11/14/2005	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0223	Email message from Penny Harding to Steve Wilton, Subject: "Paper" embedding in message: "[REDACTED]" February 24, 2006	2/24/2006	WILTON0026361	WILTON0026367	
PTX0224	Handwritten Journal, "[REDACTED]"	6/1/2008	SRPT-VYDS-0159885	SRPT-VYDS-0160000	
PTX0225	Handwritten Journal, "[REDACTED]"	6/2/2010	SRPT-VYDS-0161119	SRPT-VYDS-0161291	
PTX0226	Handwritten Journal, "[REDACTED]"	8/24/2010	SRPT-VYDS-0162229	SRPT-VYDS-0162284	
PTX0227	Handwritten Journal, "[REDACTED]"	1/25/2011	SRPT-VYDS-00159207	SRPT-VYDS-0159342	
PTX0228	LinkedIn Web Biography of Emily Naughton, Sr. Director, Field & Medical Affairs Operations at Sarepta Therapeutics (viewed on July 11, 2023)	7/11/2023	NONE	NONE	
PTX0229	Email message from Diane Frank to Brian Leppert, Emily Naughton, Subject: "proposed week's schedule" sent August 13, 2012	8/13/2012	SRPT-VYDS-0215879	SRPT-VYDS-0215879	
PTX0230	Handwritten Journal, "[REDACTED]" (last date is 14 Dec 2012)	12/14/2012	SRPT-VYDS-0163689	SRPT-VYDS-0163912	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0231	Email message from Diane Frank to Emily Naughton, Brian Leppert, Subject: "Cell culture notes" October 5, 2012	10/5/2012	SRPT-VYDS-0213962	SRPT-VYDS-0213962	
PTX0232	Email message from Diane Frank to Brian Leppert, Emily Naughton, Subject: "Compounds Arrived" November 6, 2012	11/6/2012	SRPT-VYDS-0218038	SRPT-VYDS-0218038	
PTX0233	Handwritten Journal, "[REDACTED]" "Avi BioPharma Stock Books, February 18, 2013	2/18/2013	SRPT-VYDS-0163463	SRPT-VYDS-0163688	
PTX0234	Email thread between Emily Naughton, Diane Frank, Brian Leppert Subject: "Exon53 Pre-Screen Data" December 3, 4 and 5, 2012 with attachment "[REDACTED]" (metadata date created 12/5/2012, date modified 12/5/2012)	12/5/2012	SRPT-VYDS-0217843 SRPT-VYDS-0217900	SRPT-VYDS-0217846 SRPT-VYDS-0217900	
PTX0235	Email message from Emily Naughton to Diane Frank, Brian Leppert Subject: "[REDACTED]" with attachments, sent January 29, 2013	1/29/2013	SRPT-VYDS-0216225	SRPT-VYDS-0216228	
PTX0236	Email thread between Olga Mitelman, Emily Naughton, Lisa Borland, Fred Schnell, Subject: "[REDACTED]" sent April 24, 2019	4/24/2019	SRPT-VYDS-0196850	SRPT-VYDS-0196852	
PTX0237	Notice to Take Depositions of Patrick O'Malley, Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics Inc., No. 21-1015 (D. Del. July 14, 2023)	7/14/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0238	"Type C Meeting - Briefing Materials, Golodirsen (SRP-4053) Injection, IND 119,982, 15 December 2017, Sarepta Therapeutics, Inc."	12/15/2017	SRPT-VYDS-0196643	SRPT-VYDS-0196711	
PTX0239	New Drug Application to Food and Drug Administration from Sarepta Therapeutics, "Product: Golodirsen Injection ... Subject: Pre-Submission - Submission Number One of Rolling NDA," dated August 27, 2018	8/27/2018	SRPT-VYDS-0006997	SRPT-VYDS-0006999	
PTX0240	"Meeting Request Granted" letter from Food and Drug Administration to Sarepta Therapeutics, Inc., dated June 28, 2018 [PO'Malley-05]	6/28/2018	SRPT-VYDS-0189179	SRPT-VYDS-0189184	
PTX0241	IND 119,982, Type B Meeting Briefing Material, Type B Pre-NDA Meeting Briefing Materials, Golodirsen (SRP-4053) Injection, IND 119,982, 11 September 2018 (metadata date modified 8/10/2018)	8/10/2018	SRPT-VYDS-0189075	SRPT-VYDS-0189178	
PTX0242	"Center for Drug Evaluation and Research, Application Number 211970Orig1s000, Other Action Letters," August 19, 2019	8/19/2019	SRPT-VYDS-0211215	SRPT-VYDS-0211227	
PTX0243	"Request for Formal Dispute Resolution" letter to Food and Drug Administration from Sarepta Therapeutics, "Product: SRP-4053 (Golodirsen)," dated September 13, 2019	9/13/2019	SRPT-VYDS-0213256	SRPT-VYDS-0213256	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0244	"Formal Dispute Resolution Request, For Drug Substance: Golodirsen (International Nonproprietary Name), SRP-4053 Drug Product: Golodirsen (SRP-4053)" Applicant Name: Sarepta Therapeutics, Inc.," Attention: Peter Stein, M.D., Director of Center for Drug Evaluation and Research, in response to Complete Response Letter dated August 19, 2019	8/19/2019	SRPT-VYDS-0213246	SRPT-VYDS-0213255	
PTX0245	"FDRR - Response to Request for Information" regarding "Product: SRP-4053 (Golodirsen)" from Sarepta Therapeutics, Inc. to Food and Drug Administration, dated October 24, 2019	10/24/2019	SRPT-VYDS-0213265	SRPT-VYDS-0213265	
PTX0246	Response to Information Request received from Dr. Stein on October 21, 2019 (cover letter dated October 24, 2019); document titled "1.11.3 Clinical Information Amendment"	10/24/2019	SRPT-VYDS-0213257	SRPT-VYDS-0213264	
PTX0247	"Center for Drug Evaluation and Research, Application Number 211970Orig1s000, Administrative and Correspondence Documents," November 22, 2019	11/22/2019	SRPT-VYDS-0211449	SRPT-VYDS-0211489	
PTX0248	"Center for Drug Evaluation and Research, Approval Package for: Application Number 211970Orig1s000," Generic or Proper Name golodirsen, Sponsor Sarepta Therapeutics, Inc., Approval Date December 12, 2019	12/12/2019	SRPT-VYDS-0211422	SRPT-VYDS-0211435	
PTX0249	"Golodirsen NDA 211970 - Confirmatory Study Commitment Letter" from Sarepta Therapeutics, Inc. to Food and Drug Administration, dated November 27, 2019	11/27/2019	SRPT-VYDS-0213284	SRPT-VYDS-0213284	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0250	"Center for Drug Evaluation and Research, Application Number 211970Orig1s000, Labeling" December 12, 2019	12/12/2019	SRPT-VYDS-0211289	SRPT-VYDS-0211303	
PTX0251	Paula R. Clemens, MD et al., "Safety, Tolerability, and Efficacy of Viltolarsen in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping," JAMA Neurology E1-E10 (May 26, 2020)	5/26/2020	NS00035339	NS00035348	
PTX0252	WO 2012/029986 A1 (Japanese)	8/31/2011	NONE	NONE	
PTX0253	WO 2012/029986 A1 (certified English translation)	8/31/2011	NONE	NONE	
PTX0254	Japanese Application Number JP2010-196032, Watanabe et al., "Antisense nucleic acid," Date of Application: September 1, 2010 (Japanese)	9/1/2010	NONE	NONE	
PTX0255	Japanese Application Number JP2010-196032, Watanabe et al., "Antisense nucleic acid," Date of Application: September 1, 2010 (certified English translation)	9/1/2010	NONE	NONE	
PTX0256	Handwritten Journal, "[REDACTED] cover, index, and journal pages 1-98 (Japanese followed by English translation)	5/1/2009	NS00059735	NS00059976	
PTX0257	Handwritten Journal, "[REDACTED] insert, cover, index, and journal pages 1-100 (Japanese followed by	7/1/2009	NS00059977	NS00060242	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0258	Handwritten Journal, "[REDACTED] cover, index, and journal pages 1-100 (Japanese followed by certified English translation)	5/31/2020	NS00060243	NS00060480	
PTX0259	[REDACTED] (Japanese) (metadata date created 1/27/2010, date modified 1/28/2010)	1/28/2010	NS00063643	NS00063654	
PTX0260	[REDACTED] document (certified English translation) (metadata date created 1/27/2010, date modified 1/28/2010)	1/28/2010	NS00063643	NS00063654	
PTX0261	"[REDACTED] (Japanese)	2/17/2010	NS00061181	NS00061182	
PTX0262	"[REDACTED] (certified English translation)	2/17/2010	NS00061181	NS00061183	
PTX0263	Nippon Shinyaku Co., Ltd. and NS Pharma, Inc.'s Notice of Deposition of Sarepta Therapeutics Pursuant to Fed. R. Civ. P. 30(b)(6), Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics Inc., No. 21-1015 (D. Del. April 12, 2023)	4/12/2023	NONE	NONE	
PTX0264	Nippon Shinyaku Co., Ltd. and NS Pharma, Inc.'s Notice to Take Depositions, Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics Inc., No. 21-1015 (ECF No. 277) (D. Del. July 24, 2023)	7/24/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0265	Declaration of Fred Schnell, "In the matter of European patent no. 2206781 to The University of Western Australia and opposition thereto by Nippon Shinyaku Co., Ltd." executed on September 28, 2017	9/28/2017	NONE	NONE	
PTX0266	LinkedIn Web Biography of Fred Schnell 2nd, Director, Business Development - Sarepta Therapeutics (viewed on July 19, 2023 11:29 AM)	7/19/2023	NONE	NONE	
PTX0267	Email thread from Peter Sazani to Ryszard Kole, Rick Bestwick, Dan Mourich, Hong Moulton, Subject: "[REDACTED] of research activities at AVI-NC	9/16/2008	SRPT-VYDS-0227383	SRPT-VYDS-0227407	
PTX0268	Provisional Application for Patent Cover Sheet, Inventors: Peter Sazani and Richard Kole, Docket Number 50450-8090, "Multiple Exon Skipping Compositions for DMD"	10/24/2008	NONE	NONE	
PTX0269	Email message from Peter Sazani to Ryszard Kole, Subject: "[REDACTED], November 18, 2008 attachment "[REDACTED]	10/18/2008	SRPT-VYDS-0227370	SRPT-VYDS-0227378	
PTX0270	Sequence Listing and Design Drawing ([REDACTED] Document Date 10/23/2009) first document entitled: "[REDACTED] presentation deck (metadata date created 11/4/2009, date modified 11/4/2009	11/4/2009	SRPT-VYDS-0227277	SRPT-VYDS-0227314	
PTX0271	Email message from Diane Frank to Ed Kaye, Subject: "[REDACTED] June 8, 2012	6/8/2012	SRPT-VYDS-0214702	SRPT-VYDS-0214702	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0272	European Commission, Directorate-General for Research & Innovation, SP1-Cooperation, Collaborative project, Small or medium-scale focused research project, FP7-HEALTH-2012-INNOVATION-1, Grant Agreement Number 305370, SKIP-NMD, and cover letter dated November 16, 2012 "Seventh Framework Programme, Grant Agreement No 305370, Project Title SKIP-NMD, Collaborative project, Small or medium-scale focused research project" between The European Union and University College London, November 16, 2012	11/16/2012	SRPT-VYDS-0206708	SRPT-VYDS-0206869	
PTX0273	Email thread from Diane Frank to Laine Cowan, Chris Garabedian, Ed Kaye, Peter Sazani, Rick Bestwick, Subject: "[REDACTED]" [REDACTED] July 31, 2012	7/31/2012	SRPT-VYDS-0215436	SRPT-VYDS-0215438	
PTX0274	Email message from Diane Frank to Chris Garabedian, Subject: "[REDACTED]" [REDACTED] September 7, 2012	9/7/2012	SRPT-VYDS-0213900	SRPT-VYDS-0213900	
PTX0275	Handwritten Journal, "00579, Bothell-Diane Frank Bo" Avi BioPharma Stock Books, September 12, 2012	9/12/2012	SRPT-VYDS-0164361	SRPT-VYDS-0164584	
PTX0276	Handwritten Journal, "00577, BL #3, Bothell-Brain Leppert" Avi BioPharma Stock Books, 12/2011 to 10/2012 (last entry dated 10/17/2012)	10/17/2012	SRPT-VYDS-0163913	SRPT-VYDS-0164136	
PTX0277	Handwritten Journal, "[REDACTED]" [REDACTED], excerpts from F. Schnell's general lab notebook	8/19/2013	SRPT-VYDS-0227457	SRPT-VYDS-0227480	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0278	Declaration of Fred Schnell, "In the matter of Appeal No. T518/18, European patent no. 2206781 to The University of Western Australia and opposition thereto by Nippon Shinyaku Co., Ltd." executed on April 25, 2018	4/25/2018	NONE	NONE	
PTX0279	Handwritten Journal, "Sarepta Therapeutics, [REDACTED] Eureka Lab Book, Inc.	9/27/2022	SRPT-VYDS-0227441	SRPT-VYDS-0227456	
PTX0280	WIPO International Application Number PCT/JP2011/070318, Application Number JP2010-196032, Filing Date September 1, 2010, International Filing Date, August 31, 2011 (Japanese)	9/1/2010	SRPT-VYDS-0076874	SRPT-VYDS-0076917	
PTX0281	Email thread between Fred Schnell and Emily Naughton, Navid Khan, Pratik Parikh, Olga Mitelman, Baoguang Han, Diane Frank (cc Ashish Dugar) Subject: "RE: [REDACTED] October 9-10, 2018, attaching [REDACTED] presentation deck	10/10/2018	SRPT-VYDS-0185379	SRPT-VYDS-0185456	
PTX0282	National Library of Medicine, Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) (ESSENCE), Study record dates, last update posted 2023-02-21	2/21/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0283	Diane E. Frank et al., "Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy," Nat. Library of Medicine (Mar. 5, 2020)	3/5/2020	NONE	NONE	
PTX0284	Dominic Scaglioni et al., "The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy," 9:7 Acta Neuropathological Communications (2021)	1/6/2021	NONE	NONE	
PTX0285	Email message from Erin O'Rourke to Lisa Borland, Karin Lucas, Joseph Rutkowski, Fred Schnell, Elizabeth Smyth, Charles Wajszczuk, Susan Miziniak (cc Olga Mitelman) Subject: "[REDACTED] attaching Switch related Questions, Answers, Messages 3.17.19.docx, March 18, 2019	3/18/2019	SRPT-VYDS-0188841	SRPT-VYDS-0188844	
PTX0286	Sarepta Therapeutics, [REDACTED] [REDACTED] presentation deck, date created 10/10/2018	10/10/2018	SRPT-VYDS-0185037	SRPT-VYDS-0185112	
PTX0287	Sarepta Therapeutics, [REDACTED] [REDACTED] presentation deck	3/8/2019	SRPT-VYDS-0188532	SRPT-VYDS-0188536	
PTX0288	Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s Notice of Deposition of University of Western Australia Pursuant to Fed. R. Civ. P. 30(b)(6)	5/24/2023	NONE	NONE	
PTX0289	The University of Western Australia's Responses and Objections to Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s Rule 30(b)(6) Notice of Deposition	7/14/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0290	Memorandum Opinion and Special Master Order #5, Nippon Shinyaku, Ltd., v. Sarepta Therapeutics, Inc. (D. Del. Sept. 7, 2023)	9/7/2023	NONE	NONE	
PTX0291	"Exclusive License Agreement," between The University of Western Australia and AVI BioPharma, Inc., entered into on November 24, 2008	11/24/2008	UWA0000015	UWA0000046	
PTX0292	Email thread between Abbie Adams to Steve Wilton Subject: Some Images, sent 6/13/2008	6/13/2008	WILTON0002434	WILTON0002434	
PTX0293	Email from Simon Handford to Ryszard Kole, Richard Bestwick, Steve Wilton, Andrew Sierakowski, Subject: Happy New Year..., sent 1/13/2010	1/13/2010	UWA0001127	UWA0001127	
PTX0294	Email from Abbie Adams to Steve Wilton Subject: Some Images, sent 6/13/2008	6/13/2008	WILTON0002432	WILTON0002432	
PTX0295	Images: C57 mouse, 4 weeks treatment measuring Zenon Alexa Fluor 488, Picro Mallory Trichrome stain, Hematoxylin and eosin stain	6/13/2008	WILTON0002433	WILTON0002433	
PTX0296	"[REDACTED]"	6/19/2016	SRPT-VYDS-0154890	SRPT-VYDS-0154894	
PTX0297	C57 Mouse 4 Weeks Treatment with M52 and M53 removals	3/27/2008	WILTON0001725	WILTON0001725	
PTX0298	Email from Steve Wilton to Abbie Adams and Penny Meloni, attaching 12 AOs list cited, sent on 4/24/2008	4/24/2008	WILTON0002168	WILTON0002168	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0299	"Intellectual Property Assignment & Revenue Sharing Agreement," between The University of Western Australia and Dr. Steve Wilton, Dr. Sue Fletcher, and Mr. Graham McClorey, dated February 17, 2009	2/17/2009	UWA0000047	UWA0000050	
PTX0300	Email from Abbie Adams to Steve Wilton Subject: [REDACTED] sent 3/27/2008	3/27/2008	WILTON0001724	WILTON0001724	
PTX0301	Email from UWA Postmaster to Steve Wilton Subject: Delivery Status Notification (failure), sent 4/24/2008	4/24/2008	WILTON0002167	WILTON0002167	
PTX0302	Muscular Dystrophy Association, "Caregiver Support Across the Multidisciplinary Care Continuum" available at https://mdaquest.org (on-demand webinar release date March 5, 2021, expiration date February 14, 2022)	3/5/2021	NONE	NONE	
PTX0303	Memo from State of California-Health and Human Services Agency, Department of Health Care Services to "All California Children Services Program County Administrators, Medical Consultants, Genetically Handicapped Person Program staff and Integrated Systems of Care Division Staff" Subject "Antisense Oligonucleotide Treatment of Duchenne Muscular Dystrophy" dated	12/8/2020	NS00143179	NS00143184	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0304	Memo from State of California-Health and Human Services Agency, Department of health Care Services to "All California Children Services Program County Administrators, Medical Consultants, Genetically Handicapped Person Program staff and Integrated Systems of Care Division Staff" Subject "Antisense Oligonucleotide Treatment of Duchenne Muscular Dystrophy" dated May 25, 2021	5/25/2021	NONE	NONE	
PTX0305	Alex J. Fay et al., "Targeted Treatments for Inherited Neuromuscular Diseases of Childhood," 40(3) Semin. Neurol. (June 2020) (e-published dated April 14, 2020)	4/15/2020	NONE	NONE	
PTX0306	NS Pharma "Viltepso (viltolarsen) [REDACTED] for [REDACTED]" Presentation Deck (metadata date created 1/25/2022, date modified 1/26/2022)	1/26/2022	NS00041668	NS00041711	
PTX0307	University of California San Francisco, Benioff Children's Hospitals, "Provider Stories: Jonathan Strober" web page, accessed November 13, 2023 at 8:38 AM EST	11/13/2023	NONE	NONE	
PTX0308	Highlights of Prescribing Information for VYONDYS 53 (golodirsen) injection, for intravenous use, revised 2/2021	2/1/2021	SRPT-VYDS-0006978	SRPT-VYDS-0006990	
PTX0309	Laurent Servais et al., "Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial," 32(1) Nucleic Acid Therapeutics 29-39 (Nov. 17, 2021) (e-published date November 17, 2021)	11/17/2021	SRPT-VYDS-0229421	SRPT-VYDS-0229431	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0310	F. Muntoni et al., P147 "Six-year long-term safety and efficacy of Golodirsén in patients with DMD vs mutation-matched external controls, 33(1) Neuromuscular Disorders (Oct. 2023) presented at the 28th International Congress of the World Muscle Society, October 3-7, 2023, Charleston, SC"	10/3/2023	NONE	NONE	
PTX0311	J. Iff et al., "Delayed pulmonary progression in Golodirsén-treated patients with Duchenne muscular dystrophy vs mutation-matched external controls," 33(1) Neuromuscular Disorders (Oct. 2023) presented at the 28th International Congress of the World Muscle Society, October 3-7, 2023, Charleston, SC	10/3/2023	NONE	NONE	
PTX0312	FirstWord Pharma, "KOL Views Q&A: Leading expert puts Elevidys' missed confirmatory endpoint in perspective DMD" published November 7, 2023	11/7/2023	NONE	NONE	
PTX0313	Sarepta Therapeutics, "Patients can't wait for the next breakthrough in medical research. So neither will we." presentation deck, October 30, 2023	10/30/2023	NONE	NONE	
PTX0314	Email template Subject "[REDACTED] to discuss VILTEPSO (viltolarsen)," (metadata date created 10/22/201, date modified 10/22/2021)	10/22/2021	NS00041484	NS00041487	
PTX0315	Sarepta's Notice of Rule 30(b)(1) Deposition of Stephen Sudovar , Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics Inc., No. 21-1015 (D. Del. July 14, 2023	7/14/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0316	NS Pharma, Viltepso (viltolarsen) injection, Viltepso [REDACTED] Steve Sudovar, Head, US Marketing" presentation deck (undated and no metadata)		NS00073341	NS00073368	
PTX0317	Email message from Lisa Bicknell (CDM New York) to Denise Quigley, Stephen Sudovar, Zafar Toor, Mohammed Nassar, Angela Shih, Nikkie Jones, Coleen Heaver, Amy Timney, Yahiza, Subject "[REDACTED]" with Attachments sent April 15, 2021	4/15/2021	NS00127938	NS00127940	
PTX0318	"[REDACTED], 02.26.2021, NS Pharma" presentation deck	2/26/2021	NS00127941	NS00127951	
PTX0319	"NS Pharma [REDACTED] July 14, 2021 6:30 PM - 8:30 PM ET" presentation deck	7/14/2021	NS00059145	NS00059230	
PTX0320	"NS Pharma, Viltepso® [REDACTED] Viltepso (viltolarsen) injection" presentation deck dated 08/2022 (metadata date created 8/9/2022, date modified 8/9/2022)	8/9/2022	NS00043395	NS00043422	
PTX0321	"Viltepso (viltolarsen) injection, For Healthcare Professionals", "Efficacy & Safety" available at https://www.viltepso.com/hcp/efficacy-and-safety/#efficacy-section-header-hcp , 04/2023	4/1/2023	NONE	NONE	
PTX0322	(Document Produced in Native Format) Excel workbook with three worksheets: Sheet 1, Discontinued, Unable to Convert, file name "Copy of Patient List for Randy 11.01 (version 1).xlsb.xlsx" (metadata date created 11/2/2021, date modified 11/22/2022)	11/22/2022	NS00074851	NS00074851	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0323	"Viltepso® 2020 [REDACTED] Viltepso, (viltolarsen) injection, NS Pharma" presentation deck (metadata date created 1/17/2013, date modified 1/30/2020)	1/30/2020	NS00097136	NS00097198	
PTX0324	Email thread from/to Stephen Sudovar, Mark Young, Brian Smith Subject: [REDACTED], with attachments, sent June 11, 16, 22, September 27, 28, October 5, 9, 2020	10/9/2020	NS00098489	NS00098492	
PTX0325	"Now Approved, Viltepso® (viltolarsen) injection, Getting to know VILTEPSO: A new treatment for Duchenne muscular dystrophy (DMD)" (metadata date created 8/22/2020, date modified 8/22/2020) brochure	8/22/2020	NS00098493	NS00098499	
PTX0326	"Getting Started, Viltepso® (viltolarsen) injection" brochure (metadata date created 8/22/2020, date modified 8/22/2020)	8/22/2020	NS00098500	NS00098508	
PTX0327	"Infusion Overview, Viltepso® (viltolarsen) injection" brochure (metadata date created 8/22/2020, date modified 8/22/2020)	8/22/2020	NS00098509	NS00098515	
PTX0328	"NS Support, NS Pharma Access Solutions, Helping to provide affordable access to Viltepso® (viltolarsen) injection, Options to make treatment more affordable" brochure 8/20 (metadata date created 8/27/2020, date modified 9/16/2020)	9/16/2020	NS00098516	NS00098523	
PTX0329	"NS Support, NS Pharma Access Solutions, Understanding Government-funded Health Insurance, A guide for patients with Duchenne muscular dystrophy and those who care for them" 8/20 (metadata date created 8/28/2020, date modified 8/28/2020) brochure	8/28/2020	NS00098524	NS00098537	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0330	NS Pharma Duchenne Muscular Dystrophy (DMD) [REDACTED] September 14, 2021, NS Pharma presentation deck	9/14/2021	NS00057439	NS00057508	
PTX0331	Email message from Nikkie Jones to Stephen Sudovar (cc Genie Go, Batool Kazmi, Amy Timney, Lisa Bicknell) Subject: [REDACTED] with attachment, sent [REDACTED]	3/19/2021	NS00128010	NS00128010	
PTX0332	"[REDACTED] Viltepso [REDACTED] v1, 3-19-21" report (metadata date created 3/20/2021, date modified 3/20/2021)	3/20/2021	NS00128011	NS00128025	
PTX0333	Email message from Michael Falcicchio to Stephen Sudovar, Stephanie Soto, Denise Quigley (cc to Batool Kazmi, Jason Wong, Charles Dixon) Subject: Viltepso [REDACTED] sent 1/9/2020	1/9/2020	NS00132160	NS00132160	
PTX0334	"Viltepso [REDACTED] January 9, 2020, Viltepso (viltolarsen) injection" presentation deck (metadata date create 1/17/2013, date modified 1/10/2020)	1/10/2020	NS00132161	NS00132212	
PTX0335	Email message from Brent Higgins to Stephen Sudovar (cc to Denis Quigley, Rachel Hill) Subject: [REDACTED] January 15, 2021 with attachment, sent 1/15/2021	1/15/2021	NS00132664	NS00132664	
PTX0336	"NS Pharma, [REDACTED] Viltepso (viltolarsen) injection" presentation deck (metadata date created 4/13/2010, date modified 1/15/2021)	1/15/2021	NS00132665	NS00132706	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0337	Sarepta and UWA's Notice of Rule 30(b)(1) Deposition of Kazuchika Takagaki, Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics Inc., No. 21-1015 (D. Del. June 5, 2023)	6/5/2023	NONE	NONE	
PTX0338	Defendant/Counter-Plaintiffs Sarepta and UWA "Notice of Deposition of Plaintiffs Pursuant to Fed. R. Civ. P. 30(b)(6)" (D. Del. April 24, 2023) (certified Japanese)	4/24/2023	NONE	NONE	
PTX0339	Defendant/Counter-Plaintiffs Sarepta and UWA "Notice of Deposition of Plaintiffs Pursuant to Fed. R. Civ. P. 30(b)(6)" (D. Del. April 24, 2023) (English)	4/24/2023	NONE	NONE	
PTX0340	Patent Assignment Cover Sheet Obtained From USPTO Website For U.S. Patent Application Number 14,615,504	3/26/2013	NONE	NONE	
PTX0341	REMOVED DOCUMENT FROM LIST (DUPLICATE)	11/26/2020	NONE	NONE	
PTX0342	██████████ and Nippon Shinyaku Co., Ltd. ██████████ Agreement, from August 27, 2009 to March 31, 2010, dated August 27, 2009 (certified English Translation)	8/27/2009	NS00036935	NS00036947	
PTX0343	NS Pharma, Inc. ██████████ Agreement with Nippon Shinyaku Co., Ltd., effective date April 1, 2020, dated March 16, 2020 (Japanese)	3/16/2020	NS00065827	NS00065830	
PTX0344	NS Pharma, Inc. ██████████ Agreement with Nippon Shinyaku Co., Ltd., effective date April 1, 2020, dated March 16, 2020 (certified English Translation)	3/16/2020	NS00065827	NS00065830	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0345	"Duchenne muscular dystrophy (DMD) therapeutic agent - [REDACTED] August 24, 2011, Research and Development Headquarters" (Japanese) (metadata date created 8/19/2011, date modified 8/19/2011)	8/24/2011	NS00073716	NS00073743	
PTX0346	"Duchenne muscular dystrophy (DMD) therapeutic agent - [REDACTED] August 24, 2011, Research and Development Headquarters" (certified English translation) (metadata date created 8/19/2011, date modified 8/19/2011)	8/19/2011	NS00073716	NS00073743	
PTX0347	NS Pharma, Meeting with [REDACTED] March 18, 2022 presentation deck	3/18/2022	NS00036969	NS00036974	
PTX0348	"Viltepso [REDACTED] chart (Japanese) (metadata date created 11/26/2021, date modified 11/26/2021)	11/26/2021	NS00073427	NS00073427	
PTX0349	"Viltepso [REDACTED] chart (certified English translation) (metadata date created 11/26/2021, date modified 11/26/2021)	11/26/2021	NS00073427	NS00073427	
PTX0350	(Viltepso [REDACTED]) chart (Japanese) (metadata date created 11/26/2021, date modified 11/26/2021)	11/26/2021	NS00073426	NS00073426	
PTX0351	(Viltepso [REDACTED] chart (certified English translation) (metadata date created 11/26/2021, date modified 11/26/2021)	11/26/2021	NS00073426	NS00073426	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0352	"Exhibit A, Topic 71: The location of all facilities owned, leased, rented, maintained, or used by NS in the operation of its business concerning Viltepso and/or viltolarsen" document "NS00073522 at 524-525" in response to Notice of Deposition of Plaintiffs Pursuant to Fed. R. Civ. P. 30(b)(b) Topic 71	3/4/2022	NONE	NONE	
PTX0353	"Duchenne muscular dystrophy treatment," Eastern Drug Discovery Research Institute document (metadata date created 9/11/2009, date modified 9/11/2009) (Japanese)	9/11/2009	NS00085299	NS00085323	
PTX0354	"Duchenne muscular dystrophy treatment," Eastern Drug Discovery Research Institute document (metadata date created 9/11/2009, date modified 9/11/2009) (certified English translation)	9/11/2009	NS00085299	NS00085323	
PTX0355	"[REDACTED] October 15, 2019" document, Title of Invention, "Antisense Nucleic Acid Capable of Inducing exon 53 Skipping" (Japanese followed by	10/15/2009	NS00073536; NS00091091	NS00073542; NS00091105	
PTX0356	"[REDACTED] document (Japanese) (metadata date created 1/22/2013, date modified 1/22/2013)	1/22/2013	NS00073744	NS00073785	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0357	"[REDACTED] document (certified English translation) (metadata date created 1/22/2013, date modified 1/22/2013)	1/22/2013	NS00073744	NS00073785	
PTX0358	National Center of Neurology and Psychiatry and Nippon Shinyaku Co., Ltd., "Patent Joint Application Agreement," dated August 4, 2010 (Japanese followed by English Translation)	8/4/2010	NS00036957	NS00036965	
PTX0359	Akinori Nakamura and Shin'ichi Takeda, "Symposium: Clinicopathological aspects of neuromuscular disorders - A new horizon, Exon-skipping therapy for Duchenne muscular dystrophy," 29.4 Neuropathology 494-501 (Aug. 2009) ePublished date May 22, 2009	5/22/2009	NONE	NONE	
PTX0360	"2020.04.27, Chemicals Evaluation and Research Institute, Intellectual Property Division, Nippon Shinyaku, "Requesting a quote based on a detailed protocol," dated April 27, 2020 (Japanese)	4/27/2020	NS00145005	NS00145006	
PTX0361	"2020.04.27, Chemicals Evaluation and Research Institute, Intellectual Property Division, Nippon Shinyaku, "Requesting a quote based on a detailed protocol," (certified English translation) dated April 27, 2020	4/27/2020	NS00145005	NS00145006	
PTX0362	"Analysis of 2'-O-Me Antisense oligonucleotides in primary myoblasts, Protocol: Transfection" document (metadata parent document date 4/27/2020)	4/27/2020	NS00145007	NS00145010	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0363	"Analysis of PMO Antisense oligonucleotides in primary myoblasts, Protocol: A1. Transfection Method: <i>State of the Art 2003</i> ," document (metadata parent document date	4/27/2020	NS00145011	NS00145014	
PTX0364	Sarepta's Notice of Rule 30(b)(1) Deposition of Masaya Toda , Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics, Inc., No. 21-1015 (D. Del. June 16, 2023	6/16/2023	NONE	NONE	
PTX0365	Notice of Deposition of Plaintiffs Pursuant to Fed. R. Civ. P. 30(b)(6), Nippon Shinyaku Co., Ltd. V. Sarepta Therapeutics, Inc., No. 21-1015 (D. Del. Apr 24, 2023)	4/24/2023	NONE	NONE	
PTX0366	Notice of Deposition of Plaintiffs Pursuant to Fed. R. Civ. P. 30(b)(6), Nippon Shinyaku Co., Ltd. V. Sarepta Therapeutics, Inc., No. 21-1015 (D. Del. Apr 24, 2023) (certified Japanese translation)	4/24/2023	NONE	NONE	
PTX0367	LinkedIn Web Biography of Masaya Toda - Corporate Officer, Head of Licensing & Alliance Div. at Nippon Shinyaku Co. Ltd. (viewed 6/27/2023)	6/27/2023	NONE	NONE	
PTX0368	"03/23/2022, [REDACTED] dated 03/23/2022 (certified English translation)	3/23/2022	NS00090737	NS00090744	
PTX0369	" [REDACTED] " dated 03/23/2022 (Japanese)	3/23/2022	NS00090737	NS00090744	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0370	"NS Pharma, Inc. and [REDACTED] [REDACTED] Person in charge of international business," dated September 20, 2019 (English)	9/20/2019	NS00065810	NS00065821	
PTX0371	"[REDACTED] [REDACTED] Person in charge of international business," dated September 20, 2019 (Japanese followed by certified English translation)	9/20/2019	NS00065810	NS00065821	
PTX0372	"Memorandum of Understanding, Re: [REDACTED] [REDACTED] (Compound code: NS-065/NCNP-01) from Nippon Shinyaku Co., Ltd. to NS Pharma, Inc." effective date September 20, 2019 (English)	9/20/2019	NS00036888	NS00036892	
PTX0373	"Memorandum of Understanding, Re: [REDACTED] [REDACTED] (Compound code: NS-065/NCNP-01) from Nippon Shinyaku Co., Ltd. to NS Pharma, Inc." effective date September 20, 2019 (Japanese)	9/20/2019	NS00036888	NS00036892	
PTX0374	"[REDACTED] Agreement," between Nippon Shinyaku Co., Ltd., and NS Pharma, Inc., entered into April 1, 2020 (Japanese)	4/1/2020	NS00036893	NS00036908	
PTX0375	"Memorandum of Understanding," between Nippon Shinyaku Co., Ltd., and NS Pharma, Inc., entered into April 1, 2021, "Signed for Nippon Shinyaku Co., Ltd.," by Toru Nakai (English)	4/1/2021	NS00036966	NS00036967	
PTX0376	"Memorandum of Understanding," between Nippon Shinyaku Co., Ltd., and NS Pharma, Inc., entered into April 1, 2021 (Japanese)	4/1/2021	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0377	NS Pharma, Inc., "[REDACTED]" to Mr. Yoshihiko Makita, dated January 31, 2022 (English)	1/31/2022	NS00036968	NS00036968	
PTX0378	NS Pharma, Inc., "[REDACTED]" to Mr. Yoshihiko Makita, dated January 31, 2022 (Japanese)	1/31/2022	NONE	NONE	
PTX0379	NS Pharma, Inc., "[REDACTED]" to Mr. Yoshihiko Makita, dated January 30, 2023 (English)	1/30/2023	NS00091311	NS00091311	
PTX0380	"Memorandum of Understanding," between Nippon Shinyaku Co., Ltd., and NS Pharma, Inc., entered into April 1, 2023, "Signed for Nippon Shinyaku Co., Ltd.," by Yoshihiko Makita (English)	4/1/2023	NS00091314	NS00091315	
PTX0381	"Memorandum of the Pursuit of Litigation for Co-owned Patents," dated November 26, 2020 (Japanese followed by certified English translation)	11/26/2020	NONE	NONE	
PTX0382	"Agreement," between [REDACTED] and Nippon Shinyaku Co., Ltd. "regarding [REDACTED]" dated September 20, 2019 (Japanese followed by certified English translation)	9/20/2019	NS00036928	NS00036934	
PTX0383	"[REDACTED] Agreement for Viltolarsen, between Nippon Shinyaku Co., Ltd. and [REDACTED]" dated May 30, 2022 (English)	5/30/2022	NS00090510	NS00090566	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0384	"████████ Agreement for Viltolarsen, between Nippon Shinyaku Co., Ltd. and ██████████ ██████████" dated February 24, 2022 (English and Russian)	2/24/2022	NS00090573	NS00090696	
PTX0385	Nippon Shinyaku Co., Ltd. "██████████ ██████████" dated May 11, 2022 (English) (Document Produced in Native Format)	5/11/2022	NS00035822	NS00035825	
PTX0386	"██████████ ██████████, regarding "NS-065," dated 2/6/2013 (certified English translation) (Document Produced in Native Format)	2/6/2013	NS00065602	NS00065602	
PTX0387	"██████████ ██████████, regarding "NS-065," dated 2/6/2013 (Japanese)	2/6/2013	NS00065602	NS00065602	
PTX0388	"Development Evaluation Conference I (Japan) and Development Council (USA) Review Items/Clinical Phase NS-065 (Duchenne Muscular Dystrophy Treatment) Development Matter," dated January 20, 2016 (certified English translation)	1/20/2016	NS00065748	NS00065764	
PTX0389	"Development Evaluation Conference I (Japan) and Development Council (USA) Review Items/Clinical Phase NS-065 (Duchenne Muscular Dystrophy Treatment) Development Matter," dated January 20, 2016 (Japanese)	1/20/2016	NS00065748	NS00065764	
PTX0390	Email from Kazuchika Takagaki to Kazuya Mori (cc Naoki Watanabe), Subject: "Re: ██████████ ██████████" sent December 17, 2013 (certified English translation)	12/17/2013	NS00076613	NS00076614	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0391	Email from Kazuchika Takagaki to Kazuya Mori (cc Naoki Watanabe), Subject: "[REDACTED] [REDACTED], " sent December 17, 2013 (Japanese)	12/17/2013	NS00076613	NS00076614	
PTX0392	"NS-065 [REDACTED] Memo with [REDACTED], Date and time: December 17, 2013 8:30AM to 10:30AM <Japan Time>, December 16, 18:30PM to 20:30PM <US Time>" (metadata date created 12/17/2013, date modified 12/17/2013) (certified English translation)	12/17/2013	NS00076615	NS00076620	
PTX0393	"NS-065 [REDACTED] Memo with [REDACTED]" Date and time: December 17, 2013 8:30AM to 10:30AM <Japan Time>, December 16, 18:30PM to 20:30PM <US Time>" (metadata date created 12/17/2013, date modified 12/17/2013) (Japanese)	12/17/2013	NS00076615	NS00076619	
PTX0394	Email from k.kameyama@po.nippon-shinyaku.co.jp to Carol Pohlod @avibio.com (cc k.itabashi, m.toda, h.osaki), Subject "Re: [REDACTED] Follow-up" sent January 24, 2011 (English)	1/24/2011	SRPT-VYDS-0222101	SRPT-VYDS-0222102	
PTX0395	Email from k.kameyama@po.nippon-shinyaku.co.jp to Carol Pohlod @avibio.com (cc k.itabashi, m.toda, h.osaki), Subject "Re: [REDACTED]" sent January 24, 2011 (Japanese)	1/24/2011	SRPT-VYDS-0222101	SRPT-VYDS-0222102	
PTX0396	Email thread between Matthew Gall @Sarepta.com and m.toda@po.nippon-shinyaku.co.jp (cc s.morimura, Bo Cumbo), Subject [REDACTED] [REDACTED] sent September 14 and 15, October 1, 7, 15 and 21, 2015 (English)	10/21/2015	SRPT-VYDS-0222265	SRPT-VYDS-0222274	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0397	Email thread between Matthew Gall @Sarepta.com and m.toda@po.nippon-shinyaku.co.jp (cc s.morimura, Bo Cumbo), Subject [REDACTED] sent September 14 and 15, October 1, 7, 15 and 21, 2015 (Japanese)	10/21/2015	SRPT-VYDS-0222265	SRPT-VYDS-0222274	
PTX0398	Email thread between m.toda@po.nippon-shinyaku.co.jp and Matthew Gall @Sarepta.com (cc Bo Cumbo, s.morimura), Subject "RE: [REDACTED]" sent November 4 and 30, 2015 (English)	11/30/2015	SRPT-VYDS-0222958	SRPT-VYDS-0222959	
PTX0399	Email thread between m.toda@po.nippon-shinyaku.co.jp and Matthew Gall @Sarepta.com (cc Bo Cumbo, s.morimura), Subject "RE: [REDACTED]" sent November 4 and 30, 2015 (Japanese)	11/30/2015	SRPT-VYDS-0222958	SRPT-VYDS-0222959	
PTX0400	Email thread between m.toda@po.nippon-shinyaku.co.jp and Matthew Gall @Sarepta.com (cc mgall), Subject [REDACTED] sent September 19 and 26, 2017 and October 3, 6, 7 and 13, 2017 (English)	10/13/2017	SRPT-VYDS-0222796	SRPT-VYDS-0222801	
PTX0401	Email thread between m.toda@po.nippon-shinyaku.co.jp and Matthew Gall @Sarepta.com (cc mgall), Subject [REDACTED] sent September 19 and 26, 2017 and October 3, 6, 7 and 13, 2017 (Japanese)	10/13/2017	SRPT-VYDS-0222796	SRPT-VYDS-0222801	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0402	Email thread between m.toda@po.nippon-shinyaku.co.jp and Matthew Gall @Sarepta.com, Subject "[REDACTED]" dated October 17, 26, 27 and 29, 2018 (English)	10/29/2018	SRPT-VYDS-0222970	SRPT-VYDS-0222972	
PTX0403	Email thread between m.toda@po.nippon-shinyaku.co.jp and Matthew Gall @Sarepta.com, Subject "[REDACTED]" dated October 17, 26, 27 and 29, 2018 (Japanese)	10/29/2018	SRPT-VYDS-0222970	SRPT-VYDS-0222972	
PTX0404	Email thread between m.toda@po.nippon-shinyaku.co.jp and Matthew Gall @Sarepta.com (cc Sandy Mahatme), Subject "Re: [REDACTED]" sent November 19 and December 5, 2018 (English)	12/5/2018	SRPT-VYDS-0223429	SRPT-VYDS-0223430	
PTX0405	Email thread between m.toda@po.nippon-shinyaku.co.jp and Matthew Gall @Sarepta.com (cc Sandy Mahatme), Subject "Re: [REDACTED]" sent November 19 and December 5, 2018 (Japanese)	12/5/2018	SRPT-VYDS-0223429	SRPT-VYDS-0223430	
PTX0406	Email message between m.toda@po.nippon-shinyaku.co.jp and Matthew Gall @Sarepta.com, Subject "Hello, Gall-san; from Masaya Toda (Nippon Shinyaku)" sent November 29, 2019 (English)	11/29/2019	SRPT-VYDS-0223159	SRPT-VYDS-0223159	
PTX0407	Email message between m.toda@po.nippon-shinyaku.co.jp and Matthew Gall @Sarepta.com, Subject "Hello, Gall-san; from Masaya Toda (Nippon Shinyaku)" sent November 29, 2019 (Japanese)	11/29/2019	SRPT-VYDS-0223159	SRPT-VYDS-0223159	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0408	Email thread between Masaya Toda and Matt Gall, Subject: "Re: [REDACTED] sent December 26, 27 and 31, 2019 and January 2, 2020 (English) "	1/2/2020	SRPT-VYDS-0223074	SRPT-VYDS-0223077	
PTX0409	Email thread between Masaya Toda and Matt Gall, Subject: "Re: [REDACTED] sent December 26, 27 and 31, 2019 and January 2, 2020 (Japanese) "	1/2/2020	SRPT-VYDS-0223074	SRPT-VYDS-0223077	
PTX0410	Email thread between Masaya Toda and Matt Gall (cc Amanda S. Williamson, Chris Verni), Subject: "Re: [REDACTED] btwn Sarepta and Nippon Shinyaku" sent February 25 and 26, March 25, 26, April 7, 23, 27, May 1 and 6, 2020 (English)	5/6/2020	SRPT-VYDS-0223099	SRPT-VYDS-0223106	
PTX0411	Email thread between Masaya Toda and Matt Gall (cc Amanda S. Williamson, Chris Verni), Subject: "Re: [REDACTED] btwn Sarepta and Nippon Shinyaku" sent February 25 and 26, March 25, 26, April 7, 23, 27, May 1 and 6, 2020 (Japanese)	5/6/2020	SRPT-VYDS-0223099	SRPT-VYDS-0223106	
PTX0412	Email thread between Masaya Toda, Joe Zenkus (cc Chris Verni) Subject: "RE: [REDACTED] sent May 25 and 31, June 1 and 14, July 6, 2021 (English) "	7/6/2021	SRPT-VYDS-0223211	SRPT-VYDS-0223214	
PTX0413	Email thread between Masaya Toda, Joe Zenkus (cc Chris Verni) Subject: "RE: [REDACTED] sent May 25 and 31, June 1 and 14, July 6, 2021 (Japanese) "	7/6/2021	SRPT-VYDS-0223211	SRPT-VYDS-0223214	
PTX0414	Organizational Chart, dated April 1, 2009 (Japanese)	4/1/2009	NS00073554	NS00073559	
PTX0415	Organizational Chart, dated April 1, 2009 (certified English translation)	4/1/2009	NS00073554	NS00073559	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0416	Handwritten Journal, "[REDACTED]" [REDACTED] [REDACTED] cover, index, and journal pages 1-120 (Japanese)	5/17/2011	NS00137981	NS00138039	
PTX0417	Handwritten Journal, "[REDACTED]" [REDACTED] [REDACTED] cover, index, and journal pages 1-120 (certified English translation)	5/17/2011	NS00137981	NS00138043	
PTX0418	(Document Produced in Native Format) Excel workbook with three worksheets entitled "[REDACTED]," Printout of "[REDACTED]" worksheet (metadata date created 2/28/2003, date modified 10/1/2010) (Japanese)	10/1/2010	NS00138040	NS00138040	
PTX0419	(Document Produced in Native Format) Excel workbook with three worksheets entitled "[REDACTED]," Printout of "[REDACTED]" worksheet (metadata date created 2/28/2003, date modified 10/1/2010) (Japanese followed by certified English translation)	10/1/2010	NS00138040	NS00138040	
PTX0420	Handwritten Journal, "[REDACTED]" [REDACTED] [REDACTED] cover, index, and journal pages 1-200 (Japanese followed by English translation)	7/29/2013	NS00074094	NS00074344	
PTX0421	REMOVED DOCUMENT FROM LIST (DUPLICATE)	8/31/2011	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0422	WIPO International Application Number PCT/JP2011/070318 (certified English translation)	8/31/2011	NONE	NONE	
PTX0423	" [REDACTED] " (metadata date created 6/17/2009, date modified 6/17/2009) (Japanese)	6/17/2009	NS00061035	NS00061035	
PTX0424	" [REDACTED] " (metadata date created 6/17/2009, date modified 6/17/2009) (certified English translation)	6/17/2009	NS00061035	NS00061035	
PTX0425	" [REDACTED] " (meta data date created 6/17/2009, date modified 6/17/2009) (Japanese)	6/17/2009	NS00061118	NS00061118	
PTX0426	" [REDACTED] " (meta data date created 6/17/2009, date modified 6/17/2009) (certified English translation)	6/17/2009	NS00061118	NS00061118	
PTX0427	" [REDACTED] " presentation deck (metadata date created 5/12/2009, date modified 7/8/2009) (Japanese)	7/8/2009	NS00061808	NS00061819	
PTX0428	" [REDACTED] " presentation deck (metadata date created 5/12/2009, date modified 7/8/2009) (certified English translation)	7/8/2009	NS00061808	NS00061819	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0429	"[REDACTED]" (metadata date created 7/30/2009, date modified 7/30/2009) (Japanese)	7/30/2009	NS00060995	NS00060995	
PTX0430	"[REDACTED]" (metadata date created 7/30/2009, date modified 7/30/2009) (certified English translation)	7/30/2009	NS00060995	NS00060995	
PTX0431	"[REDACTED]" (metadata date created 8/5/2009, date modified 8/6/2009) (Japanese)	8/6/2009	NS00061119	NS00061120	
PTX0432	"[REDACTED]" (metadata date created 8/5/2009, date modified 8/6/2009) (certified English translation)	8/6/2009	NS00061119	NS00061120	
PTX0433	"[REDACTED]" (metadata date created 8/18/2009, date modified 8/19/2009) (Japanese)	8/19/2009	NS00061106	NS00061107	
PTX0434	"[REDACTED]" (metadata date created 8/18/2009, date modified 8/19/2009) (certified English translation)	8/19/2009	NS00061106	NS00061107	
PTX0435	"[REDACTED]" (metadata date created 8/26/2009, date modified 8/26/2009) (Japanese)	8/26/2009	NS00061116	NS00061117	
PTX0436	"[REDACTED]" (metadata date created 8/26/2009, date modified 8/26/2009) (certified English translation)	8/26/2009	NS00061116	NS00061117	
PTX0437	Laboratory Notebook "[REDACTED]" [REDACTED] cover, index, and journal pages 1-197 (Japanese followed by certified English translation)	12/24/2009	NS00066456	NS00066668	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0438	Handwritten Journal, "[REDACTED] cover, index, and journal pages 29-42 (Japanese followed by English translation)	9/9/2016	NS00091284	NS00091309	
PTX0439	Murdoch University in Perth Australia Web Biography of Professor Steve Wilton PhD, BSc (Hons) Foundation Chair in Molecular Therapy (viewed on June 9, 2023 12:27 PM)	6/9/2023	NONE	NONE	
PTX0440	Francesco Muntoni et al., "128th ENMC International Workshop on 'Preclinical optimization and Phase I/II Clinical Trials Using Antisense Oligonucleotides in Duchenne Muscular Dystrophy' 22-24 October 2004, Naarden, The Netherlands," 15 Neuromuscular Disorders 450-457 (Feb. 18, 2005)	2/18/2005	NS00143623	NS00143630	
PTX0441	Australia Provisional Specification, Application No. 2004903474, patent by The University of Western Australia, filed on June	6/28/2004	NONE	NONE	
PTX0442	Email thread between Steve Wilton and Ryszard Kole, dated August 9 and 28, 2008	8/28/2008	WILTON0018621	WILTON0018624	
PTX0443	Email to Steve Wilton from Penny Harding, Subject: "Oligos for exon 53 (Penny)", sent November 16, 2004	11/16/2004	WILTON0026199	WILTON0026199	
PTX0444	Email thread between Steve Wilton and Francesco Muntoni, Subject "ENMC workshop on antisense", sent April 22, 2004, Nov. 30, 2004, Dec. 1, 2004 [SWilton-15]	12/1/2004	WILTON0026203	WILTON0026207	
PTX0445	Email thread between Steve Wilton and Francesco Muntoni, Subject "G'day", sent Dec. 15, 2004 and Dec. 20, 2004	12/20/2004	WILTON0026210	WILTON0026212	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0446	Handwritten Journal, "Laboratory Notebook, [REDACTED] " cover and pages 1-118	1/18/2005	SRPT-VYDS-0155714	SRPT-VYDS-0155832	
PTX0447	Email from Abbie Fall to Steve Wilton, Subject "[REDACTED]", sent 2/3/2005	2/3/2005	WILTON0026221	WILTON0026221	
PTX0448	Email thread between Steve Wilton and Francesco Muntoni (cc Jenny Morgan), Subject "RE: Exon 51 and 53 AOs", sent 26 May 2005	5/26/2005	WILTON0026261	WILTON0026262	
PTX0449	Handwritten Journal, "[REDACTED] Feint & Paged" (last entry not redacted is 2nd February 2006)	2/2/2006	SRPT-VYDS-0158109	SRPT-VYDS-0158290	
PTX0450	Email thread between Steve Wilton, Francesco Muntoni and Virginia Arechavala, Subject "RE: Exon 51 and 53 AOs", sent October 29 and 31, 2005	10/31/2005	WILTON0026297	WILTON0026298	
PTX0451	Email from Steve Wilton to Abbie Adams Subject: FW: exon 53 paper, sent 12/23/2008	12/23/2008	WILTON0012314	WILTON0012314	
PTX0452	Email thread between Steve Wilton and Neera Gulati (Suneel's mother), sent February 3, 2010	2/3/2010	WILTON0018419	WILTON0018423	
PTX0453	Email thread between Steve Wilton and Neera Gulati (Suneel's mother), sent May 17 & 25, 2010	5/25/2010	WILTON0017584	WILTON0017589	
PTX0454	Email thread between Steve Wilton and Neera Gulati (Suneel's mother), Subject "Re: Suneel's Light", July 24 & 28, 2010	7/28/2010	WILTON0018072	WILTON0018075	
PTX0455	Email thread between Steve Wilton and Neera Gulati (Suneel's mother), Subject "Re: Suneel's Light", sent July 24 & 30, 2010	7/30/2010	WILTON0017531	WILTON0017534	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0456	Email thread between Abby Bronson, Mike Gait, Eric Hoffman, Steve Wilton, (cc Francesco Muntoni, Matthew Wood), Subject "[REDACTED]" sent November 12, 14, 15, and 16, 2010	11/16/2010	WILTON0018079	WILTON0018086	
PTX0457	Email thread between Steve Wilton and Neera Gulati, Subject "[REDACTED]", sent February 28, 2011	2/28/2011	WILTON0017608	WILTON0017610	
PTX0458	Email thread between Steve Wilton and Francesco Muntoni, Subject "Sorry for delay. . .", October 6 and November 9, 2011	11/9/2011	WILTON0017886	WILTON0017888	
PTX0459	Email thread between Steve Wilton, Matthew JA Wood, Francesco Muntoni, and J. George Dickson, Subject "[REDACTED]", February 4 and 25, and March 2, 2011	3/2/2011	WILTON0018019	WILTON0018024	
PTX0460	Notice to Take Depositions, Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics Inc., No. 21-1015 (D. Del. July 11, 2023)	7/11/2023	NONE	NONE	
PTX0461	LinkedIn Web Biography of Ryan Wong, CPA, Vice President - Financial Strategy, Planning & Analysis and Treasurer at Sarepta Therapeutics, as of July 5, 2023	7/5/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0462	Email chain from Bo Cumbo to Brian Forsa, Todd Boutwell, Patrick Moss, Karin Helgaard, Joel Iff, (cc Alisha Nielsen, Compendia) Subject: "FW: Sarepta Therapeutics, Inc. - New Product Introduction: VYONDYS53 (golodirsen) injection," with attachments , sent December 13, 2019; Attachment, "RE: Introduction of VYONDYS 53TM (golodirsen) Single Dose Vial, Injection for IV Use" press release	12/13/2019	SRPT-VYDS-0220619 SRPT-VYDS-0220621 SRPT-VYDS-0220623 SRPT-VYDS-0220647 SRPT-VYDS-0220648 SRPT-VYDS-0220649	SRPT-VYDS-0220620 SRPT-VYDS-0220622 SRPT-VYDS-0220646 SRPT-VYDS-0220647 SRPT-VYDS-0220648 SRPT-VYDS-0220649	
PTX0463	"Supply and Services Agreement" between Sarepta Therapeutics, Inc. and [REDACTED] effective date May 1, 2019	5/1/2019	SRPT-VYDS-0213508 SRPT-VYDS-0213511	SRPT-VYDS-0213509 SRPT-VYDS-0213541	
PTX0464	Email message from Melinda Hurley to Bo Cumbo, Brian Forsa, Dan Madden, Doug Ingram, Joe Bratica, maria Tornsen, Melinda Hurley, Michael O'Neil, Patrick Moss, Sandy Mahatme, Subject: "[REDACTED] with attachment, "[REDACTED]" December 27, 2019	12/27/2019	SRPT-VYDS-0218928	SRPT-VYDS-0218935	
PTX0465	Email message from Jeremy Wright to Andrew Bauchman, Brian Forsa, Carlos Chacon, Dallan Murray, Dan Madden, Doug Ingram, Ian Estepan, Jessica Xu, Joe Bratica, Michael Maurer, Patrick Moss, Ryan Wong, Subject "[REDACTED]" attaching "[REDACTED]"	8/20/2021	SRPT-VYDS-0219258	SRPT-VYDS-0219270	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0466	Email message from Jeremy Wright to Brian Forsa, Dallan Murray, Dan Madden, Doug Ingram, Ian Estepan, Joe Bratica, Maria Tornsen, Melinda Hurley, Michael O'Neil, Patrick Moss, Subject "[REDACTED] attaching "[REDACTED]	1/12/2021	SRPT-VYDS-0219638	SRPT-VYDS-0219647	
PTX0467	Email message from Jeremy Wright to Andrew Bauchman, Brian Forsa, Carlos Chacon, Dallan Murray, Dan Madden, Doug Ingram, Ian Estepan, Jane Bendfeldt, Jessica Xu, Joe Bratica, Michael Maurer, Patrick Moss, Ryan Wong, Subject "[REDACTED] attaching "[REDACTED]	1/14/2022	SRPT-VYDS-0219798	SRPT-VYDS-0219805	
PTX0468	"[REDACTED] (metadata date created 4/6/2020, date modified 4/6/2020)	4/6/2020	SRPT-VYDS-0213320	SRPT-VYDS-0213322	
PTX0469	[REDACTED] (no metadata on this file)	9/1/2022	SRPT-VYDY-0208199	SRPT-VYDY-0208200	
PTX0470	Professor Matthew J.A. Wood, Short CV, submitted in connection with Interference Proceedings, prepared in 2014 (filed with PTAB in Patent Interference No. 106,007 on April 10, 2015)	4/10/2015	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0471	Highlights of Prescribing Information for AMONDYS 45 (casimersen) injection, for intravenous use, Revised 3/2023	3/1/2023	NONE	NONE	
PTX0472	Highlights of Prescribing Information for EXONDYS 51 (eteplirsen) injection, for intravenous use, revised 1/2022	1/1/2022	NONE	NONE	
PTX0473	Highlights of Prescribing Information for Vyondys 53 (golodirsen) injection, for intravenous use, revised 12/2019	12/1/2019	SRPT-VYDS-0232110	SRPT-VYDS-0232122	
PTX0474	Declaration of Matthew J.A. Wood, M.D., D. Phil., before the Patent Trial and Appeal Board in the matter of <i>University of Western Australia v. Academisch Ziekenhuis Leiden</i> , Interference Nos. 106,007, 106,008, & 106,013, executed on November 18, 2014	11/18/2014	NS00143268	NS00143451	
PTX0475	Linda J. Popplewell, et al., "Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials," 20.2 Neuromuscular Disorders 102-110 (Feb. 2010)	1/15/2010	SRPT-VYDS-0007688	SRPT-VYDS-0007701	
PTX0476	WO 2010/048586 A1	4/29/2010	NONE	NONE	
PTX0477	WIPO International Publication Number WO 2011/057350 A1, International Application No. PCT/AU20 20/00 1520, Wilton et al., "Antisense Molecules and Methods for Treating Pathologies," International Publication Date May 19, 2011	5/19/2011	SRPT-VYDS-0228438	SRPT-VYDS-0228539	
PTX0478	Notice to Take Depositions, Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics Inc., No. 21-1015 (D. Del. July 14, 2023)	7/14/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0479	Zenkus Depo Binder Section 01 - Document Recorded on December 10, 2018, and Certified on April 11, 2022 - Assignment of PCT/AU2005/000943 from Wilton, Fletcher and McClorey to UWA, effective as of June 28, 2004, and signed on May 11 and 13, 2010	5/13/2010	SRPT-VYDS-0211490	SRPT-VYDS-0211505	
PTX0480	Zenkus Depo Binder Section 02 - Document Recorded on January 17, 2008, and Certified on April 14, 2023 - "Patent Assignment Agreement" between SmithKline Beecham Corporation and UWA, entered into March 10, 2006	3/10/2006	SRPT-VYDS-0213812	SRPT-VYDS-0213826	
PTX0481	Depo Prep Binder Section 05 - "Exclusive License Agreement," between The University of Western Australia and Avi BioPharma, Inc. entered into on November 24, 2008	11/24/2008	SRPT-VYDS-0154831	SRPT-VYDS-0154862	
PTX0482	Depo Prep Binder Section 06 - "Amended and Restated Exclusive License Agreement," between The University of Western Australia and Sarepta Therapeutics and Sarepta International CV, effective as of November 24, 2008, and restatement date as of April 10, 2013	4/10/2013	SRPT-VYDS-0154863	SRPT-VYDS-0154889	
PTX0483	Depo Prep Binder Section 08 - "Appendix A, Patent Assignment Agreement" between SmithKline Beecham Corporation, dba GlaxoSmithKline and The University of Western Australia, entered into on March 10,	3/10/2006	SRPT-VYDS-0154895	SRPT-VYDS-0154901	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0484	Depo Prep Binder Section 09 - Letter to Mr. Simon Handford (UWA) from Sarepta regarding "Letter agreement b [REDACTED] ... with respect to the Amended Restated Exclusive License Agreement between Sarepta and UWA, effective as of November 24, 2008"	8/15/2013	SRPT-VYDS-0200990	SRPT-VYDS-0200991	
PTX0485	Depo Prep Binder Section 10 - "Services Agreement" between [REDACTED] effective September 11, 2013	9/11/2013	SRPT-VYDS-0207064	SRPT-VYDS-0207087	
PTX0486	Depo Prep Binder Section 14 - "Seventh Framework Programme, "Grant agreement for: Collaborative project" date November 10, 2014	11/10/2014	SRPTVYDS-0206934	SRPTVYDS-0207063	
PTX0487	"Amendment No. 2 to License Agreement" between Sarepta Therapeutics, Inc. and ST International Holdings Two, Inc. and BioMarin Leiden Holding BV, BioMarin Nederlands BV, and BioMarin Technologies BV, effective as of November 17, 2021	11/17/2021	SRPT-VYDS-0207178	SRPT-VYDS-0207237	
PTX0488	LinkedIn Web Profile for Joe Zenkus, Senior Vice President, Business Development and Strategic Alliances at Sarepta Therapeutics (captured on July 14, 2023)	7/14/2023	NONE	NONE	
PTX0489	"Amendment No. 1 to License Agreement," between Sarepta Therapeutics, Inc. and ST International Holdings Two, Inc. and BioMarin Leiden Holding BV, BioMarin Nederlands BV, and BioMarin Technologies BV, entered into on April 14, 2019	4/14/2019	SRPT-VYDS-0207088	SRPT-VYDS-0207091	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0490	"[REDACTED]"	11/1/2012	SRPT-VYDS-0206870	SRPT-VYDS-0206933	
PTX0491	"Non-Exclusive License Agreement" between Royal Holloway and Sarepta entered into on December 5, 2013	12/5/2013	SRPT-VYDS-0206683	SRPT-VYDS-0206707	
PTX0492	"License, Collaboration, and Option Agreement by and between Sarepta Therapeutics Three, LLC and F. Hoffmann-LaRoche Ltd, dated December 21, 2019"	12/21/2019	SRPT-VYDS-0204720	SRPT-VYDS-0204833	
PTX0493	Email chain from Masaya Toda to Bo Cumbo (cc Cheryl Roegner, M. Umehara) Subject: "RE: [REDACTED] and [REDACTED]" "Introduction" with Attachment "150106_Nipipon Shinyaku_Corporate profile.pdf" November 20, 2014 - January 8, 2015	1/8/2015	SRPT-VYDS-0222226	SRPT-VYDS-0222264	
PTX0494	Email thread from Masaya Toda to Joe Zenkus (cc Chris Verni, T. Edamitsu) Subject "RE: Draft note to NS" May 25 - June 9, 2021	6/9/2021	SRPT-VYDS-0223093	SRPT-VYDS-0223095	
PTX0495	Email message from Joe Zenkus to Masaya Toda (cc T. Edamitsu, Chris Verni) Subject: "follow-up" sent June 10, 2021	6/10/2021	SRPT-VYDS-0223092	SRPT-VYDS-0223092	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0496	Japanese Complaint filed by Sarepta against Nippon Shinyaku (Japanese followed by certified English translation) (filed in Japan on June 5, 2023)	6/5/2023	NONE	NONE	
PTX0497	Excerpt of Japanese Complaint filed by Sarepta against Nippon Shinyaku (Japanese followed by certified English translation) (filed in Japan on June 5, 2023)	6/5/2023	NONE	NONE	
PTX0498	Sarepta Therapeutics, Inc.'s Non-Infringement Contentions, served July 11, 2023	7/11/2023	NONE	NONE	
PTX0499	Exhibits A-1 to A-7 to Sarepta Therapeutics, Inc.'s Non-Infringement Contentions, served July 11, 2023	6/11/2023	NONE	NONE	
PTX0500	Sarepta's Supplemental Responses and Objections to NS's Interrogatories (Nos. 1-6, 8-23, 25-30, 32-34)	8/15/2023	NONE	NONE	
PTX0501	Sarepta and NS's Joint Claim Construction Brief for the NS Patents (D.I. 173)	3/20/2023	NONE	NONE	
PTX0502	Sarepta's Final Invalidity Contentions <u>PLUS Exhibits A-1 to A-6; B-1 to B-7</u>	7/11/2023	NONE	NONE	
PTX0503	NS's Amended Final Infringement Contentions	7/27/2023	NONE	NONE	
PTX0504	Second Amended Complaint for Breach of Contract, Declaratory Judgment of Patent Invalidity, and Patent Infringement	1/14/2022	NONE	NONE	
PTX0505	Sarepta's Second Amended Answer, Defenses, and Counterclaims to NS's Second Amended Complaint	8/16/2023	NONE	NONE	
PTX0506	Counter-Defendants' Answer to Counter-Plaintiffs' Amended Counterclaims	9/1/2023	NONE	NONE	
PTX0507	Counter-Defendants' Amended Answer to Counter-Plaintiffs' Counterclaims & New Counterclaims	8/16/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0508	2010/0130591 A1 ("591 Publication")	5/27/2010	SRPT-VYDS-0011122	SRPT-VYDS-0011320	
PTX0509	EP 2206781 A2	7/14/2010	NS00141250	NS00141365	
PTX0510	WO 2004/083432 A1, Van Ommen et al., "Modulation of Exon Recognition in Pre-mRNA by Interfering with the Secondary RNA Structure"	9/30/2004	SRPT-VYDS-0230074	SRPT-VYDS-0230144	
PTX0511	PCT Patent Publication No. WO 2006/000057	1/5/2006	SRPT-VYDS-0229639	SRPT-VYDS-0229760	
PTX0512	U.S. Patent Application Publication No. 2019/0292208 A1	9/26/2019	SRPT-VYDS-0006844	SRPT-VYDS-0006977	
PTX0513	"2.2 Introduction to Summary" Section of the Biologics License Application Submitted by Sarepta to the FDA for Golodirsen (metadata date modified 8/27/2018)	8/27/2018	SRPT-VYDS-0007014	SRPT-VYDS-0007015	
PTX0514	"2.6.1 Introduction" Section of the Biologics License Application Submitted by Sarepta to the FDA for Golodirsen (metadata date modified 12/19/2018)	12/19/2018	SRPT-VYDS-0007043	SRPT-VYDS-0007047	
PTX0515	Sarepta Therapeutics, Inc. Form 10-K (2021)	3/1/2022	NS00141999	NS00142290	
PTX0516	U.S. Patent Application Publication No. 2013/0211062 A1	8/15/2013	SRPT-VYDS-0010037	SRPT-VYDS-0010100	
PTX0517	Sarepta Profit Spreadsheet for [REDACTED]	9/30/2022	SRPT-VYDS-0208199	SRPT-VYDS-0208200	
PTX0518	Sarepta's Marketing and Full Prescribing Information for VYONDYS 53 (golodirsen)	2/1/2021	SRPT-VYDS-0212852	SRPT-VYDS-0212865	
PTX0519	VYONDYS 53 (golodirsen) Injection Dosing and Administration Guide	1/1/2020	SRPT-VYDS-0212977	SRPT-VYDS-0212988	
PTX0520	Sarepta's Marketing and Full Prescribing Information for VYONDYS 53 (golodirsen)	2/1/2021	SRPT-VYDS-0213053	SRPT-VYDS-0213081	
PTX0521	Second Amendment to Commercial Supply Agreement between [REDACTED] and [REDACTED]	7/18/2019	SRPT-VYDS-0213381	SRPT-VYDS-0213382	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0522	First Amendment to Commercial Supply Agreement between [REDACTED] and [REDACTED].	2/22/2019	SRPT-VYDS-0213393	SRPT-VYDS-0213403	
PTX0523	Fourth Amendment to Commercial Supply Agreement between [REDACTED] and [REDACTED].	9/2/2020	SRPT-VYDS-0213404	SRPT-VYDS-0213410	
PTX0524	Supply and Services Agreement between [REDACTED] and [REDACTED].	6/5/2019	SRPT-VYDS-0213411	SRPT-VYDS-0213444	
PTX0525	Email from M. Hurley to Bo Cumbo, et al. re: "Weekly Sales Summary 9/4/20"	9/4/2020	SRPT-VYDS-0218669	SRPT-VYDS-0218669	
PTX0526	VYONDYS 53 Weekly Sales Summary 2020 for January-September, Week 1, 2020 <i>(partially redacted)</i>	1/1/2020	SRPT-VYDS-0218670	SRPT-VYDS-0218678	
PTX0527	Email Thread between M. Hurley and Bo Cumbo, et al. re: "Weekly Sales Summary 8/28/20"	8/28/2020	SRPT-VYDS-0218679	SRPT-VYDS-0218680	
PTX0528	VYONDYS 53 Weekly Sales Summary 2020 for January-August, Week 4, 2020 <i>(partially redacted)</i>	1/1/2020	SRPT-VYDS-0218681	SRPT-VYDS-0218689	
PTX0529	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 8/21/20"	8/24/2020	SRPT-VYDS-0218690	SRPT-VYDS-0218690	
PTX0530	VYONDYS 53 Weekly Sales Summary 2020 for January-August, Week 3, 2020 <i>(partially redacted)</i>	1/1/2020	SRPT-VYDS-0218691	SRPT-VYDS-0218699	
PTX0531	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 8/28/20"	8/28/2020	SRPT-VYDS-0218700	SRPT-VYDS-0218700	
PTX0532	VYONDYS 53 Weekly Sales Summary 2020 for January-August, Week 4, 2020 <i>(partially redacted)</i>	1/1/2020	SRPT-VYDS-0218701	SRPT-VYDS-0218709	
PTX0533	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 8/14/20"	8/14/2020	SRPT-VYDS-0218710	SRPT-VYDS-0218710	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0534	VYONDYS 53 Weekly Sales Summary 2020 for January-August, Week 2, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218711	SRPT-VYDS-0218719	
PTX0535	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 8/6/20"	8/7/2020	SRPT-VYDS-0218720	SRPT-VYDS-0218720	
PTX0536	VYONDYS 53 Weekly Sales Summary 2020 for January-August, Week 1, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218721	SRPT-VYDS-0218729	
PTX0537	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 7/31/20"	7/31/2020	SRPT-VYDS-0218730	SRPT-VYDS-0218730	
PTX0538	VYONDYS 53 Weekly Sales Summary 2020 for January-July, Week 5, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218731	SRPT-VYDS-0218739	
PTX0539	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 7/24/20"	7/27/2020	SRPT-VYDS-0218740	SRPT-VYDS-0218740	
PTX0540	VYONDYS 53 Weekly Sales Summary 2020 for January-July, Week 4, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218741	SRPT-VYDS-0218749	
PTX0541	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary"	7/17/2020	SRPT-VYDS-0218750	SRPT-VYDS-0218750	
PTX0542	VYONDYS 53 Weekly Sales Summary 2020 for January-July, Week 3, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218751	SRPT-VYDS-0218759	
PTX0543	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 7/10/20"	7/10/2020	SRPT-VYDS-0218760	SRPT-VYDS-0218760	
PTX0544	VYONDYS 53 Weekly Sales Summary 2020 for January-July, Week 2, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218761	SRPT-VYDS-0218769	
PTX0545	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 7/2/20"	7/2/2020	SRPT-VYDS-0218770	SRPT-VYDS-0218770	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0546	VYONDYS 53 Weekly Sales Summary 2020 for January-July, Week 1, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218771	SRPT-VYDS-0218779	
PTX0547	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary"	6/28/2020	SRPT-VYDS-0218780	SRPT-VYDS-0218780	
PTX0548	VYONDYS 53 Weekly Sales Summary 2020 for January-June, Week 4, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218781	SRPT-VYDS-0218786	
PTX0549	Email from M. Hurley to B. Cumbo, et al. re: "Sales Summary 6/19/20"	6/22/2020	SRPT-VYDS-0218787	SRPT-VYDS-0218787	
PTX0550	VYONDYS 53 Weekly Sales Summary 2020 for January-June, Week 3, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218788	SRPT-VYDS-0218793	
PTX0551	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 6/12/20"	6/12/2020	SRPT-VYDS-0218794	SRPT-VYDS-0218794	
PTX0552	VYONDYS 53 Weekly Sales Summary 2020 for January-June, Week 2, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218795	SRPT-VYDS-0218800	
PTX0553	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 6/5/20"	6/5/2020	SRPT-VYDS-0218801	SRPT-VYDS-0218801	
PTX0554	VYONDYS 53 Weekly Sales Summary 2020 for January-June, Week 1, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218802	SRPT-VYDS-0218807	
PTX0555	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 5/29/20"	5/29/2020	SRPT-VYDS-0218808	SRPT-VYDS-0218808	
PTX0556	VYONDYS 53 Weekly Sales Summary 2020 for January-May, Week 4, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218809	SRPT-VYDS-0218814	
PTX0557	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 5/22/20"	5/22/2020	SRPT-VYDS-0218815	SRPT-VYDS-0218815	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0558	VYONDYS 53 Weekly Sales Summary 2020 for January-May, Week 3, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218816	SRPT-VYDS-0218821	
PTX0559	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 5/15/20"	5/15/2020	SRPT-VYDS-0218822	SRPT-VYDS-0218822	
PTX0560	VYONDYS 53 Weekly Sales Summary 2020 for January-May, Week 2, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218823	SRPT-VYDS-0218828	
PTX0561	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 5/8/20"	5/8/2020	SRPT-VYDS-0218829	SRPT-VYDS-0218829	
PTX0562	VYONDYS 53 Weekly Sales Summary 2020 for January-May, Week 1, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218830	SRPT-VYDS-0218835	
PTX0563	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary"	5/1/2020	SRPT-VYDS-0218836	SRPT-VYDS-0218836	
PTX0564	VYONDYS 53 Weekly Sales Summary 2020 for January-April, Week 5, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218837	SRPT-VYDS-0218842	
PTX0565	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 4/24/20"	4/24/2020	SRPT-VYDS-0218843	SRPT-VYDS-0218843	
PTX0566	VYONDYS 53 Weekly Sales Summary 2020 for January-April, Week 4, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218844	SRPT-VYDS-0218849	
PTX0567	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 4/17/20"	4/20/2020	SRPT-VYDS-0218850	SRPT-VYDS-0218850	
PTX0568	VYONDYS 53 Weekly Sales Summary 2020 for January-April, Week 3, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218851	SRPT-VYDS-0218856	
PTX0569	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary"	4/13/2020	SRPT-VYDS-0218857	SRPT-VYDS-0218857	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0570	VYONDYS 53 Weekly Sales Summary 2020 for January-April, Week 2, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218858	SRPT-VYDS-0218863	
PTX0571	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 4/3/2020"	4/5/2020	SRPT-VYDS-0218864	SRPT-VYDS-0218864	
PTX0572	VYONDYS 53 Weekly Sales Summary 2020 for January-April, Week 1, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218865	SRPT-VYDS-0218870	
PTX0573	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 3/27/20"	3/27/2020	SRPT-VYDS-0218871	SRPT-VYDS-0218871	
PTX0574	VYONDYS 53 Weekly Sales Summary 2020 for January-March, Week 4, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218872	SRPT-VYDS-0218874	
PTX0575	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 3/20/20"	3/20/2020	SRPT-VYDS-0218875	SRPT-VYDS-0218875	
PTX0576	VYONDYS 53 Weekly Sales Summary 2020 for January-March, Week 3, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218876	SRPT-VYDS-0218878	
PTX0577	Email Thread from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 3/13/30 [sic]"	3/13/2020	SRPT-VYDS-0218879	SRPT-VYDS-0218880	
PTX0578	VYONDYS 53 Weekly Sales Summary 2020 for January-March, Week 2, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218881	SRPT-VYDS-0218883	
PTX0579	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 3/13/30 [sic]"	3/13/2020	SRPT-VYDS-0218884	SRPT-VYDS-0218884	
PTX0580	VYONDYS 53 Weekly Sales Summary 2020 for January-March, Week 2, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218885	SRPT-VYDS-0218887	
PTX0581	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 3/6/20"	3/6/2020	SRPT-VYDS-0218888	SRPT-VYDS-0218888	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0582	VYONDYS 53 Weekly Sales Summary 2020 for January-March, Week 1, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218889	SRPT-VYDS-0218891	
PTX0583	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 2/28/20"	2/28/2020	SRPT-VYDS-0218892	SRPT-VYDS-0218892	
PTX0584	VYONDYS 53 Weekly Sales Summary 2020 for January-February, Week 4, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218893	SRPT-VYDS-0218895	
PTX0585	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary"	2/2/2020	SRPT-VYDS-0218896	SRPT-VYDS-0218896	
PTX0586	VYONDYS 53 Weekly Sales Summary 2020 for January-February, Week 3, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218897	SRPT-VYDS-0218899	
PTX0587	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 2/14/20"	2/20/2020	SRPT-VYDS-0218900	SRPT-VYDS-0218900	
PTX0588	VYONDYS 53 Weekly Sales Summary 2020 for January-February, Week 2, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218901	SRPT-VYDS-0218903	
PTX0589	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 2/7/20"	2/7/2020	SRPT-VYDS-0218904	SRPT-VYDS-0218904	
PTX0590	VYONDYS 53 Weekly Sales Summary 2020 for January-February, Week 1, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218905	SRPT-VYDS-0218907	
PTX0591	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 1/31/20"	2/2/2020	SRPT-VYDS-0218908	SRPT-VYDS-0218908	
PTX0592	VYONDYS 53 Weekly Sales Summary 2020 through January, Week 5, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218909	SRPT-VYDS-0218911	
PTX0593	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 1/24/20"	1/24/2020	SRPT-VYDS-0218912	SRPT-VYDS-0218912	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0594	VYONDYS 53 Weekly Sales Summary 2020 through January, Week 4, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218913	SRPT-VYDS-0218915	
PTX0595	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 1/17/20"	1/17/2020	SRPT-VYDS-0218916	SRPT-VYDS-0218916	
PTX0596	VYONDYS 53 Weekly Sales Summary 2020 through January, Week 3, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218917	SRPT-VYDS-0218919	
PTX0597	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 1/10/20"	1/13/2020	SRPT-VYDS-0218920	SRPT-VYDS-0218920	
PTX0598	VYONDYS 53 Weekly Sales Summary 2020 through January, Week 2, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218921	SRPT-VYDS-0218923	
PTX0599	Email from M. Hurley to B. Cumbo, et al. re: "Weekly Sales Summary 1/3/20"	1/6/2020	SRPT-VYDS-0218924	SRPT-VYDS-0218924	
PTX0600	VYONDYS 53 Weekly Sales Summary 2020 through January, Week 1, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0218925	SRPT-VYDS-0218927	
PTX0601	Email from C. Chacon to B. Forsa, et al. re: "Weekly Sales Summary"	7/16/2021	SRPT-VYDS-0218936	SRPT-VYDS-0218936	
PTX0602	VYONDYS 53 Weekly Sales Summary 2019 for January-July, Week 3, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0218937	SRPT-VYDS-0218941	
PTX0603	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary"	2/4/2022	SRPT-VYDS-0218942	SRPT-VYDS-0218942	
PTX0604	Weekly Gross Revenue Flash Report for Week 5 of 2021 (Jan. 31 - Feb. 4, 2021) (<i>partially redacted</i>)	2/4/2021	SRPT-VYDS-0218943	SRPT-VYDS-0218950	
PTX0605	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary"	2/11/2022	SRPT-VYDS-0218951	SRPT-VYDS-0218951	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0606	Weekly Gross Revenue Flash Report for Week 5 of 2021 (Jan. 31 - Feb. 4, 2021) (<i>partially redacted</i>)	2/4/2021	SRPT-VYDS-0218952	SRPT-VYDS-0218959	
PTX0607	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary"	2/18/2022	SRPT-VYDS-0218960	SRPT-VYDS-0218960	
PTX0608	Weekly Gross Revenue Flash Report for Week 7 of 2022 (Feb. 14-18, 2022) (<i>partially redacted</i>)	2/18/2022	SRPT-VYDS-0218961	SRPT-VYDS-0218968	
PTX0609	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary 3/4/22"	3/4/2022	SRPT-VYDS-0218969	SRPT-VYDS-0218969	
PTX0610	Weekly Gross Revenue Flash Report for Week 9 of 2022 (Feb. 28 - Mar. 4, 2022) (<i>partially redacted</i>)	3/4/2022	SRPT-VYDS-0218970	SRPT-VYDS-0218977	
PTX0611	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary 3/11/22"	3/11/2022	SRPT-VYDS-0218978	SRPT-VYDS-0218978	
PTX0612	Weekly Gross Revenue Flash Report for Week 10 of 2022 (Mar. 7-11, 2022) (<i>partially redacted</i>)	3/11/2022	SRPT-VYDS-0218979	SRPT-VYDS-0218986	
PTX0613	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary 3/25/22"	3/25/2022	SRPT-VYDS-0218987	SRPT-VYDS-0218987	
PTX0614	Weekly Gross Revenue Flash Report for Week 12 of 2022 (Mar. 21-25, 2022) (<i>partially redacted</i>)	3/25/2022	SRPT-VYDS-0218988	SRPT-VYDS-0218995	
PTX0615	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary 4/1/22"	4/1/2022	SRPT-VYDS-0218996	SRPT-VYDS-0218996	
PTX0616	Weekly Gross Revenue Flash Report for Week 12 of 2022 (Mar. 28 - Apr. 1, 2022) (<i>partially redacted</i>)	4/1/2022	SRPT-VYDS-0218997	SRPT-VYDS-0219005	
PTX0617	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary"	4/8/2022	SRPT-VYDS-0219006	SRPT-VYDS-0219006	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0618	Weekly Gross Revenue Flash Report for Week 13 of 2022 (Apr. 4-8, 2022) (<i>partially redacted</i>)	4/8/2022	SRPT-VYDS-0219007	SRPT-VYDS-0219015	
PTX0619	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary 4/22/22"	4/22/2022	SRPT-VYDS-0219016	SRPT-VYDS-0219016	
PTX0620	Weekly Gross Revenue Flash Report for Week 16 of 2022 (Apr. 18-22, 2022) (<i>partially redacted</i>)	4/22/2022	SRPT-VYDS-0219017	SRPT-VYDS-0219025	
PTX0621	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary 4/29/22"	4/29/2022	SRPT-VYDS-0219026	SRPT-VYDS-0219026	
PTX0622	Weekly Gross Revenue Flash Report for Week 16 of 2022 (Apr. 25-29, 2022) (<i>partially redacted</i>)	4/29/2022	SRPT-VYDS-0219027	SRPT-VYDS-0219035	
PTX0623	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary"	12/27/2021	SRPT-VYDS-0219036	SRPT-VYDS-0219036	
PTX0624	VYONDYS 53 Weekly Sales Report for January-December, Week 4, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219037	SRPT-VYDS-0219047	
PTX0625	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary"	12/17/2021	SRPT-VYDS-0219048	SRPT-VYDS-0219048	
PTX0626	VYONDYS 53 Weekly Sales Report for January-December, Week 3, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219049	SRPT-VYDS-0219059	
PTX0627	Email from J. Wright to A. Bauchman, et al. re: "Gross Sales Updates"	12/20/2021	SRPT-VYDS-0219060	SRPT-VYDS-0219060	
PTX0628	VYONDYS 53 Weekly Sales Report for January-December, Week 3, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219061	SRPT-VYDS-0219071	
PTX0629	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary 12/10/21"	12/10/2021	SRPT-VYDS-0219072	SRPT-VYDS-0219072	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0630	VYONDYS 53 Weekly Sales Report for January-December, Week 2, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219073	SRPT-VYDS-0219084	
PTX0631	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary"	12/3/2021	SRPT-VYDS-0219085	SRPT-VYDS-0219085	
PTX0632	VYONDYS 53 Weekly Sales Report for January-December, Week 1, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219086	SRPT-VYDS-0219096	
PTX0633	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary"	11/24/2021	SRPT-VYDS-0219097	SRPT-VYDS-0219097	
PTX0634	VYONDYS 53 Weekly Sales Report for January-November, Week 4, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219098	SRPT-VYDS-0219109	
PTX0635	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary"	11/19/2021	SRPT-VYDS-0219110	SRPT-VYDS-0219110	
PTX0636	VYONDYS 53 Weekly Sales Report for January-November, Week 3, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219111	SRPT-VYDS-0219122	
PTX0637	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary 11/5/2021"	11/5/2021	SRPT-VYDS-0219123	SRPT-VYDS-0219123	
PTX0638	VYONDYS 53 Weekly Sales Report for January-November, Week 1, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219124	SRPT-VYDS-0219135	
PTX0639	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary 10/29"	10/29/2021	SRPT-VYDS-0219136	SRPT-VYDS-0219136	
PTX0640	VYONDYS 53 Weekly Sales Report for January-October, Week 5, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219137	SRPT-VYDS-0219148	
PTX0641	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary"	10/22/2021	SRPT-VYDS-0219149	SRPT-VYDS-0219149	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0642	VYONDYS 53 Weekly Sales Report for January-October, Week 4, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219150	SRPT-VYDS-0219161	
PTX0643	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary"	10/15/2021	SRPT-VYDS-0219162	SRPT-VYDS-0219162	
PTX0644	VYONDYS 53 Weekly Sales Report for January-October, Week 3, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219163	SRPT-VYDS-0219174	
PTX0645	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary"	10/8/2021	SRPT-VYDS-0219175	SRPT-VYDS-0219175	
PTX0646	VYONDYS 53 Weekly Sales Report for January-October, Week 2, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219176	SRPT-VYDS-0219185	
PTX0647	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary 10/1/2021"	10/1/2021	SRPT-VYDS-0219186	SRPT-VYDS-0219186	
PTX0648	VYONDYS 53 Weekly Sales Report for January-October, Week 1, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219187	SRPT-VYDS-0219197	
PTX0649	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary 9/24/21"	9/24/2021	SRPT-VYDS-0219198	SRPT-VYDS-0219198	
PTX0650	VYONDYS 53 Weekly Sales Report for January-October, Week 4, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219199	SRPT-VYDS-0219209	
PTX0651	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary 9/17"	9/17/2021	SRPT-VYDS-0219210	SRPT-VYDS-0219210	
PTX0652	VYONDYS 53 Weekly Sales Report for January-September, Week 3, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219211	SRPT-VYDS-0219221	
PTX0653	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary"	9/10/2021	SRPT-VYDS-0219222	SRPT-VYDS-0219222	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0654	VYONDYS 53 Weekly Sales Report for January-September, Week 2, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219223	SRPT-VYDS-0219233	
PTX0655	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary 9/3"	9/3/2021	SRPT-VYDS-0219234	SRPT-VYDS-0219234	
PTX0656	VYONDYS 53 Weekly Sales Report for January-September, Week 1, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219235	SRPT-VYDS-0219245	
PTX0657	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary"	8/27/2021	SRPT-VYDS-0219246	SRPT-VYDS-0219246	
PTX0658	VYONDYS 53 Weekly Sales Report for January-August, Week 4, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219247	SRPT-VYDS-0219257	
PTX0659	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary" (<i>partially redacted</i>)	8/13/2021	SRPT-VYDS-0219271	SRPT-VYDS-0219272	
PTX0660	VYONDYS 53 Weekly Sales Report for January-August, Week 2, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219273	SRPT-VYDS-0219283	
PTX0661	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary 8/6/21"	8/6/2021	SRPT-VYDS-0219284	SRPT-VYDS-0219284	
PTX0662	VYONDYS 53 Weekly Sales Report for January-August, Week 1, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219285	SRPT-VYDS-0219295	
PTX0663	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary 7/30/21"	7/30/2021	SRPT-VYDS-0219296	SRPT-VYDS-0219296	
PTX0664	VYONDYS 53 Weekly Sales Report for January-July, Week 5, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219297	SRPT-VYDS-0219307	
PTX0665	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales 7/23"	7/23/2021	SRPT-VYDS-0219308	SRPT-VYDS-0219308	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0666	VYONDYS 53 Weekly Sales Report for January-July, Week 4, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219309	SRPT-VYDS-0219320	
PTX0667	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Report 7/9"	7/9/2021	SRPT-VYDS-0219321	SRPT-VYDS-0219321	
PTX0668	VYONDYS 53 Weekly Sales Report for January-July, Week 2, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219322	SRPT-VYDS-0219333	
PTX0669	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Report 7/2/21"	7/2/2021	SRPT-VYDS-0219334	SRPT-VYDS-0219334	
PTX0670	VYONDYS 53 Weekly Sales Report for January-July, Week 1, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219335	SRPT-VYDS-0219345	
PTX0671	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Report 6/25/21"	6/25/2021	SRPT-VYDS-0219346	SRPT-VYDS-0219346	
PTX0672	VYONDYS 53 Weekly Sales Report for January-June, Week 4, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219347	SRPT-VYDS-0219357	
PTX0673	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Report 6/25/21"	6/18/2021	SRPT-VYDS-0219358	SRPT-VYDS-0219358	
PTX0674	VYONDYS 53 Weekly Sales Report for January-June, Week 3, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219359	SRPT-VYDS-0219369	
PTX0675	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales 6/11"	6/11/2021	SRPT-VYDS-0219370	SRPT-VYDS-0219370	
PTX0676	VYONDYS 53 Weekly Sales Report for January-June, Week 2, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219371	SRPT-VYDS-0219381	
PTX0677	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales 6/4/21"	6/4/2021	SRPT-VYDS-0219382	SRPT-VYDS-0219382	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0678	VYONDYS 53 Weekly Sales Report for January-June, Week 1, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219383	SRPT-VYDS-0219393	
PTX0679	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Report"	5/28/2021	SRPT-VYDS-0219394	SRPT-VYDS-0219394	
PTX0680	VYONDYS 53 Weekly Sales Report for January-May, Week 4, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219395	SRPT-VYDS-0219405	
PTX0681	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Report 5/21/21"	5/21/2021	SRPT-VYDS-0219406	SRPT-VYDS-0219406	
PTX0682	VYONDYS 53 Weekly Sales Report for January-May, Week 3, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219407	SRPT-VYDS-0219419	
PTX0683	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Report"	5/14/2021	SRPT-VYDS-0219420	SRPT-VYDS-0219420	
PTX0684	VYONDYS 53 Weekly Sales Report for January-May, Week 2, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219421	SRPT-VYDS-0219436	
PTX0685	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Report 5/7/2021"	5/7/2021	SRPT-VYDS-0219437	SRPT-VYDS-0219437	
PTX0686	VYONDYS 53 Weekly Sales Report for January-May, Week 1, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219438	SRPT-VYDS-0219453	
PTX0687	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Through 4/30/2021"	4/30/2021	SRPT-VYDS-0219454	SRPT-VYDS-0219454	
PTX0688	VYONDYS 53 Weekly Sales Report for January-April, Week 5, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219455	SRPT-VYDS-0219470	
PTX0689	Email from J. Wright to B. Forsa, et al. re: "Weekly Gross Sales Report"	4/23/2021	SRPT-VYDS-0219471	SRPT-VYDS-0219471	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0690	VYONDYS 53 Weekly Sales Report for January-April, Week 5, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219472	SRPT-VYDS-0219487	
PTX0691	Email from J. Wright to B. Forsa, et al. re: "Gross Sales Report"	4/9/2021	SRPT-VYDS-0219488	SRPT-VYDS-0219488	
PTX0692	VYONDYS 53 Weekly Sales Report for January-April, Week 2, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219490	SRPT-VYDS-0219505	
PTX0693	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Summary 4/2/21"	4/2/2021	SRPT-VYDS-0219506	SRPT-VYDS-0219507	
PTX0694	VYONDYS 53 Weekly Sales Report for January-March, Week 5, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219508	SRPT-VYDS-0219522	
PTX0695	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Report 3/26/21"	3/26/2021	SRPT-VYDS-0219523	SRPT-VYDS-0219523	
PTX0696	VYONDYS 53 Weekly Sales Report for January-March, Week 4, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219524	SRPT-VYDS-0219537	
PTX0697	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Report 3/19/2021"	3/19/2021	SRPT-VYDS-0219538	SRPT-VYDS-0219538	
PTX0698	VYONDYS 53 Weekly Sales Report for January-March, Week 3, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219539	SRPT-VYDS-0219552	
PTX0699	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Report 3/5/21"	3/5/2021	SRPT-VYDS-0219553	SRPT-VYDS-0219553	
PTX0700	VYONDYS 53 Weekly Sales Report for January-March, Week 1, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219554	SRPT-VYDS-0219567	
PTX0701	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Summary 2/26/21"	2/26/2021	SRPT-VYDS-0219568	SRPT-VYDS-0219568	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0702	VYONDYS 53 Weekly Sales Summary for January-February, Week 4, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219569	SRPT-VYDS-0219577	
PTX0703	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Summary 2/19/21"	2/19/2021	SRPT-VYDS-0219578	SRPT-VYDS-0219578	
PTX0704	VYONDYS 53 Weekly Sales Summary for January-February, Week 3, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219579	SRPT-VYDS-0219587	
PTX0705	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Summary 2/12/21"	2/12/2021	SRPT-VYDS-0219588	SRPT-VYDS-0219588	
PTX0706	VYONDYS 53 Weekly Sales Summary for January-February, Week 2, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219589	SRPT-VYDS-0219597	
PTX0707	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Summary 2/5/21"	2/5/2021	SRPT-VYDS-0219598	SRPT-VYDS-0219598	
PTX0708	VYONDYS 53 Weekly Sales Summary for January-February, Week 1, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219599	SRPT-VYDS-0219607	
PTX0709	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Summary 1/29/2021"	1/29/2021	SRPT-VYDS-0219608	SRPT-VYDS-0219608	
PTX0710	VYONDYS 53 Weekly Sales Summary through January, Week 4, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219609	SRPT-VYDS-0219617	
PTX0711	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Summary 1/22/2021"	1/22/2021	SRPT-VYDS-0219618	SRPT-VYDS-0219618	
PTX0712	VYONDYS 53 Weekly Sales Summary through January, Week 3, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219619	SRPT-VYDS-0219627	
PTX0713	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Summary 1/15/2021"	1/15/2021	SRPT-VYDS-0219628	SRPT-VYDS-0219628	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0714	VYONDYS 53 Weekly Sales Summary through January, Week 2, 2021 (<i>partially redacted</i>)	1/1/2021	SRPT-VYDS-0219629	SRPT-VYDS-0219637	
PTX0715	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Summary 12/18/2020"	12/18/2020	SRPT-VYDS-0219648	SRPT-VYDS-0219648	
PTX0716	VYONDYS 53 Weekly Sales Summary 2020 for January - December, Week 3, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0219649	SRPT-VYDS-0219657	
PTX0717	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Summary 12/11/20"	12/11/2020	SRPT-VYDS-0219658	SRPT-VYDS-0219658	
PTX0718	VYONDYS 53 Weekly Sales Summary 2020 for January - December, Week 2, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0219659	SRPT-VYDS-0219667	
PTX0719	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Summary 12/4/20"	12/4/2020	SRPT-VYDS-0219668	SRPT-VYDS-0219668	
PTX0720	VYONDYS 53 Weekly Sales Summary 2020 for January - December, Week 1, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0219669	SRPT-VYDS-0219677	
PTX0721	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Summary 11/20/20"	11/20/2020	SRPT-VYDS-0219678	SRPT-VYDS-0219678	
PTX0722	VYONDYS 53 Weekly Sales Summary 2020 for January - November, Week 3, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0219679	SRPT-VYDS-0219687	
PTX0723	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Summary 11/27/20"	11/29/2020	SRPT-VYDS-0219688	SRPT-VYDS-0219688	
PTX0724	VYONDYS 53 Weekly Sales Summary 2020 for January - November, Week 4, 2020 (<i>partially redacted</i>)	1/1/2020	SRPT-VYDS-0219689	SRPT-VYDS-0219697	
PTX0725	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Summary 11/13/20"	11/13/2020	SRPT-VYDS-0219698	SRPT-VYDS-0219698	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0726	VYONDYS 53 Weekly Sales Summary 2020 for January - November, Week 2, 2020 <i>(partially redacted)</i>	1/1/2020	SRPT-VYDS-0219699	SRPT-VYDS-0219707	
PTX0727	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Summary 11/6/2020"	11/6/2020	SRPT-VYDS-0219708	SRPT-VYDS-0219708	
PTX0728	VYONDYS 53 Weekly Sales Summary 2020 for January - November, Week 1, 2020 <i>(partially redacted)</i>	1/1/2020	SRPT-VYDS-0219709	SRPT-VYDS-0219717	
PTX0729	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Summary 10/30/30"	10/30/2020	SRPT-VYDS-0219718	SRPT-VYDS-0219718	
PTX0730	VYONDYS 53 Weekly Sales Summary 2020 for January - October, Week 4, 2020 <i>(partially redacted)</i>	1/1/2020	SRPT-VYDS-0219719	SRPT-VYDS-0219727	
PTX0731	Email from J. Wright to B. Forsa, et al. re: "Weekly Sales Summary 10/23/20"	10/23/2020	SRPT-VYDS-0219728	SRPT-VYDS-0219728	
PTX0732	VYONDYS 53 Weekly Sales Summary 2020 for January - October, Week 3, 2020 <i>(partially redacted)</i>	1/1/2020	SRPT-VYDS-0219729	SRPT-VYDS-0219737	
PTX0733	Email from J. Wright to B. Cumbo, et al. re: "Weekly Sales Summary 10/16/20"	10/16/2020	SRPT-VYDS-0219738	SRPT-VYDS-0219738	
PTX0734	VYONDYS 53 Weekly Sales Summary 2020 for January - October, Week 2, 2020 <i>(partially redacted)</i>	1/1/2020	SRPT-VYDS-0219739	SRPT-VYDS-0219747	
PTX0735	Email from J. Wright to B. Cumbo, et al. re: "Weekly Sales Summary 10/9/20"	10/9/2020	SRPT-VYDS-0219748	SRPT-VYDS-0219748	
PTX0736	VYONDYS 53 Weekly Sales Summary 2020 for January - October, Week 1, 2020 <i>(partially redacted)</i>	1/1/2020	SRPT-VYDS-0219749	SRPT-VYDS-0219757	
PTX0737	Email from J. Wright to B. Cumbo, et al. re: "Weekly Sales Summary 10/2/20"	10/2/2020	SRPT-VYDS-0219758	SRPT-VYDS-0219758	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0738	VYONDYS 53 Weekly Sales Summary 2020 for January - September, Week 5, 2020 (partially redacted)	1/1/2020	SRPT-VYDS-0219759	SRPT-VYDS-0219767	
PTX0739	Email from J. Wright to B. Cumbo, et al. re: "Weekly Sales Summary 9/25/20"	9/25/2020	SRPT-VYDS-0219768	SRPT-VYDS-0219768	
PTX0740	VYONDYS 53 Weekly Sales Summary 2020 for January - September, Week 4, 2020 (partially redacted)	1/1/2020	SRPT-VYDS-0219769	SRPT-VYDS-0219777	
PTX0741	Email from J. Wright to B. Cumbo, et al. re: "Weekly Sales Summary 9/18/20"	9/18/2020	SRPT-VYDS-0219778	SRPT-VYDS-0219778	
PTX0742	VYONDYS 53 Weekly Sales Summary 2020 for January - September, Week 3, 2020 (partially redacted)	1/1/2020	SRPT-VYDS-0219779	SRPT-VYDS-0219787	
PTX0743	Email from J. Wright to B. Cumbo, et al. re: "Weekly Sales Summary 9/11/20"	9/11/2020	SRPT-VYDS-0219788	SRPT-VYDS-0219788	
PTX0744	VYONDYS 53 Weekly Sales Summary 2020 for January - September, Week 2, 2020 (partially redacted)	1/1/2020	SRPT-VYDS-0219789	SRPT-VYDS-0219797	
PTX0745	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary"	1/21/2022	SRPT-VYDS-0219806	SRPT-VYDS-0219806	
PTX0746	Weekly Gross Revenue Flash Report for Week 3 of 2021 (Jan. 17-21, 2021) (partially redacted)	1/21/2021	SRPT-VYDS-0219807	SRPT-VYDS-0219813	
PTX0747	Email from J. Wright to A. Bauchman, et al. re: "Weekly Sales Summary"	1/28/2022	SRPT-VYDS-0219814	SRPT-VYDS-0219814	
PTX0748	Weekly Gross Revenue Flash Report for Week 4 of 2021 (Jan. 24-28, 2021) (partially redacted)	1/28/2021	SRPT-VYDS-0219815	SRPT-VYDS-0219821	
PTX0749	Sixth Amendment to Commercial Outsourcing Services Agreement between [REDACTED] and [REDACTED]	12/7/2022	SRPT-VYDS-0219875	SRPT-VYDS-0219882	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0750	Third Amendment to Commercial Outsourcing Services Agreement between [REDACTED] and [REDACTED]	4/28/2020	SRPT-VYDS-0219933	SRPT-VYDS-0219938	
PTX0751	Commercial Supply Agreement between [REDACTED] and [REDACTED]	11/13/2015	SRPT-VYDS-0219991	SRPT-VYDS-0220030	
PTX0752	Fifth Amendment to Commercial Outsourcing Services Agreement between [REDACTED] and [REDACTED]	7/12/2022	SRPT-VYDS-0220031	SRPT-VYDS-0220039	
PTX0753	Second Amendment to Commercial Outsourcing Services Agreement between [REDACTED] and [REDACTED]	11/1/2019	SRPT-VYDS-0220070	SRPT-VYDS-0220073	
PTX0754	First Amendment to Commercial Outsourcing Services Agreement between [REDACTED] and [REDACTED]	10/11/2018	SRPT-VYDS-0220074	SRPT-VYDS-0220079	
PTX0755	Adams, Abbie, et al. "Antisense Oligonucleotide Induced Exon Skipping and the Dystrophin Gene Transcript: Cocktails and Chemistries," BMC Molecular Biology 8.57	7/2/2007	SRPT-VYDS-0008288	SRPT-VYDS-0008295	
PTX0756	Errington, Stephen J., et al. "Target Selection for Antisense Oligonucleotide Induced Exon Skipping in the Dystrophin Gene," J. Gene Med. 5.6 (2003): 518-527	1/21/2003	NS00035839	NS00035848	
PTX0757	Mann, Christopher J., et al. "Improved Antisense Oligonucleotide Induced Exon Skipping in the <i>mdx</i> Mouse Model of Muscular Dystrophy," J. Gene Med. (2002) 4(6): 644-654	8/2/2002	SRPT-VYDS-0008356	SRPT-VYDS-0008364	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0758	McClore, G., et al. "Induced Dystrophin Exon Skipping in Human Muscle Explants," Neuromuscul. Disord. (2006) 16(9-10): 583-590	10/11/2006	SRPT-VYDS-0075949	SRPT-VYDS-0075958	
PTX0759	Popplewell, Linda, et al. "Design of Phosphorordiamidate Morpholino Oligomers (PMOs) for the Induction of Exon Skipping of the Human DMD Gene," Muscular Therapy (2009) 17(3): 554-561	3/1/2009	SRPT-VYDS-0008344	SRPT-VYDS-0008355	
PTX0760	Summerton, James, and Dwight Weller. "Morpholino Antisense Oligomers: Design, Preparation, and Properties," Antisense Nucleic Acid Drug Dev. (1997) 7(3): 187-195	1/1/1997	SRPT-VYDS-0013767	SRPT-VYDS-0013780	
PTX0761	Summerton, James. "Morpholino Antisense Oligomers: The Case for an RNase H-independent Structural Type," Biochimica et Biophysica Acta (1999) 1489: 141-158	5/18/1999	SRPT-VYDS-0008296	SRPT-VYDS-0008313	
PTX0762	Summerton, James. "Morpholinos and PNAs Compared," Letters in Peptide Science (2003) 10: 215-236	1/1/2004	SRPT-VYDS-0011916	SRPT-VYDS-0011937	
PTX0763	Vickers, Timothy A. "Effects of RNA Secondary Structure on Cellular Antisense Activity," Nucleic Acids Res. (2000) 28(6): 1340-1347	1/26/2000	SRPT-VYDS-0007729	SRPT-VYDS-0007740	
PTX0764	Wilton, Steve D., and Susan Fletcher. "Antisense Oligonucleotides in the Treatment of Duchenne Muscular Dystrophy: Where Are We Now?" Neuromuscular Disorders 15.6 (2005): 399-402	1/1/2005	WILTON0025140	WILTON0025145	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0765	Wilton, Steve D., et al. "Antisense Oligonucleotide-Induced Exon Skipping Across the Human Dystrophin Gene Transcript," Molecular Therapy 15.7 (2007):	1/1/2007	SRPT-VYDS-0007603	SRPT-VYDS-0007615	
PTX0766	University of Western Australia v. Academisch Ziekenhuis Leiden, Interference No. 106,007, Decisions - Motions - 37 CFR § 41.125(a) (Substitute) (PTAB May 12, 2016)	5/12/2016	SRPT-VYDS-0076984	SRPT-VYDS-0077036	
PTX0767	University of Western Australia v. Academisch Ziekenhuis Leiden, Interference No. 106,007, UWA Reply 1 to AZL Opposition 1 (PTAB April 3, 2015)	4/3/2015	NS00141366	NS00141393	
PTX0768	Abbie Fall Laboratory Notebook "[REDACTED]" (partially redacted)	2/1/2006	SRPT-VYDS-0162285	SRPT-VYDS-0162461	
PTX0769	Clayton Fragall Laboratory Notebook "[REDACTED]" (partially redacted)	6/1/2009	SRPT-VYDS-0159343	SRPT-VYDS-0159420	
PTX0770	Jiminy Synthesis Book 12 (partially redacted)	4/1/2008	SRPT-VYDS-0161481	SRPT-VYDS-0161649	
PTX0771	Jiminy Synthesis Laboratory Notebook 15 (partially redacted)	4/1/2010	SRPT-VYDS-0160521	SRPT-VYDS-0160639	
PTX0772	Lauren Westcott Laboratory Notebook "[REDACTED]" (partially redacted)	5/20/2005	SRPT-VYDS-0158291	SRPT-VYDS-0158435	
PTX0773	[REDACTED]		NS00141394	NS00141395	
PTX0774	[REDACTED]		NS00141396	NS00141396	
PTX0775	Declaration of Fred Schnell in the matter of Appeal No. T518/18, European Patent No. 2206781 to the University of Western Australia	4/5/2018	SRPT-VYDS-0228268	SRPT-VYDS-0228275	
PTX0776	Email Thread between S. Wilton and R. Kole re: "Agreement"	9/25/2008	WILTON0017925	WILTON0017928	
PTX0777	Nippon Shinyaku Co., Ltd., "Nippon Shinyaku's DNA" (last visited 10/14/2023)	10/14/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0778	Nippon Shinyaku Co., Ltd., "Pharmaceuticals Division" (last visited 10/14/2023)	10/14/2023	NONE	NONE	
PTX0779	Nippon Shinyaku Co., Ltd., "Business		NONE	NONE	
PTX0780	Viltepso, "Home"		NONE	NONE	
PTX0781	Nippon Shinyaku Co., Ltd., "Leading Product Revenue"		NONE	NONE	
PTX0782	OFX, "Historical Exchange Rates"		NONE	NONE	
PTX0783	Nippon Shinyaku Co., Ltd., "Group		NONE	NONE	
PTX0784	NS Pharma, "Home"		NONE	NONE	
PTX0785	Sarepta Therapeutics, "AVI BioPharma Announces Corporate Name Change to Sarepta Therapeutics and Stock Ticker Symbol Change to 'SRPT' Effective Today"	7/12/2012	UWA0000001	UWA0000002	
PTX0786	Sarepta Therapeutics, Inc. Form 10-K (2022)	1/1/2023	NS00142291	NS00142699	
PTX0787	Sarepta Therapeutics, "Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy," Sarepta Therapeutics, https://www.elevidys.com/downloads/ELEVIDYS_Launch_Approval_Press_June_2023.pdf	6/22/2023	NONE	NONE	
PTX0788	The University of Western Australia, "Our History"		NONE	NONE	
PTX0789	"Sarepta Therapeutics and University of Western Australia Announce Exclusive Worldwide Licensing Agreement for Exon-Skipping Program in Duchenne Muscular Dystrophy," Sarepta Therapeutics, https://investorrelations.sarepta.com/static-files/e20a099e-f99d-4237-8651-fa9c6d479090	4/11/2023	SRPT-VYDS-0206582	SRPT-VYDS-0206584	
PTX0790		8/26/2020	SRPT-VYDS-0209514	SRPT-VYDS-0209518	
PTX0791	Muscular Dystrophy UK, "What is exon skipping and how does it work?"	3/9/2020	NS00052022	NS00052028	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0792	Muscular Dystrophy News Today, "Prednisone"	2/17/2022	NONE	NONE	
PTX0793	Emflaza, "Differences in Corticosteroids"		NONE	NONE	
PTX0794	FDA - Package Insert for ELEVIDYS (Revised 6/2023)	6/1/2023	NONE	NONE	
PTX0795	REMOVED DOCUMENT FROM LIST (DUPLICATE)	9/10/2019	SRPT-VYDS-0210679	SRPT-VYDS-0210695	
PTX0796	"Providing FDA-approved therapies," Sarepta Therapeutics, https://www.sarepta.com/products-pipeline/products	12/13/2022	SRPT-VYDS-0212668	SRPT-VYDS-0212668	
PTX0797	NS Pharma, "Pipeline"	3/20/2022	NS00043067	NS00043068	
PTX0798	Cision PR Newswire - "FDA Grants Breakthrough Therapy Designation to NS-089/NCNP-02 for the Treatment of Duchenne Muscular Dystrophy"	7/27/2023	NONE	NONE	
PTX0799	"Pipeline," Dyne Therapeutics, https://www.dyne-tx.com/pipeline/		NONE	NONE	
PTX0800	"Pipeline," PepGen, https://www.pepgen.com/pipeline/		NONE	NONE	
PTX0801	"Pipeline," Wave Life Sciences, https://wavelifesciences.com/pipeline/		NONE	NONE	
PTX0802	Pfizer - "Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy"	1/7/2021	NONE	NONE	
PTX0803	Genetic Engineering & Biotechnology News, "FDA Lifts Clinical Hold on Pfizer DMD Gene Therapy Linked to Patient Death"	4/28/2022	NONE	NONE	
PTX0804	Nippon Shinyaku Co. Ltd. And NS Pharma, Inc.'s Second Supplemental Responses and Objections to Sarepta Therapeutics, Inc.'s First Set of Interrogatories (Nos. 1-11)	8/15/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0805	FDA - "FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation"	8/12/2020	SRPT-VYDS-0209511	SRPT-VYDS-0209513	
PTX0806	Clemens, Paula R., et al. "Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study." J Neuromuscul Dis. 2023;10(3):439-447. doi: 10.3233/JND 221656. PMID: 37005891; PMCID: PMC10200237	5/2/2023	SRPT-VYDS-0229855	SRPT-VYDS-0229863	
PTX0807	Model - (metadata date created 2/9/2022, date modified 8/2/2023)	8/2/2023	NS00140986	NS00140986	
PTX0808	"Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations," U.S. Food & Drug Administration, https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=211970&Appl_type=N (last visited 9/7/23)	9/7/2023	NS00141991	NS00141992	
PTX0809	FDA - "Drug Trials Snapshots: VYONDYS 53"	12/26/2019	NONE	NONE	
PTX0810	Exchange Rates UK, "Russian Rouble to US Dollar Spot Exchange Rates for 2022"		NONE	NONE	
PTX0811	EXONDYS 51 Homepage		NONE	NONE	
PTX0812	Exondys 51 label, revised January 2022, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206488s027s028s029lbl.pdf ,	1/1/2022	NONE	NONE	
PTX0813	Royal Holloway, University of London, "Our History, Your Future"	1/1/2023	NONE	NONE	
PTX0814	Royal Holloway, University of London		NONE	NONE	
PTX0815	Brain Involvement in Dystrophinopathies, "Academisch Ziekenhuis Leiden (Leiden University Medical Center (LUMC))"		NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0816	Genetic Engineering & Biotechnology News, "BioMarin to Acquire Prosensa for Up to \$840M"	11/24/2014	NONE	NONE	
PTX0817	Goemans, Nathalie M., et al. "Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study," PLoS One	9/2/2016	NONE	NONE	
PTX0818	BiopharmaDive, "BioMarin ends Duchenne program, withdraws EU application for drisapersen"	5/31/2016	NONE	NONE	
PTX0819	Settlement Agreement among Sarepta Therapeutics, Inc., Sarepta International C.V., and The University of Western Australia, and BioMarin Leiden Holding BV, BioMarin Nederlands BV, BioMarin Technologies BV, and Academisch Ziekenhuis Leiden, as attached to Sarepta's Form 10Q for the fiscal quarter ended June 30, 2017	7/17/2017	SRPT-VYDS-0205761	SRPT-VYDS-206131	
PTX0820	Sarepta Therapeutics - "Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy,	12/23/2019	NONE	NONE	
PTX0821	Agreement between [REDACTED] and Nippon Shinyaku Co., Ltd.	1/24/2022	NS00090767	NS00090820	
PTX0822	Agreement between [REDACTED] and Nippon Shinyaku Co., Ltd.	2/10/2023	NS00090821	NS00090875	
PTX0823	FDA, "Biologics License Applications (BLA) Process (CBER)"	1/27/2021	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0824	Mitsubishi UFJ Research and Consulting Co., Ltd. - 2023 Exchange Quotations (Japanese followed by certified English translation)	2/10/2023	NONE	NONE	
PTX0825	VYONDYS 53 Financial Summary		SRPT-VYDS-0227829	SRPT-VYDS-0227829	
PTX0826	FDA News Release, FDA grants accelerated approval to first drug for Duchenne muscular dystrophy; https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-drug-duchenne-muscular-dystrophy (2016)	9/19/2016	NS00056716	NS00056718	
PTX0827	EXONDYS 51 Prescribing Information	9/1/2016	NS00141741	NS00141750	
PTX0828	FDA - "Drug Trials Snapshots: VILTEPSO"	8/18/2020	NONE	NONE	
PTX0829	Spreadsheet of [REDACTED] (metadata date created 5/30/2023, date modified 6/5/2023)	6/5/2023	SRPT-VYDS-0219874	SRPT-VYDS-0219874	
PTX0830	VYONDYS 53 Prescribing Information	2/1/2021	NS00142747	NS00142759	
PTX0831	"Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53," Sarepta Therapeutics, https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fda-approval-vyondys-53tm	12/12/2019	SRPT-VYDS-0206469	SRPT-VYDS-0206474	
PTX0832	NS Japan Actual Shipping Costs to the United States (last date on document 7/1/2023)	7/1/2023	NS00141003	NS00141003	
PTX0833	P&L Spreadsheet (metadata date created 7/23/2010, date modified 1/8/2020)	1/8/2020	NS00140996	NS00140996	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0834	Sarepta Therapeutics - "Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53"	2/14/2019	NS00126431	NS00126434	
PTX0835	NS Pharma - "VILTEPSO (viltolarsen) injection Now Commercially Available in the U.S."	8/19/2020	NONE	NONE	
PTX0836	FDA Grants Accelerated Approval to First Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation, U.S. FDA (Dec. 12, 2019), https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation	12/12/2019	NS00048946	NS00048949	
PTX0837	Center for Drug Evaluation and Research, Application No. 211970Orig1s000 Summary Review	8/19/2019	SRPT-VYDS-0211304	SRPT-VYDS-0211333	
PTX0838	Golodirsen for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53 (metadata date created 12/6/2019, date modified 12/19/2019)	12/19/2019	SRPT-VYDS-0211529	SRPT-VYDS-0211533	
PTX0839	Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s First Supplemental Responses and Objections to Sarepta Therapeutics, Inc.'s Fourth Set of Interrogatories (No. 21) and Appendix	7/27/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0840	Nippon Shinyaku Co., Ltd., v. Sarepta Therapeutics, Inc., Appeal from the United States District Court for the District of Delaware in No. 1:21-cv-01015-LPS (2022)	2/8/2022	NONE	NONE	
PTX0841	Abe, Ikubo & Katayama: Attorneys Fees for Nippon Shinyaku - US IP Litigation (last date on document 9/7/2023)	9/7/2023	NS00141004	NS00141004	
PTX0842	Attorney Fees, Invoice No. 21070880 [Japanese] (last date on document 6/30/2021) with certified English translation	6/30/2021	NS00153770	NS00153774	
PTX0843	Attorney Fees, Invoice No. 21080775 [Japanese] (last date on document 7/30/2021) with certified English translation	7/30/2021	NS00153775	NS00153779	
PTX0844	Attorney Fees, Invoice No. 21090728 [Japanese] (last date on document 8/27/2021) with certified English translation	8/27/2021	NS00153780	NS00153786	
PTX0845	Attorney Fees, Invoice No. 21100811 [Japanese] (last date on document 9/30/2021) with certified English translation	9/30/2021	NS00153787	NS00153793	
PTX0846	Attorney Fees, Invoice No. 21110680 [Japanese] (last date on document 10/29/2021) with certified English translation	10/29/2021	NS00153794	NS00153800	
PTX0847	Attorney Fees, Invoice No. 21120834 [Japanese] (last date on document 11/25/2021) with certified English translation	11/25/2021	NS00153801	NS00153807	
PTX0848	Attorney Fees, Invoice No. 22010759 [Japanese] (last date on document 12/27/2021) with certified English translation	12/27/2021	NS00153808	NS00153814	
PTX0849	Attorney Fees, Invoice No. 22021533 [Japanese] (last date on document 1/31/2022) with certified English translation	1/31/2022	NS00153815	NS00153821	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0850	Attorney Fees, Invoice No. 22030892 [Japanese] (last date on document 2/26/2022) with certified English translation	2/26/2022	NS00153822	NS00153826	
PTX0851	Attorney Fees, Invoice No. 22040739 [Japanese] (last date on document 3/24/2022) with certified English translation	3/24/2022	NS00153827	NS00153831	
PTX0852	Attorney Fees, Invoice No. 22050733 [Japanese] (last date on document 4/28/2022) with certified English translation	4/28/2022	NS00153832	NS00153836	
PTX0853	Attorney Fees, Invoice No. 22060794 [Japanese] (last date on document 5/30/2022) with certified English translation	5/30/2022	NS00153837	NS00153841	
PTX0854	Attorney Fees, Invoice No. 22070753 [Japanese] (last date on document 6/30/2022) with certified English translation	6/30/2022	NS00153842	NS00153847	
PTX0855	Attorney Fees, Invoice No. 22080688 [Japanese] (last date on document 7/29/2022) with certified English translation	7/29/2022	NS00153848	NS00153853	
PTX0856	Attorney Fees, Invoice No. 22090781 [Japanese] (last date on document 8/31/2022) with certified English translation	8/31/2022	NS00153854	NS00153859	
PTX0857	Attorney Fees, Invoice No. 22100744 [Japanese] (last date on document 9/29/2022) with certified English translation	9/29/2022	NS00153860	NS00153865	
PTX0858	Attorney Fees, Invoice No. 22110713 [Japanese] (last date on document 10/27/2022) with certified English translation	10/27/2022	NS00153866	NS00153871	
PTX0859	Attorney Fees, Invoice No. 22120679 [Japanese] (last date on document 11/29/2022) with certified English translation	11/29/2022	NS00153872	NS00153877	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0860	Attorney Fees, Invoice No. 23010757 [Japanese] (last date on document 12/26/2022) with certified English translation	12/26/2022	NS00153878	NS00153883	
PTX0861	Attorney Fees, Invoice No. 23020630 [Japanese] (last date on document 1/26/2023) with certified English translation	1/26/2023	NS00153884	NS00153889	
PTX0862	Attorney Fees, Invoice No. 23030742 [Japanese] (last date on document 2/28/2023) with certified English translation	2/28/2023	NS00153890	NS00153894	
PTX0863	Attorney Fees, Invoice No. 23040716 [Japanese] (last date on document 3/28/2023) with certified English translation	3/28/2023	NS00153895	NS00153899	
PTX0864	Attorney Fees, Invoice No. 23050721 [Japanese] (last date on document 4/27/2023) with certified English translation	4/27/2023	NS00153900	NS00153904	
PTX0865	Attorney Fees, Invoice No. 23060702 [Japanese] (last date on document 5/31/2023) with certified English translation	5/31/2023	NS00153905	NS00153909	
PTX0866	Attorney Fees, Invoice No. 23070749 [Japanese] (last date on document 6/30/2023) with certified English translation	6/30/2023	NS00153910	NS00153914	
PTX0867	Attorney Fees, Invoice No. 23080735 [Japanese] (last date on document 7/30/2023) with certified English translation	7/30/2023	NS00153915	NS00153919	
PTX0868	Attorney Fees, Invoice No. 23090795 [Japanese] (last date on document 8/31/2023) with certified English translation	8/31/2023	NS00153920	NS00153926	
PTX0869	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	6/15/2021	NS00138041	NS00138045	
PTX0870	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	7/19/2021	NS00138046	NS00138057	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0871	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	8/20/2021	NS00138058	NS00138070	
PTX0872	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	10/14/2021	NS00138071	NS00138083	
PTX0873	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	10/29/2021	NS00138084	NS00138102	
PTX0874	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	11/22/2021	NS00138103	NS00138120	
PTX0875	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	1/13/2022	NS00138121	NS00138136	
PTX0876	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	1/25/2022	NS00138137	NS00138149	
PTX0877	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	2/17/2022	NS00138150	NS00138165	
PTX0878	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	3/22/2022	NS00138166	NS00138180	
PTX0879	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	4/28/2022	NS00138181	NS00138194	
PTX0880	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	5/17/2022	NS00138195	NS00138206	
PTX0881	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	8/20/2021	NS00138207	NS00138213	
PTX0882	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	10/14/2021	NS00138214	NS00138224	
PTX0883	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	10/29/2021	NS00138225	NS00138231	
PTX0884	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	11/22/2021	NS00138232	NS00138241	
PTX0885	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	1/13/2022	NS00138242	NS00138250	
PTX0886	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	1/25/2022	NS00138251	NS00138257	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0887	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	2/17/2022	NS00138258	NS00138268	
PTX0888	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	3/22/2022	NS00138269	NS00138279	
PTX0889	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	4/28/2022	NS00138280	NS00138286	
PTX0890	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	5/17/2022	NS00138287	NS00138291	
PTX0891	NS Pharma "[REDACTED]" (metadata parent date 9/16/2022, date modified 9/16/2022)	9/16/2022	NS00043079	NS00043112	
PTX0892	NS Pharma "[REDACTED]" (metadata date created 1/17/2013, date modified 8/2/2022)	8/22/2022	NS00042266	NS00042285	
PTX0893	VYONDYS [REDACTED]	12/1/2022	SRPT-VYDS-0213311	SRPT-VYDS-0213311	
PTX0894	Email Thread between A. Klimchak and P. Moss et al. re: Unofficial Viltepso Price	8/17/2020	SRPT-VYDS-0209626	SRPT-VYDS-0209627	
PTX0895	"Competition and Monopoly: Single Firm Conduct Under Section 2 of the Sherman Act: Chapter 1," Department of Justice, https://www.justice.gov/archives/atr/competition-and-monopoly-single-firm-conduct-under-section-2-sherman-act-chapter-1#:~:text=Section%20%20thus%20aims%20neither,alike%2D%2Dto%20continue%20striving.	3/18/2022	NS00141526	NS00141740	
PTX0896	"Horizontal Merger Guidelines," U.S. Department of Justice and Federal Trade Commission, (August 19, 2010)	8/19/2020	NS00141422	NS00141456	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0897	Bladen et. al., "The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations," Human Mutation 36:4, (April 2015)	3/17/2015	NS00141457	NS00141464	
PTX0898	Darras, Basil T. "Dystrophinopathies," GeneReviews, (September 5, 2000), https://www.ncbi.nlm.nih.gov/books/NBK1119/	9/5/2000	NONE	NONE	
PTX0899	Goa, Quan and McNally, Elizabeth M, "The Dystrophin Complex: structure, function and implications for therapy," National Library of Medicine, (July 1, 2016), https://www.ncbi.nlm.nih.gov/pmc/Publication/PMC4767260/	7/1/2016	NS00049423	NS00049455	
PTX0900	Werden, Gregory J. "Four Suggestions on Market Delineation," The Antitrust Bulletin, Vol. 37, pp. 107-121 (1992)	3/1/1992	NS00142765	NS00142779	
PTX0901	Hay et. al. "Clinical development success rates for investigational drugs," Nature Biotechnology, Vol. 32 No. 1, (January 2014)	1/9/2014	NS00141514	NS00141525	
PTX0902	Salop, Steve, "Raising Rivals Costs," The American Economic Review, Vol. 73, No. 2, Papers and Proceedings of the Ninety-Fifth Annual Meeting of the American Economic Association, (May 1983)	5/1/1983	NS00141993	NS00141998	
PTX0903	Shadid, M., et al., "Antisense oligonucleotides: absorption, distribution, metabolism, and excretion," Expert Opinion on Drug Metabolism & Toxicology, Vol. 17, No. 11, (2021)	10/22/2021	NS00141409	NS00141421	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0904	Stocking, George W. & Mueller, Willard F., "The Cellophane Case and The New Competition," 45 American Economic Review 29, (1995)	3/1/1995	NS00142700	NS00142735	
PTX0905	"2019 Report of the Economic Survey," American Intellectual Property Law Association, https://ipwatchdog.com/wp-content/uploads/2021/08/AIPLA-Report-of-the-Economic-Survey-Relevant-Excerpts.pdf	1/1/2019	NONE	NONE	
PTX0906	AMONDYS 45 Prescribing Information	2/1/2021	NS00141397	NS00141408	
PTX0907	"Accelerated Approval Program," U.S. Food & Drug Administration, https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program	5/30/2023	NONE	NONE	
PTX0908	"Access & Coverage Resources for New Therapies," Parent Project Muscular Dystrophy, https://www.parentprojectmd.org/care/insurance-access-coverage-resources/for-new-therapies/		NONE	NONE	
PTX0909	Center Director Decisional Memo, Food and Drug Administration, https://www.fda.gov/media/169707/download (last date is May 12, 2023)	5/12/2023	NS00142957	NS00142963	
PTX0910	"Children's National gives first commercial dose of new FDA-approved gene therapy for Duchenne muscular dystrophy," Innovationdistrict, https://innovationdistrict.childrensnational.org/childrens-national-gives-first-dose-of-new-dmd-drug/#:~:text=How%20it%20works,the%20largest%20known%20human%20gene	8/2/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0911	"Cost to Develop and Win Marketing Approval for a New Drug Is \$2.6 Billion," Tufts Center for the Study of Drug Development, https://f.hubspotusercontent10.net/hubfs/94689	11/18/2014	NONE	NONE	
PTX0912	"Drugmaker Raises U.S. Price of Muscular-Dystrophy Treatment," Wall Street Journal, https://www.wsj.com/Publication/drugmaker-raises-u-s-price-of-muscular-dystrophy-treatment-1516295645	1/18/2018	NONE	NONE	
PTX0913	"Duchenne Muscular Dystrophy (DMD) – Causes/Inheritance," Muscular Dystrophy Association, https://www.mda.org/disease/duchenne-muscular-dystrophy/causes-inheritance	3/15/2020	NS00051631	NS00051635	
PTX0914	"Duchenne Muscular Dystrophy Medical Management," Muscular Dystrophy Association, https://www.mda.org/disease/duchenne-muscular-dystrophy/medical-management		NONE	NONE	
PTX0915	"Duchenne Muscular Dystrophy," NORD, https://rarediseases.org/rare-diseases/duchenne-muscular-dystrophy/	6/28/2023	NONE	NONE	
PTX0916	"Drug Approval Process," U.S. Food and Drug Administration, https://www.fda.gov/media/82381/download		NONE	NONE	
PTX0917	"Elevidys," U.S. Food & Drug Administration, https://www.fda.gov/vaccines-blood-biologics/tissue-tissue-products/elevidys	7/13/2023	NONE	NONE	
PTX0918	Elevidys Prescribing Information	10/1/2023	NONE	NONE	
PTX0919	Emflaza website, https://www.emflaza.com/		NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0920	"Exon skipping is a potential treatment approach for correcting and restoring production of dystrophin," CureDuchenne, https://cureduchenne.org/cure/exon-skipping/	5/12/2020	NS00137444	NS00137448	
PTX0921	"FDA Approved Drugs," U.S. Food & Drug Administration, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm		NONE	NONE	
PTX0922	"FDA Approves First Corticosteroid, Emflaza, to Treat Range of Duchenne MD Patients," Muscular Dystrophy News, https://muscular dystrophynews.com/news/emflaza-first-corticosteroid-treatment-for-duchenne-muscular-dystrophy-approved-by-fda/	2/10/2017	NS00142949	NS00142951	
PTX0923	"FDA Approves SRP-9001 as First Gene Therapy for Duchenne Muscular Dystrophy," NeurologyLive, https://www.neurologylive.com/view/fda-approves-srp-9001-first-gene-therapy-for-duchenne-muscular-dystrophy	6/22/2023	NONE	NONE	
PTX0924	"FDA gives speedy approval to another Duchenne drug," BioPharmaDive, https://www.biopharmadive.com/news/viltolars-en-duchenne-fda-approval-ns-pharma/583410/	8/13/2020	NONE	NONE	
PTX0925	"Follow The Pill: Understanding the U.S. Commercial Pharmaceutical Supply Chain," Kaiser Family Foundation, February 28, 2005, https://www.kff.org/other/report/follow-the-pill-understanding-the-u-s/	2/28/2005	NS00141751	NS00141782	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0926	"How are drugs approved for use in the United States," National Institutes of Health, https://www.nichd.nih.gov/health/topics/pharma/conditioninfo/approval	12/20/2021	NONE	NONE	
PTX0927	"How We Can Help," Sarepta Therapeutics, https://www.vyondys53.com/getting-support/how-sarepta-case-managers-help		NONE	NONE	
PTX0928	"Leveraging RNA technology to treat rare disease," Sarepta Therapeutics, https://www.sarepta.com/science/rna-platform		NONE	NONE	
PTX0929	"Momentum," Sarepta Therapeutics, https://clinicaltrials.sarepta.com/momentumtrial		NONE	NONE	
PTX0930	"Nippon Shinyaku Co., LTD. Integrated Report 2022," Nippon Shinyaku, https://www.nippon-shinyaku.co.jp/file/download.php?file_id=6768	1/1/2022	NS00141947	NS00141990	
PTX0931	"Notice Regarding Impairment Loss for Products under Development," Astella Gene Therapies, https://www.astellasgenetherapies.com/press_release/notice-regarding-impairment-loss-for-products-under-development	4/22/2022	NONE	NONE	
PTX0932	"NS Pharma's VILTEPSO (viltolarsen) injection Now FDA-Approved in the U.S. for the Treatment of Duchenne Muscular Dystrophy in Patients Amenable to Exon 53 Skipping Therapy," NS Pharma available at https://www.nspharma.com/pdfs/ViltepsoApprovalPressRelease.pdf	8/12/2020	NS00043966	NS00043969	
PTX0933	"NS Support + Resources," Viltepso.com, https://www.viltepso.com/support		NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0934	"NS Support Resource Guide," NS Pharma, https://www.viltepsa.com/pdf/49798_ID01Q.02_NSSupport_ResourceGuide_DIGITAL-FORM.pdf		NONE	NONE	
PTX0935	"Occupational Employment and Wage Statistics," U.S. Bureau of Labor Statistics, https://www.bls.gov/oes/current/naics4_325400.htm#11-0000		NONE	NONE	
PTX0936	"Our Pipeline," Sarepta Therapeutics, https://www.sarepta.com/products-pipeline/pipeline		NONE	NONE	
PTX0937	"Parent Project Muscular Dystrophy Hosts 29th Annual Conference in Dallas, Texas," https://www.prnewswire.com/news-releases/parent-project-muscular-dystrophy-hosts-29th-annual-conference-in-dallas-texas-301866131.html	6/28/2023	NONE	NONE	
PTX0938	Arlene Weintraub, "PTC in the Hot Seat Again Over Price Hikes on DMD Med Emflaza," Fierce Pharma, https://www.fiercepharma.com/financials/ptc-hot-seat-again-over-price-hikes-dmd-med-emflaza	1/19/2018	NONE	NONE	
PTX0939	"Research Overview – Duchenne Therapeutic Pipeline," Cure Duchenne, http://cureduchenne.org/cure/research-	6/21/2021	NONE	NONE	
PTX0940	"Sarepta prices Duchenne gene therapy at \$3.2M," BioPharmaDive, https://www.biopharmadive.com/news/sarepta-duchenne-elevidys-price-million-gene-therapy/653720/	6/22/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0941	"Steroids in Duchenne: What You Need To Know," Cure Duchenne, https://cureduchenne.org/care/steroids/		NONE	NONE	
PTX0942	"What is Gene Therapy," U.S. Food & Drug Administration, https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy	7/25/2018	NONE	NONE	
PTX0943	"Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations," U.S. Food & Drug Administration, https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=212154&Appl_type=N	2/11/2022	SRPT-VYDS-0011423	SRPT-VYDS-0011424	
PTX0944	"Deflazacort, Eteplirsén, and Golodirsén for Duchenne Muscular Dystrophy: Effectiveness and Value, Final Evidence Report," ICER, https://icer.org/wp-content/uploads/2020/10/ICER-DMD-Final-Report-081519-2-1.pdf	8/15/2019	NS00091429	NS00091591	
PTX0945	Guglieri M, et al., "Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial." JAMA. 2022, 327(15):1456–1468. doi:10.1001/jama.2022.4315	4/19/2022	NS00143009	NS00143021	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0946	Birnkrant DJ, et al., "DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management." Lancet Neurol. 2018 Mar; 17(3):251-267. doi: 10.1016/S1474-4422(18)30024-3. Epub 2018 Feb 3. Erratum in: Lancet Neurol. 2018 Apr 4; PMID: 29395989; PMCID: PMC5869704. https://pubmed.ncbi.nlm.nih.gov/29395989/	3/1/2018	NS00143047	NS00143081	
PTX0947	Strober, J.B., "Therapeutics in Duchenne Muscular Dystrophy," NeuroRx: The Journal of the Am. Society for Experimental NeuroTherapeutics. Apr. 2006, 3(2):225-34. doi: 10.1016/j.nurx.2006.01.005	4/1/2006	NS00143195	NS00143204	
PTX0948	Strober, J.B., "Genetics of pediatric neuromuscular disease." Curr Opin Pediatr. Dec. 2000, 12(6):549-53. doi: 10.1097/00008480-200012000-00006. PMID: 11106273.	12/1/2000	NS00143190	NS00143194	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0949	Birnkrant DJ, et al., "DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management." Lancet Neurol. Apr. 2018, 17(4):347-361. doi: 10.1016/S1474-4422(18)30025-5. Epub 2018 Feb 3. PMID: 29395990; PMCID: PMC5889091. https://pubmed.ncbi.nlm.nih.gov/29395990/	4/1/2018	NS00112172	NS00112186	
PTX0950	Birnkrant DJ, et al., "DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan." Lancet Neurol. 2018 May;17(5):445-455. doi: 10.1016/S1474-4422(18)30026-7. Epub 2018 Feb 2. PMID: 29398641; PMCID: PMC5902408. https://pubmed.ncbi.nlm.nih.gov/29398641/	5/1/2018	NS00112187	NS00112197	
PTX0951	Strober, J.B., "Do all patients with Duchenne muscular dystrophy require surgery for the correction of scoliosis?" Nat Rev Neurol 3, 18–19 (2007), https://doi.org/10.1038/ncpneuro0359	1/1/2007	NS00143205	NS00143206	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0952	Bann CM, et al. "Measuring quality of life in muscular dystrophy." Neurology. 2015 Mar 10;84(10):1034-42. doi: 10.1212/WNL.0000000000001336. Epub 2015 Feb 6. PMID: 25663223; PMCID: PMC4352095	3/10/2015	NS00142794	NS00142802	
PTX0953	Chrzanowski, S., et al., "Deflazacort – New Costs of an Old Medicine." JAMA Neurol. 2018;75(2):143–144. Doi:10.1001/jamaneurol.2017.3704	2/1/2018	NS00142811	NS00142812	
PTX0954	Griggs RC, Miller JP, Greenberg CR, et al. "Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy." Neurology. 2016; 87(20):2123-2131	11/15/2016	NS00142998	NS00143008	
PTX0955	Cure Duchenne, "Duchenne Population Amenable to Exon Skipping"	6/26/2020	NS00047966	NS00047966	
PTX0956	FDA, "FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation"	2/25/2021	NS00142968	NS00142970	
PTX0957	The Pink Sheet, "FDA's Pepaxto Decider: Peter Marks To Handle Oncopeptides' Appeal Of Accelerated Approval Withdrawal," Aug. 25, 2023	8/25/2023	NS00142974	NS00142980	
PTX0958	Komaki H, et al. "Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy." Sci Transl Med. 2018 Apr 18;10(437):eaan0713. doi: 10.1126/scitranslmed.aan0713. PMID: 29669851	4/18/2018	SRPT-VYDS-0183317	SRPT-VYDS-0183328	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0959	Clemens PR, et al., "Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy." J Neuromuscul Dis. 2022;9(4):493-501. doi: 10.3233/JND-220811. PMID: 35634851; PMCID: PMC9398057	1/1/2022	SRPT-VYDS-0235633	SRPT-VYDS-0235641	
PTX0960	Diane E. Frank, et al., on behalf of the SKIP-NMD Study Group. "Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy." Neurology. May 2020, 94 (21) e2270-e2282; DOI: 10.1212/WNL.0000000000009233, (corrected at: Increased Dystrophin Production With Golodirsen in Patients With Duchenne Muscular Dystrophy Neurology May 2023, 100 (19) 936; DOI: 10.1212/WNL.0000000000012406)	5/26/2020	SRPT-VYDS-0229866	SRPT-VYDS-0229878	
PTX0961	Scaglioni D, et al., "The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy." Acta Neuropathol Commun. 2021 Jan 6; 9(1):7. doi: 10.1186/s40478-020-01106-1. PMID: 33407808; PMCID: PMC7789286	1/6/2021	NS00143132	NS00143148	
PTX0962	REMOVED DOCUMENT FROM LIST (DUPLICATE)	2/1/2022	SRPT-VYDS-0229421	SRPT-VYDS-0229431	
PTX0963	Clinicaltrials.gov. "NCT02500381, Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) (ESSENCE)," Study Record Versions, July 14, 2015	7/14/2015	NS00143207	NS00143230	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0964	REMOVED DOCUMENT FROM LIST (DUPLICATE)	10/27/2023	NS00046479	NS00046486	
PTX0965	AMONDYS 45 Prescribing Information	3/1/2023	NS00142780	NS00142793	
PTX0966	FDA, "FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy"	6/22/2023	NS00142952	NS00142953	
PTX0967	Strober, J.B., Tennekoon GI. "Progressive Spinal Muscular Atrophies." Journal of Child Neurology. 1999; 14(11):691-695. doi:10.1177/088307389901401101	11/1/1999	NS00143185	NS00143189	
PTX0968	Zolgensma Prescribing Information	10/1/2023	NONE	NONE	
PTX0969	Spinraza Prescribing Information	2/1/2023	NS00143160	NS00143178	
PTX0970	Evrysdi Prescribing Information	10/1/2023	NONE	NONE	
PTX0971	Aartsma-Rus A, et al. "Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy." Neuromuscul Disord. 2002 Oct; 12 Suppl 1:S71-7. doi: 10.1016/s0960-8966(02)00086-x. PMID: 12206800.	10/1/2002	SRPT-VYDS-0008639	SRPT-VYDS-0008650	
PTX0972	Aartsma-Rus A, et al. "Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients." Hum Mol Genet. 2003 Apr 15; 12(8):907-14. doi: 10.1093/hmg/ddg100. PMID: 12668614.	4/15/2003	NS00143452	NS00143459	
PTX0973	Aartsma-Rus A, et al. "Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations." Hum Mutat. 2009 Mar; 30(3):293-9. doi: 10.1002/humu.20918. PMID: 19156838.	3/1/2009	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0974	Arora V, et al. "Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics." Curr Pharm Biotechnol. 2004 Oct; 5(5):431-9. doi: 10.2174/1389201043376706. PMID: 15544491.	10/1/2004	SRPT-VYDS-0009289	SRPT-VYDS-0009297	
PTX0975	Basu S, Wickstrom E. "Synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellular uptake." Bioconjug Chem. 1997 Jul-Aug; 8(4):481-8. doi: 10.1021/bc9700650. PMID:	1/1/1997	NS00143497	NS00143504	
PTX0976	Bendicksen L., et al. "The Regulatory Repercussions of Approving Muscular Dystrophy Medications on the Basis of Limited Evidence." Ann. of Internal Medicine. 2023 Aug. 22; 176(9):1251-1256. https://doi.org/10.7326/M23-1073 .	8/22/2023	NS00143505	NS00143511	
PTX0977	Braasch DA, Corey DR. "Novel antisense and peptide nucleic acid strategies for controlling gene expression." Biochemistry. 2002 Apr 9; 41(14):4503-10. doi: 10.1021/bi0122112. PMID: 11926811.	4/1/2002	NS00143512	NS00143519	
PTX0978	Braasch DA, Corey DR. "Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA." Chem Biol. 2001 Jan; 8(1):1-7. doi: 10.1016/s1074-5521(00)00058-2. PMID: 11182314.	1/1/2001	NS00143520	NS00143526	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0979	Bremmer-Bout M, et al. "Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides." Mol Ther. 2004 Aug; 10(2):232-40. doi: 10.1016/j.ymthe.2004.05.031. PMID: 15294170.	8/1/2004	SRPT-VYDS-0007386	SRPT-VYDS-0007396	
PTX0980	Bradley. "First antisense drug is approved with fleeting success." Nat. Milestones 2019, 5:59	12/1/2019	NS00143527	NS00143527	
PTX0981	Douglas A. and Matthew J.A. Wood. "Splicing therapy for neuromuscular disease." Mol. Cell Neurosci. 2013 Sep; 56:169-185. doi: 10.1016/j.mcn.2013.04.005	9/1/2013	SRPT-VYDS-0009272	SRPT-VYDS-0009288	
PTX0982	Croze F, Prud'homme GJ. Gene therapy of streptozotocin-induced diabetes by intramuscular delivery of modified preproinsulin genes. J Gene Med. 2003 May;5(5):425-37. doi: 10.1002/jgm.359.	5/1/2003	NONE	NONE	
PTX0983	Manning M, Hudgins L; Professional Practice and Guidelines Committee. "Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities." Genet Med. 2010 Nov;12(11):742-5. doi: 10.1097/GIM.0b013e3181f8baad. Erratum in: Genet Med. 2020 Dec;22(12):2126. PMID: 20962661; PMCID: PMC3111046.	11/1/2010	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0984	Geary RS, et al. "Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides." Adv Drug Deliv Rev. 2015 Jun 29;87:46-51. doi: 10.1016/j.addr.2015.01.008. Epub 2015 Feb 7. PMID: 25666165.	6/29/2015	NS00143536	NS00143541	
PTX0985	Hammond S, et al. "Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides." Mol Ther Nucleic Acids. 2014 Nov 25; 3(11): e212. doi: 10.1038/mtna.2014.63	11/25/2014	NS00143542	NS00143552	
PTX0986	Fang J, et al. "An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo." Mol Ther. 2007 Jun;15(6):1153-9. doi: 10.1038/sj.mt.6300142. Epub 2007 Mar 20.	6/1/2007	NONE	NONE	
PTX0987	Heemskerk H., et al. "In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping." J. Gene Med. 2009 Mar;11(3):257-66. doi: 10.1002/jgm.1288.	3/1/2009	NS00049729	NS00049738	
PTX0988	Iwamoto N, et al. "Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides." Nat Biotechnol. 2017 Sep; 35(9):845-851. doi: 10.1038/nbt.3948. Epub 2017 Aug 21. PMID: 28829437.	8/21/2017	NS00143553	NS00143563	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0989	Järver P, et al. "A chemical view of oligonucleotides for exon skipping and related drug applications." Nucleic Acid Ther. 2014 Feb; 24(1):37-47. doi: 10.1089/nat.2013.0454. Epub 2013 Oct 30. PMID: 24171481; PMCID: PMC3923385.	2/14/2014	NS00143564	NS00143574	
PTX0990	Thakur S., et al. "A perspective on oligonucleotide therapy: Approaches to patient customization." Sec. Experimental Pharmacology and Drug Discovery. 2022 Oct 19; 13. https://doi.org/10.3389/fphar.2022.1006304	10/19/2022	NONE	NONE	
PTX0991	Kinali M, et al. "Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study." Lancet Neurol. 2009 Oct; 8(10):918-28. doi: 10.1016/S1474-4422(09)70211-X. Epub 2009 Aug 25. Erratum in: Lancet Neurol. 2009 Dec; 8(12):1083. PMID: 19713152; PMCID: PMC2755039.	10/1/2009	SRPT-VYDS-0007820	SRPT-VYDS-0007833	
PTX0992	Koshkin A, et al. "LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition." Tetrahedron. 1998 Apr. 2; 54(14):3607-30. https://doi.org/10.1016/S0040-4020(98)00094-5 .	4/2/1998	NS00143593	NS00143616	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0993	Mann CJ, et al. "Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse." Proc Natl Acad Sci U S A. 2001 Jan 2; 98(1):42-7. doi: 10.1073/pnas.98.1.42. PMID: 11120883; PMCID: PMC14541.	1/2/2001	NS00143617	NS00143622	
PTX0994	Fragall et al., "Mismatched Single Stranded Antisense Oligonucleotides can Induce Efficient Dystrophin Splice Switching." BNC Medical Genetics. 2011; 12:141.	10/20/2011	NS00143528	NS00143535	
PTX0995	Mercuri E, et al. "Muscle imaging in clinical practice: diagnostic value of muscle magnetic resonance imaging in inherited neuromuscular disorders." Curr Opin Neurol. 2005 Oct; 18(5):526-37. doi: 10.1097/01.wco.0000183947.01362.fe. PMID: 16155435.	10/1/2005	NONE	NONE	
PTX0996	Cunningham A, et al. "Peptides and peptidomimetics as regulators of protein-protein interactions." Curr. Opin. Struct. Biol. 2017 June; 44:59-66. doi:	6/1/2017	NONE	NONE	
PTX0997	Stein C., and Sanjay Goel. "Therapeutic Oligonucleotides: The Road Not Taken." Clin. Cancer Res. 2011 Oct. 14; 17(20):6369-6372. https://doi.org/10.1158/1078-0432.CCR-11-2013	10/14/2011	NS00143631	NS00143634	
PTX0998	U.S. Patent No. 5,185,444	2/9/1993	SRPT-VYDS-0009167	SRPT-VYDS-0009200	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX0999	't Hoen, Peter A.C., et al. "Generation and characterization of transgenic mice with the full-length human DMD gene." J Biol Chem. 2008 Feb 29; 283(9):5899-907. doi: 10.1074/jbc.M709410200. Epub 2007 Dec 13. PMID: 18083704.	2/29/2008	NS00143639	NS00143650	
PTX1000	van Deutekom JC, et al. "Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells." Hum Mol Genet. 2001 Jul 15; 10(15):1547-54. doi: 10.1093/hmg/10.15.1547. PMID: 11468272.	7/15/2001	NS00150216	NS00150223	
PTX1001	van Deutekom JC, et al. "Local dystrophin restoration with antisense oligonucleotide PRO051." N Engl J Med. 2007 Dec 27; 357(26):2677-86. doi: 10.1056/NEJMoa073108. PMID: 18160687.	12/27/2007	SRPT-YVDS-0229593	SRPT-YVDS-0229603	
PTX1002	Wu B, et al. "Targeted Skipping of Human Dystrophin Exons in Transgenic Mouse Model Systemically for Antisense Drug Development." PLoS One. 2011 May 17; 6(5):e19906. doi:10.1371/journal.pone.0019906	5/17/2011	NS00143659	NS00153668	
PTX1003	Stein C. "Delivery of Antisense Oligonucleotides to Cells: A Consideration of Some of the Barriers." Oligos & Peptides 2014,	3/1/2014	NS00143635	NS00143638	
PTX1004	Jason, T. L., et al. "Toxicology of antisense therapeutics." Toxicol. Appl. Pharmacol. 2004 Apr. 17; 201:66-83. doi:10.1016/j.taap.2004.04.017	4/17/2004	NS00143575	NS00143592	
PTX1005	U.S. Patent Application No. 15/274,772	9/23/2016	SRPT-VYDS-0091229	SRPT-VYDS-0094252	
PTX1006	U.S. Patent Application No. 14/740,097	6/15/2015	SRPT-VYDS-0123193	SRPT-VYDS-0130129	
PTX1007	U.S. Patent Application No. 13/741,150	1/14/2013	SRPT-VYDS-0130130	SRPT-VYDS-0150693	
PTX1008	U.S. Patent Application No. 13/168,857	6/24/2011	SRPT-VYDS-0122977	SRPT-VYDS-0123192	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1009	U.S. Patent Application No. 12/837,359	7/15/2010	SRPT-VYDS-0150694	SRPT-VYDS-0153403	
PTX1010	U.S. Patent Application No. 11/570,691	1/15/2008	SRPT-VYDS-0153404	SRPT-VYDS-0154715	
PTX1011	Nippon Shinyaku Co., Ltd., "2.3 Quality Overall Summary - 2.3.S.1 General Information" Viltolarsen (metadata date created 9/28/2019, date modified 9/28/2019)	9/28/2019	NS00035829	NS00035831	
PTX1012	Nippon Shinyaku's Noninfringement Contents	7/11/2023	NONE	NONE	
PTX1013	U.S. Patent Application No. 16/359,213	3/20/2019	SRPT-VYDS-0080977	SRPT-VYDS-0080981	
PTX1014	U.S. Patent No. 9,079,934 B2	7/14/2015	NS00154329	NS00154391	
PTX1015	U.S. Patent Application No. 15/619,996		NONE	NONE	
PTX1016	U.S. Patent No. 10,329,319	9/1/2010	NONE	NONE	
PTX1017	U.S. Patent Application No. 16/449,537	6/24/2019	SRPT-VYDS-0016524	SRPT-VYDS-0016530	
PTX1018	U.S. Patent Application No. 14/776,533	3/14/2014	SRPT-VYDS-0020871	SRPT-VYDS-0021539	
PTX1019	Declaration of Gunnar J. Hanson Under 37 C.F.R. § 1.132	12/13/2018	SRPT-VYDS-0021467	SRPT-VYDS-0021479	
PTX1020	EP3018211 Opposition File, Feb. 22, 2021 Preliminary Opinion	2/22/2021	SRPT-VYDS-0012547	SRPT-VYDS-0012554	
PTX1021	U.S. Patent No. 11,142,767	10/12/2021	NONE	NONE	
PTX1022	Shen X, Corey DR. "Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs." Nucleic Acids Res. 2018 Feb 28;46(4):1584-1600. doi: 10.1093/nar/gkx1239. PMID: 29240946; PMCID: PMC5829639.	2/28/2018	NS00053314	NS00053330	
PTX1023	BioMarin Investors, "BioMarin Announces Withdrawal of Market Authorization Application for Kyndrisa (drisapersen) in Europe"	5/31/2016	SRPT-VYDS-0228249	SRPT-VYDS-0228252	
PTX1024	FDA Briefing Document: Peripheral and Central Nervous System Drugs Advisory Committee Meeting, NDA 206031, Drisapersen	11/24/2015	SRPT-VYDS-0227851	SRPT-VYDS-0228237	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1025	REMOVED DOCUMENT FROM LIST (DUPLICATE)	3/8/2012	SRPT-VYDS-0013116	SRPT-VYDS-0013211	
PTX1026	Spreadsheet of Sequences		SRPT-VYDS-0185566	SRPT-VYDS-0185566	
PTX1027	U.S. Provisional Application No. 61/591,354	1/27/2012	SRPT-VYDS-0228731	SRPT-VYDS-0228824	
PTX1028	U.S. Patent Application Publication No. US 2012/0190728 A1	7/26/2012	SRPT-VYDS-0012496	SRPT-VYDS-0012538	
PTX1029	WO 2008/036127 A2	3/27/2008	SRPT-VYDS-0243584	SRPT-VYDS-0243751	
PTX1030	WO 2009/064471 A1	5/22/2009	SRPT-VYDS-0007297	SRPT-VYDS-0007345	
PTX1031	Moulton, Jon D., and Shan Jiang. "Gene Knockdowns in Adult Animals: PPMOs and Vivo-Morpholinos," Molecules 14.3 (2009): 1304-1323	3/25/2009	SRPT-VYDS-0008651	SRPT-VYDS-0008670	
PTX1032	U.S. Patent No. 11,000,600 B2	5/11/2021	SRPT-VYDS-0010360	SRPT-VYDS-0010516	
PTX1033	U.S. Patent No. 11,395,855	7/26/2022	NONE	NONE	
PTX1034	Moulton, "Using Morpholinos to Control Gene Expression," Curr. Protocol. Nucleic Acid Chem. (2006) 4.30.1-4.30.24	1/1/2006	SRPT-VYDS-0235774	SRPT-VYDS-0235797	
PTX1035	U.S. Patent No. 9,840,706 B2	12/12/2017	NS00154392	NS00154461	
PTX1036	U.S. Patent No. 10,421,966 B2	9/24/2019	NS00154521	NS00154632	
PTX1037	U.S. Patent No. 10,870,676 B2	12/22/2020	NS00154633	NS00154698	
PTX1038	U.S. Patent No. 10,968,450 B2	4/6/2021	NS00154699	NS00154812	
PTX1039	U.S. Patent No. 10,995,337 B2	5/4/2021	NS00154813	NS00154923	
PTX1040	U.S. Patent Application No. 15/420,823	1/31/2017	NS00154924	NS00156005	
PTX1041	U.S. Patent Application Publication No. US 2023/0097387 A1	3/30/2023	NS00156006	NS00156056	
PTX1042	U.S. Patent No. US RE47,691 E	11/5/2019	NS00156057	NS00156166	
PTX1043	U.S. Patent Application No. 15/645,842	7/12/2018	NS00156167	NS00156404	
PTX1044	U.S. Patent No. 9,434,948 File History	9/11/2015	SRPT-VYDS-0057510	SRPT-VYDS-0058788	
PTX1045	U.S. Patent No. 9,447,416 File History	9/17/2015	SRPT-VYDS-0072805	SRPT-VYDS-0074083	
PTX1046	U.S. Patent No. 9,453,225 File History	9/17/2015	SRPT-VYDS-0074084	SRPT-VYDS-0075348	
PTX1047	U.S. Patent No. 9,024,007 B2	5/5/2015	SRPT-VYDS-0080380	SRPT-VYDS-0080486	
PTX1048	WO 2014/100714	12/20/2013	SRPT-VYDS-0228540	SRPT-VYDS-0228610	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1049	U.S. Patent Application No. 14/743,856	6/18/2015	NONE	NONE	
PTX1050	U.S. Continuation Application No. 15/420,823	1/3/2017	NONE	NONE	
PTX1051	Sarepta's Final Infringement Contentions	6/22/2023	NONE	NONE	
PTX1052	Counter-Defendants' Answer to Counter-Plaintiffs' Counterclaims	5/5/2023	NONE	NONE	
PTX1053	Sarepta Form 10-K for 2011	1/1/2012	NONE	NONE	
PTX1054	REMOVED DOCUMENT FROM LIST (DUPLICATE)	5/30/2022	NONE	NONE	
PTX1055	U.S. Patent No. 8,232,384	7/31/2012	SRPT-VYDS-0094253	SRPT-VYDS-0094341	
PTX1056	Morgan Lewis Invoice No. 4467007 for Nippon Shinyaku Co., Ltd.	6/23/2020	NS00153998	NS00154005	
PTX1057	Morgan Lewis Invoice No. 4483535 for Nippon Shinyaku Co., Ltd.	7/13/2020	NS00154006	NS00154016	
PTX1058	Morgan Lewis Invoice No. 4505791 for Nippon Shinyaku Co., Ltd.	8/14/2020	NS00154017	NS00154027	
PTX1059	Morgan Lewis Invoice No. 4526066 for Nippon Shinyaku Co., Ltd.	9/12/2020	NS00154028	NS00154037	
PTX1060	Morgan Lewis Invoice No. 4564716 for Nippon Shinyaku Co., Ltd.	11/12/2020	NS00154038	NS00154046	
PTX1061	Morgan Lewis Invoice No. 4572988 for Nippon Shinyaku Co., Ltd.	11/30/2020	NS00154047	NS00154057	
PTX1062	Morgan Lewis Invoice No. 4598693 for Nippon Shinyaku Co., Ltd.	12/31/2020	NS00154058	NS00154065	
PTX1063	Morgan Lewis Invoice No. 4611100 for Nippon Shinyaku Co., Ltd.	1/21/2021	NS00154066	NS00154074	
PTX1064	Morgan Lewis Invoice No. 4627511 for Nippon Shinyaku Co., Ltd.	2/11/2021	NS00154075	NS00154082	
PTX1065	Morgan Lewis Invoice No. 4656459 for Nippon Shinyaku Co., Ltd.	3/22/2021	NS00154083	NS00154089	
PTX1066	Morgan Lewis Invoice No. 4578144 for Nippon Shinyaku Co., Ltd.	4/27/2021	NS00154090	NS00154095	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1067	Morgan Lewis Invoice No. 4693086 for Nippon Shinyaku Co., Ltd.	5/18/2021	NS00154096	NS00154100	
PTX1068	Morgan Lewis Invoice No. 4985150 for Nippon Shinyaku Co., Ltd.	6/30/2022	NS00154101	NS00154112	
PTX1069	Morgan Lewis Invoice No. 4997678 for Nippon Shinyaku Co., Ltd.	7/22/2022	NS00154113	NS00154125	
PTX1070	Morgan Lewis Invoice No. 502758 for Nippon Shinyaku Co., Ltd.	8/30/2022	NS00154126	NS00154137	
PTX1071	Morgan Lewis Invoice No. 5028813 for Nippon Shinyaku Co., Ltd.	9/2/2022	NS00154138	NS00154148	
PTX1072	Morgan Lewis Invoice No. 5058343 for Nippon Shinyaku Co., Ltd.	10/25/2022	NS00154149	NS00154157	
PTX1073	Morgan Lewis Invoice No. 5082356 for Nippon Shinyaku Co., Ltd.	11/30/2022	NS00154158	NS00154168	
PTX1074	Morgan Lewis Invoice No. 5088286 for Nippon Shinyaku Co., Ltd.	12/6/2022	NS00154169	NS00154183	
PTX1075	Morgan Lewis Invoice No. 5107795 for Nippon Shinyaku Co., Ltd.	1/10/2023	NS00154184	NS00154198	
PTX1076	Morgan Lewis Invoice No. 5126305 for Nippon Shinyaku Co., Ltd.	2/7/2023	NS00154199	NS00154214	
PTX1077	Morgan Lewis Invoice No. 5148461 for Nippon Shinyaku Co., Ltd.	3/10/2023	NS00154215	NS00154231	
PTX1078	Morgan Lewis Invoice No. 5174801 for Nippon Shinyaku Co., Ltd.	4/26/2023	NS00154232	NS00154255	
PTX1079	Morgan Lewis Invoice No. 5191105 for Nippon Shinyaku Co., Ltd.	5/15/2023	NS00154256	NS00154275	
PTX1080	Morgan Lewis Invoice No. 5218283 for Nippon Shinyaku Co., Ltd.	6/23/2023	NS00154276	NS00154294	
PTX1081	Morgan Lewis Invoice No. 5237945 for Nippon Shinyaku Co., Ltd.	7/25/2023	NS00154295	NS00154328	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1082	Morten Hviid & Matthew Olczak (2016) Raising Rivals' Fixed Costs, International Journal of the Economics of Business, 23:1, 19-36, DOI: 10.1080/13571516.2015.1055913	8/6/2015	NONE	NONE	
PTX1083	Markati T, De Waele L, Schara-Schmidt U, Servais L. "Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy," Frontiers in Pharmacology, (November 1, 2021), https://www.ncbi.nlm.nih.gov/pmc/Publication/PMC8591262/pdf/fphar-12-735912.pdf	11/1/2021	NONE	NONE	
PTX1084	Market Definition in Antitrust: Theory and Case, American Bar Association (2012) p. 307	3/8/2012	NONE	NONE	
PTX1085	Rubinfeld and Maness, "The Strategic Use of Patents: Implications for Antitrust," in Antitrust, Patents, and Copyright: EU and US Perspectives, Francois Leveque and Howard Shelanski editors, (2005)	1/1/2005	NONE	NONE	
PTX1086	"A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) (ENVISION)," National Library of Medicine, https://clinicaltrials.gov/study/NCT05881408?term=elevidys&rank=2	12/21/2023	NS00055896	NS00055903	
PTX1087	"BioMarin to Pay Up to \$840 Million for Prosensa," The Wall Street Journal, https://www.wsj.com/Publication/biomarin-to-pay-up-to-840-million-for-prosensa-1416826801	11/24/2014	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1088	"BioMarin to Stop Developing Current Drugs for Duchenne Muscular Dystrophy," The Wall Street Journal, https://www.wsj.com/Publication/biomarin-to-stop-developing-current-drugs-for-duchenne-muscular-dystrophy-1464733329		NONE	NONE	
PTX1089	Penumudi, T., and N. Glover. "FDA Rejects BioMarin's Muscle Wasting Drug; Sarepta Drug in Focus," Reuters (Jan. 14, 2016, 8:40 AM), https://www.reuters.com/article/us-biomarin-pharma-fda/fda-rejects-biomarins-muscle-wasting-drug-sarepta-drug-in-focus-idUSKCN0US10X20160114 (last accessed Oct. 10, 2023)	1/14/2016	NONE	NONE	
PTX1090	"Justice Department Withdraws Report on Antitrust Monopoly Law," U.S. Department of Justice, (May 11, 2009), https://www.justice.gov/opa/pr/justice-department-withdraws-report-antitrustmonopoly-law	5/11/2009	NONE	NONE	
PTX1091	"Our Pipeline," BioMarin, https://www.biomarin.com/our-treatments/pipeline	3/13/2024	NONE	NONE	
PTX1092	"Sarepta Slumps as Concerns Emerge Around Upcoming Gene Therapy Data," Reuters, https://www.reuters.com/business/healthcare-pharmaceuticals/sarepta-slumps-concerns-emergearound-upcoming-gene-therapy-data-2023-06-23/	6/23/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1093	"An Extension Study to Evaluate Casimersen or Golodirsén in Patients With Duchenne Muscular Dystrophy," CLINICALTRIALS.GOV (last updated Aug. 21, 2023), https://clinicaltrials.gov/study/NCT03532542?term=golodirsén&rank=1 (last accessed Oct. 11,	8/21/2023	NONE	NONE	
PTX1094	"Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy," CLINICALTRIALS.GOV (last updated Sept. 28, 2023), https://clinicaltrials.gov/study/NCT03179631?term=Phase%20III&intr=Ataluren&rank=8 (last accessed Oct. 10, 2023)	9/28/2023	NONE	NONE	
PTX1095	"Press Release: MDA Celebrates FDA Approval of Vyondys 53 for Treatment of DMD Amenable to Exon 53 Skipping," MUSCULAR DYSTROPHY ASSOCIATION (Dec. 13, 2019), https://www.mda.org/press-releases/mda-celebrates-fda-approval-vyondys-53-treatment-dmd-amenable-exon-53-skipping (last accessed Oct.	12/13/2019	SRPT-VYDS-0228239	SRPT-VYDS-0228242	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1096	"Press Release: Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments," SAREPTA THERAPEUTICS (Aug. 2, 2023, 4:05 PM), https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-second-quarter-2023-financial (last accessed Oct. 11, 2023)	8/2/2023	NONE	NONE	
PTX1097	"Press Release: Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues," SAREPTA THERAPEUTICS (Jan. 9, 2023, 1:28 PM), https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-reports-preliminary-fourth-quarter-and-full	1/9/2023	NONE	NONE	
PTX1098	"PTC Receives Refuse to File Letter from FDA for Translarna (ataluren)," PTC THERAPEUTICS (Feb. 23, 2016), https://ir.ptcbio.com/news-releases/news-release-details/ptc-receives-refuse-file-letter-fda-translarnatm-ataluren (last accessed Oct. 10, 2023)	2/23/2016	NONE	NONE	
PTX1099	Clinicaltrials.gov. "NCT02500381, Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) (ESSENCE)," Study Record Versions, September 28, 2016	2/21/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1100	"Press Release: Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments," SAREPTA THERAPEUTICS (Mar. 1, 2021)	3/1/2021	SRPT-VYDS-0009669	SRPT-VYDS-0009678	
PTX1101	Golodirsén Development Safety Update Report 8	10/26/2022	SRPT-VYDS-0207979	SRPT-VYDS-0208198	
PTX1102	"Press Release: Prosensa Initiates First Patient Dosing in Phase I/II Trial of PRO053," SEC (Aug. 9, 2023, 10:31 AM)	8/9/2023	SRPT-VYDS-0228238	SRPT-VYDS-0228238	
PTX1103	"A Phase I/II Study of BMN053 in Subjects with Duchenne Muscular Dystrophy (DMD)," CLINICALTRIALS.GOV (Aug. 9, 2023, 10:30 AM)	8/9/2023	SRPT-VYDS-0228243	SRPT-VYDS-0228247	
PTX1104	"Search Orphan Drug Designations and Approvals" Study, U.S. FDA (Jan. 23, 2013)	1/23/2013	SRPT-VYDS-0228248	SRPT-VYDS-0228248	
PTX1105	"Sarepta Therapeutics Announces FDA Approval of VYONDYS 53 (golodirsén) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53," SAREPTA THERAPEUTICS (Dec. 12, 2019, 18:19)	12/12/2019	SRPT-VYDS-0228253	SRPT-VYDS-0228256	
PTX1106	U.S. Patent No. US RE47,691 E (Certified), Wilton et al., "Antisense Oligonucleotides for Inducing Exon Skipping and Methods of Use Thereof," Date of Reissued Patent Dec. 17, 2019	12/17/2019	SRPT-VYDS-0154716	SRPT-VYDS-0154829	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1107	"A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy," CLINICALTRIALS.GOV (last updated Dec. 13, 2022), https://clinicaltrials.gov/study/NCT03362502	12/13/2022	NONE	NONE	
PTX1108	"Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy," CLINICALTRIALS.GOV (last updated Aug. 31, 2023), https://clinicaltrials.gov/study/NCT04281485	8/31/2023	NONE	NONE	
PTX1109	"Press Release: Solid Biosciences Provides First Quarter Business Update and Financial Results," SOLID BIOSCIENCES (May 11, 2023)	5/11/2023	NONE	NONE	
PTX1110	"Press Release: REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society," REGENXBIO (Oct. 3, 2023)	10/3/2023	NONE	NONE	
PTX1111	"Press Release: Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting," ULTRAGENYX (May 8, 2023)	5/8/2023	NONE	NONE	
PTX1112	U.S. Patent No. 6,653,467, Matsuo et al., "Medicament for Treatment of Duchenne Muscular Dystrophy."	11/25/2003	SRPT-VYDS-00229318	SRPT-VYDS-00229329	
PTX1113	U.S. Patent Application No. 14/776,533 Office Action Response	8/28/2017	SRPT-VYDS-0089321	SRPT-VYDS-0089352	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1114	U.S. Patent Application No. 14/776,533 Office Action Response	12/14/2018	SRPT-VYDS-0089151	SRPT-VYDS-0089188	
PTX1115	Aartsma-Rus, A., and F. Muntoni. "Workshop Report: 194th ENMC International Workshop. 3rd ENMC Workshop on Exon Skipping: Towards Clinical Application of Antisense-mediated Exon Skipping for Duchenne Muscular Dystrophy, 8-10 December 2012, Naarden, The Netherlands." <i>Neuromuscular Disorders</i> 23:934-94 (2013)	6/17/2013	NS00103415	NS00103425	
PTX1116	Aung-Htut, May T. et al., "Systematic Approach to Developing Splice Modulating Antisense Oligonucleotides" <i>International Journal of Molecular Sciences</i> 20:5030. (2019) https://doi.org/10.3390/ijms20205030	10/11/2019	SRPT-VYDS-0241561	SRPT-VYDS-0241572	
PTX1117	F. Muntoni, et al. "149th ENMC International Workshop and 1st TREAT-NMD Workshop on: 'Planning Phase I/II Clinical Trials Using Systemically Delivered Antisense Oligonucleotides in Duchenne Muscular Dystrophy.'" <i>Neuromuscular Disorders</i> 18(3):268-275 (2008)	3/1/2008	NONE	NONE	
PTX1118	N. Watanabe, et al. "NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy." <i>Molecular Therapy: Nucleic Acids</i> 13:442-449 (2018) and Supplemental Information	12/13/2018	SRPT-VYDS-0229611	SRPT-VYDS-0229620	
PTX1119	U.S. Patent No. 9,035,040	5/19/2015	NS00156630	NS00156732	
PTX1120	U.S. Patent Application No. 13/902,376, Response to Office Action	3/21/2014	NS00156573	NS00156608	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1121	U.S. Patent Application No. 14/317,952, Amendment in Response to Non-Final Office Action	2/6/2015	NS00156609	NS00156629	
PTX1122	Aartsma-Rus, Annemieke et al., "Guidelines for Antisense Oligonucleotide Design and Insight Into Splice-modulating Mechanisms," 17(3)	3/1/2009	SRPT-VYDS-0008671	SRPT-VYDS-0008680	
PTX1123	Arechavala-Gomeza, V. et al., "Comparative Analysis of Antisense Oligonucleotide Sequences for Targeted Skipping of Exon 51 During Dystrophin Pre-mRNA Splicing in Human Muscle," 18(9) Human. Gene Ther. 798-810 (September 2007)	9/1/2007	SRPT-VYDS-0009069	SRPT-VYDS-0009085	
PTX1124	Institute for Clinical and Economic Review "Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy: Effectiveness and Value" Final Evidence Report	4/22/2022	NS00137465	NS00137624	
PTX1125	Sarepta's 2017 Form 10-K for the fiscal year ended December 31, 2017, submitted on March 1, 2018	3/1/2018	SRPT-VYDS-0202780	SRPT-VYDS-0202926	
PTX1126	Sarepta's 2018 Form 10-K	1/1/2018	SRPT-VYDS-0203987	SRPT-VYDS-0204122	
PTX1127	U.S. Patent No. 8,084,061	12/27/2011	NONE	NONE	
PTX1128	University of Western Australia v. Academisch Ziekenhuis Leiden, Interference No. 106,007, UWA Motion 1 (PTAB Nov. 18, 2014)	11/18/2014	NONE	NONE	
PTX1129	Declaration of Gardner Gendron	1/11/2024	NONE	NONE	
PTX1130	International PCT Application No. PCT/JP2011/070318 (Japanese)	8/31/2011	NONE	NONE	
PTX1131	Sarepta Therapeutics, Inc.'s Responses to Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s First Set of Requests for Admission (Nos. 1-10)	4/3/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1132	Sarepta Therapeutics, Inc.'s Supplemental Responses and Objections to Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s First Set of Requests for Admission (Nos. 2-3)	7/14/2023	NONE	NONE	
PTX1133	Sarepta Therapeutics, Inc.'s Objections and Responses to Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s Second Set of Requests for Admission (Nos. 11-56)	7/27/2023	NONE	NONE	
PTX1134	Sarepta Therapeutics, Inc.'s Supplemental Objections and Responses to Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s Second Set of Requests for Admission (Nos. 36-38)	8/3/2023	NONE	NONE	
PTX1135	Sarepta's Responses and Objections to NS'S First Set of Requests for Production to Sarepta (Nos. 1-149)	4/11/2022	NONE	NONE	
PTX1136	Sarepta's Responses and Objections to NS'S First Set of Interrogatories (Nos. 1-13)	4/11/2022	NONE	NONE	
PTX1137	Sarepta's and UWA's Supplemental Responses and Objections to NS's Interrogatories (Nos. 6-9 and 15)	6/9/2023	NONE	NONE	
PTX1138	Chan et al., "Antisense Oligonucleotides: From Design to Therapeutic Application," Clin. Exp. Pharmacol. Physiol. (2006) 33(5-6): 533-540 ("Chan 2006")	2/5/2006	SRPT-VYDS-0009046	SRPT-VYDS-0009055	
PTX1139	Pon, "Solid-Phase Supports for Oligonucleotide Synthesis," Curr. Protoc. Nucleic Acid Chem. (2000) 00(1): 3.1.1.-	1/1/2000	NONE	NONE	
PTX1140	Collins English Dictionary, 11th ed. (2011)	1/1/2011	NONE	NONE	
PTX1141	Comprehensive Organic Synthesis, 2d ed. (2014) Vol. 2, pp. 273-339	1/1/2014	NONE	NONE	
PTX1142	Declaration of Nathan W. Luedtke, Ph.D. dated February 27, 2023	2/27/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1143	Flickinger et al., "Spatial Photorelease of Oligonucleotides, Using a Safety-Catch Photolabile Linker" Organic Letters, Vol. 8, No. 11 2357-2360 (2006)	3/15/2006	NONE	NONE	
PTX1144	Weichert, F., "Topic: Safety-Catch Linker (SCAL)"	NONE	NONE	NONE	
PTX1145	Ti et al., "Transient Protection: Efficient One-Flash Syntheses of Protected Deoxynucleosides," J. Am. Chem. Soc., 104, 1316-1319 (1982)	1/1/1982	NONE	NONE	
PTX1146	MacCoss, et al., "Facile detritylation of nucleoside derivatives by using trifluoroacetic acid"	5/18/1977	SRPT-VYDS-0007713	SRPT-VYDS-0007717	
PTX1147	Reply Declaration of Dr. Bradley L. Pentelute	3/13/2023	NONE	NONE	
PTX1148	Aartsma-Rus et al., "Antisense-Mediated Exon Slipping: A Versatile Tool with Therapeutic and Research Applications," RNA (2007) 13(10): 1609-1624 ("Aartsma-Rus 2007")	10/1/2007	SRPT-VYDS-0009201	SRPT-VYDS-0009220	
PTX1149	"DNA and Chromosomes" Molecular Biology of the Cell, Fourth Edition, (191-374)	1/1/2002	SRPT-VYDS-0007858	SRPT-VYDS-0007981	
PTX1150	Botvin Madorsky at al., "Psychosocial Aspects of Death and Dying in Duchenne Muscular Dystrophy," Arch. Phys. Med. Rehabil. (1984) 65(2): 79-82 ("Botvin Madorsky 1984")	2/1/1984	NONE	NONE	
PTX1151	Nippon Shinyaku Co. Ltd., Opposition Against European Patent No. 2206781 B1 ("NS Notice of Opposition")	8/25/2016	NONE	NONE	
PTX1152	Koenig et al., "The Complete Sequence of Dystrophin Predicts a Rod-Shaped Cytoskeletal Protein," Cell (1988) 53(2):219-228 ("Koenig 1988")	4/22/1988	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1153	Prosecution History of U.S. Application No. 15/273,772 (Excerpt)	9/23/2016	SRPT-VYDS-0091229 SRPT-VYDS-0091258 SRPT-VYDS-0091344 SRPT-VYDS-0094151 SRPT-VYDS-0094177	SRPT-VYDS-0091229 SRPT-VYDS-0091266 SRPT-VYDS-0091347 SRPT-VYDS-0094162 SRPT-VYDS-0094185	
PTX1154	Summerton et al., "Morpholino and Phosphorothioate Antisense Oligomers Compared in Cell-Free and In-Cell Systems," Antisense Nucleic Acid Drug Dev. (1997) 7(2): 63-70 ("Summerton 1997(b)")	1/1/1997	NS00061980	NS00061988	
PTX1155	Suzuki et al., "Gene Therapy for Duchenne Muscular Dystrophy," Future Neurol. (2006) 2(1): 87-96 ("Suzuki 2007")	1/1/2007	NONE	NONE	
PTX1156	Wilton et al., "Specific Removal of the Nonsense Mutation from the <i>mdx</i> Dystrophin mRNA Using Antisense Oligonucleotides," Neuromuscul. Disord. (1999) 9(5):330-338 ("Wilton 1999")	1/1/1999	WILTON0025929	WILTON0025949	
PTX1157	Wilton et al., "Antisense Oligonucleotides, Exon Skipping and the Dystrophin Gene Transcript," Acta Myol. (2005) 24(3): 222-229 ("Wilton 2005")	12/1/2005	WILTON0021804	WILTON0021811	
PTX1158	Aartsma-Rus et al., "Less is More: Therapeutic Exon Skipping for Duchenne Muscular Dystrophy," Lancet Neurol. (2009) 8(10): 873-875 ("Aartsma-Rus 2009")	10/1/2009	SRPT-VYDS-0009041	SRPT-VYDS-0009045	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1159	Swanson, "FDA Approves Sarepta Therapeutics' Vyondys 53 for Treatment of DMD Amenable to Exon 53 Skipping," Muscular Dystrophy Association: Quest (December 13, 2019), https://mdaquest.org/fda-approves-sarepta-therapeutics-vyondys-53-for-treatment-of-dmd-amenable-to-exon-53-skipping/ ("MDA 2019")	12/13/2019	NONE	NONE	
PTX1160	Opening Declaration of Cy A. Stein, M.D., Ph.D. dated January 4, 2023	1/4/2023	NONE	NONE	
PTX1161	U.S. Patent No. 8,084,601 (Poppewell)	12/27/2011	NONE	NONE	
PTX1162	Gene Tools, LLC, Morpholino History, Production, and Properties, available at https://www.gene-tools.com/history_production_and_properties (last accessed Feb. 6, 2023)	2/6/2023	NONE	NONE	
PTX1163	Helm, J., Towards Personalized Allele-Specific Antisense Oligonucleotide Therapies for Toxic Gain-of Function Neurodegenerative Diseases, <i>Pharmaceutics</i> 2022, 14, 1708	1/1/2022	NONE	NONE	
PTX1164	LEQVIO Prescribing Information, Revised 12/2021	12/1/2021	NONE	NONE	
PTX1165	The Writing Center, Parallel Structure available at https://writingcenter.gmu.edu/writing-resources/grammar-style/parallel-structure (last accessed Feb. 6, 2023)	2/6/2023	NONE	NONE	
PTX1166	Merriam Webster Online Dictionary definition of "within" available at https://www.merriam-webster.com/dictionary/within (last accessed Feb. 6, 2023)	2/6/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1167	Prosecution History of RE47,691 (Excerpt) [2 PDF files]	11/2/2018	SRPT-VYDS-0005577; NONE	SRPT-VYDS-0005595; NONE	
PTX1168	Grammar Monster definition of “non-restrictive clause” available at https://www.grammar-monster.com/glossary/non-restrictive_clauses.htm (last accessed Feb. 6,	2/6/2023	NONE	NONE	
PTX1169	Koenig et al., “Complete Cloning of the Duchenne Muscular Dystrophy (DMD) cDNA and Preliminary Genomic Organization of the DMD Gene in Normal and Affected Individuals,” Cell (1987) 50(3):509-517 (“Koenig 1987”)	1/1/1987	NONE	NONE	
PTX1170	Havens et al., “Targeting RNA Splicing for Disease Therapy,” WIREs RNA (2013) 4(3): 247-266 (“Havens 2013”)	1/1/2013	NONE	NONE	
PTX1171	Merriam-Webster, Inc., Merriam-Webster’s Collegiate Dictionary 1341 (10th ed. 2000) (“Merriam-Webster Dictionary”)	1/1/2000	NONE	NONE	
PTX1172	Univ. of Chi. Press, The Chicago Manual of Style Online § 6.19, https://www.chicagomanualofstyle.org/book/ed17/part2/ch06/psec019.html (last visited Feb. 21, 2023)	2/21/2023	NONE	NONE	
PTX1173	Reply Declaration of Cy A. Stein, M.D., Ph.D. dated February 27, 2023	2/27/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1174	"[REDACTED] Agreement" between [REDACTED] of Nippon Shinyaku Co., Ltd., "concerning" [REDACTED] (Japanese)	4/1/2010	NS00036948	NS00036951	
PTX1175	"[REDACTED] Agreement" between [REDACTED] of Nippon Shinyaku Co., Ltd., "[REDACTED] (certified English translation)	4/1/2010	NS00036952	NS00036956	
PTX1176	NS Pharma Third Quarter 2021 ASP Report	9/30/2021	NS00036987	NS00036987	
PTX1177	NS Pharma Fourth Quarter 2021 ASP Report	12/31/2021	NS00036988	NS00036988	
PTX1178	NS Pharma First Quarter 2022 ASP Report	3/31/2022	NS00036989	NS00036989	
PTX1179	NS Pharma Second Quarter 2022 ASP Report	6/30/2022	NS00036990	NS00036990	
PTX1180	NS Pharma Third Quarter 2022 ASP Report	9/30/2022	NS00036991	NS00036991	
PTX1181	NS Pharma Fourth Quarter 2022 ASP Report	12/31/2022	NS00036992	NS00036992	
PTX1182	U.S. Patent No. 10,683,322 File History	8/12/2021	NS00034978	NS00035327	
PTX1183	Spreadsheet with [REDACTED] Data (metadata parent date 2/10/2011, date created 6/18/2009, date modified 2/10/2011)	2/10/2011	NS00065425	NS00065425	
PTX1184	Laboratory Notebook, "[REDACTED] (Japanese followed by certified English translation) (partially redacted) date range 3-15-2021 through October 12, 2012	10/12/2012	NS00066669	NS00066746	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1185	Laboratory Notebook, "[REDACTED] [REDACTED] cover and index (Japanese followed by certified English translation)	9/8/2010	NS00060719	NS00060934	
PTX1186	Slides of [REDACTED] (Japanese followed by certified English translation) (metadata parent date 1/26/2010, date created 4/15/2009, date modified 1/26/2010)	1/26/2010	NS00061464	NS00061467	
PTX1187	REMOVED DOCUMENT FROM LIST (DUPLICATE)	1/26/2010	NS00061464	NS00061467	
PTX1188	Research & Development Planning Dept., "[REDACTED] [REDACTED] (Japanese followed by certified English translation)	1/24/2013	NS00091140	NS00091192	
PTX1189	NCNP Invention disclosure (Japanese followed by certified English translation) "Drafted on August 4, 2010"	8/4/2010	NS00074007	NS00074012	
PTX1190	NCNP Invention disclosure (English) "Drafted on August 4, 2010"	8/4/2010	NS00074013	NS00074018	
PTX1191	NCNP Invention disclosure (Japanese followed by certified English translation), "Neurology/Psychiatry Issue No. 164, August 4, 2010"	8/4/2010	NS00074019	NS00074020	
PTX1192	NCNP Invention disclosure (English) "Neurology/Psychiatry Issue No. 164, August 4, 2010"	8/4/2010	NS00074021	NS00074022	
PTX1193	NS-065/NCNP-01 Investigator's Brochure, version 4.0	4/5/2017	NS00040050	NS00040151	
PTX1194	NS-065/NCNP-01 Investigator's Brochure, version 5.0	5/18/2018	NS00040152	NS00040280	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1195	NS-065/NCNP-01 Investigator's Brochure, version 3.1	7/14/2016	NS00040281	NS00040382	
PTX1196	NS-065/NCNP-01 Investigator's Brochure, version 8.0	6/25/2021	NS00040383	NS00040607	
PTX1197	NS-065/NCNP-01 Investigator's Brochure, version 6.0	6/28/2019	NS00040608	NS00040817	
PTX1198	Spreadsheet with H53 30nM Sample Data		NS00065377	NS00065377	
PTX1199	Spreadsheet with H53 30nM and 100nM Sample Data		NS00065379	NS00065379	
PTX1200	Spreadsheet with H53 30nM Sample Data		NS00065381	NS00065381	
PTX1201	Spreadsheet with H53 10nM and 30nM Sample Data		NS00065387	NS00065387	
PTX1202	Spreadsheet with H53 10nM, 30nM, and 100nM Sample Data		NS00065389	NS00065389	
PTX1203	Spreadsheet with H53 10nM, 30nM, and 100nM Sample Data		NS00065391	NS00065391	
PTX1204	Spreadsheet with H53 30nM and 100nM Sample Data		NS00065392	NS00065392	
PTX1205	Spreadsheet with H53 30nM and 100nM Sample Data		NS00065395	NS00065395	
PTX1206	Spreadsheet with H53 1uM, 3uM, and 10uM Sample Data		NS00065396	NS00065396	
PTX1207	Spreadsheet with H53 1uM, 3uM, and 10uM Sample Data		NS00065397	NS00065397	
PTX1208	Spreadsheet with H53 1uM, 3uM, and 10uM Sample Data		NS00065409	NS00065409	
PTX1209	Spreadsheet with H53 1uM, 3uM, and 10uM Sample Data		NS00065411	NS00065411	
PTX1210	Laboratory Notebook, "[REDACTED] [REDACTED] (Japanese followed by certified English translation)	12/1/2009	NS00060481	NS00060718	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1211	Slides of [REDACTED] (Japanese followed by certified English translation)	7/29/2010	NS00085516	NS00085521	
PTX1212	NS-065/NCNP-01 Investigator's Brochure, version 7.0	5/29/2020	NS00040818	NS00040838	
PTX1213	"Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-label, 4-year Extension Study" Presentation Slide (metadata date created 9/24/2022, date modified	9/24/2022	NS00041265	NS00041265	
PTX1214	Viltolarsen (NS-065/NCNP-01) 3rd Development Safety Update Report for Reporting Period May 14, 2016 to May 13, 2017	6/30/2017	NS00038774	NS00038804	
PTX1215	Viltolarsen (NS-065/NCNP-01) 4th Development Safety Update Report for Reporting Period May 14, 2017 to May 13, 2018	7/6/2018	NS00038805	NS00038837	
PTX1216	Viltolarsen (NS-065/NCNP-01) 5th Development Safety Update Report for Reporting Period May 14, 2018 to May 13, 2019	7/11/2019	NS00038838	NS00038882	
PTX1217	Viltolarsen (NS-065/NCNP-01) 6th Development Safety Update Report for Reporting Period May 14, 2019 to May 13, 2020	7/1/2020	NS00038883	NS00038939	
PTX1218	Viltolarsen (NS-065/NCNP-01) 7th Development Safety Update Report for Reporting Period May 14, 2020 to May 13, 2021, Date of DSUR: 24-Jun-2021, signed June 24 & 25, 2021	6/25/2021	NS00038940	NS00039215	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1219	Study of NS-065/NCNP-01-201, "A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys with Duchenne Muscular Dystrophy (DMD)"	5/30/2019	NS00039502	NS00039680	
PTX1220	"[REDACTED] Agreement," between [REDACTED] and [REDACTED] Nippon Shinyaku Co., Ltd. "[REDACTED]" dated May 30, 2018 (Japanese followed by certified English translation)	5/30/2018	NS00036909	NS00036927	
PTX1221	K-b-57-(1) Agreement [REDACTED] and Nippon Shinyaku Co., Ltd. (Japanese followed by certified English translation)	3/4/2013	NS00091198	NS00091206	
PTX1222	[REDACTED] and Nippon Shinyaku Co., Ltd.'s Joint Research Agreement	6/16/2018	NS00091207	NS00091223	
PTX1223	[REDACTED] and Nippon Shinyaku Co., Ltd. Agreement	10/25/2021	NS00090456	NS00090489	
PTX1224	Statement of Work for [REDACTED] Agreement between Nippon Shinyaku Co., Ltd. and [REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	
[REDACTED]	[REDACTED] Agreement between Nippon Shinyaku Co., Ltd. and [REDACTED] (English and Russian)	8/26/2022	NS00090697	NS00090722	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1226	Agreement between Nippon Shinyaku Co., Ltd. and [REDACTED]	8/26/2022	NS00090567	NS00090572	
PTX1227	Form 5 - Joint Study Decision Notification (Japanese followed by certified English translation)	8/27/2009	NS00090449	NS00090449	
PTX1228	Eastern Drug Discovery Institute, "Business Trip Report" (Japanese followed by certified English translation)	6/25/2009	NS00090891	NS00090893	
PTX1229	Eastern Drug Discovery Institute, "Outsourced Study Review Opinion" (Japanese followed by certified English translation)	3/31/2009	NS00090894	NS00090896	
PTX1230	Eastern Drug Discovery Study Institute, "Contracted Study Review Request" (Japanese followed by certified English translation)	3/13/2009	NS00090897	NS00090899	
PTX1231	Eastern Drug Discovery Study Institute, "Study of Duchenne Muscular Dystrophy Treatment with Nucleic Acid Derivatives" (Japanese followed by certified English translation)	3/31/2009	NS00090900	NS00090902	
PTX1232	[REDACTED] and Nippon Shinyaku Co., Ltd.'s Memorandum [REDACTED] (Japanese followed by certified English translation)	6/16/2014	NS00091193	NS00091197	
PTX1233	ClinicalTrials.gov, "Exploratory Study of NS-065/NCNP-01 in DMD," last updated February 26, 2020, last accessed June 12, 2020	2/26/2020	NS00046540	NS00046546	
PTX1234	Takeda, Shin'ichi, et al. "Exon-Skipping in Duchenne Muscular Dystrophy," Journal of Neuromuscular Diseases (2021): 1-16	6/24/2021	NS00053735	NS00053750	
PTX1235	Nippon Shinyaku Co., Ltd., "2 Summaries, 2.4 Nonclinical Overview" (metadata date created 2/1/2019, date modified 1/31/2019)	2/1/2019	NS00065469	NS00065540	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1236	Nippon Shinyaku Co., Ltd., "2.7 Clinical Written and Tabulated Summaries, 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods" Viltolarsen (metadata date created 9/28/2019, date modified 9/28/2019)	9/28/2019	NS00065939	NS00065957	
PTX1237	Nippon Shinyaku Co., Ltd., "2.7 Clinical Written and Tabulated Summaries, 2.7.2 Summary of Clinical Pharmacology Studies" (metadata date created 9/28/2019, date modified 9/28/2019)	9/28/2019	NS00065958	NS00065999	
PTX1238	Nippon Shinyaku Co., Ltd., "2.7 Clinical Written and Tabulated Summaries, 2.7.4 Summary of Clinical Safety" (metadata date created 9/28/2019, date modified 9/28/2019)	9/28/2019	NS00066109	NS00066219	
PTX1239	Nippon Shinyaku Co., Ltd., "2.7 Clinical Written and Tabulated Summaries, 2.7.6 Synopses of Individual Studies" (metadata date created 9/28/2019, date modified 9/28/2019)	9/28/2019	NS00066226	NS00066227	
PTX1240	Nippon Shinyaku Co., Ltd., "5.3.5.3 Safety Update Report - NDA 212154 Integrated Summary of Safety, 2.7.4 Summary of Clinical Safety" (metadata date created 1/1/2020, date modified 1/1/2020)	1/1/2020	NS00066228	NS00066342	
PTX1241	Nippon Shinyaku Co., Ltd., "NS-065/NCNP-01 Clinical Study Report: A Phase I/II Study of NS-065/NCNP-01 in Patients with Duchenne Muscular Dystrophy, A Dose-finding Study"	7/30/2018	NS00128908	NS00129028	
PTX1242	Nippon Shinyaku Co., Ltd. and NS Pharma, Inc.'s [REDACTED]	4/1/2020	NS00036879	NS00036881	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1243	██████████ and Nippon Shinyaku Co., Ltd.'s Memorandum ██████████ (Japanese followed by certified English translation)	11/26/2020	NS00090904	NS00090913	
PTX1244	██████████ and Nippon Shinyaku Co., Ltd. (Japanese followed by certified English translation)	2/18/2013	NS00091128	NS00091139	
PTX1245	██████████ and Nippon Shinyaku Co., Ltd.'s Memorandum ██████████ (Japanese followed by certified English translation)	3/3/2015	NS00091117	NS00091119	
PTX1246	██████████ and Nippon Shinyaku Co., Ltd.'s Memorandum ██████████ (Japanese followed by certified English translation)	3/2/2016	NS00091120	NS00091122	
PTX1247	██████████ and Nippon Shinyaku Co., Ltd.'s Memorandum ██████████ (Japanese followed by certified English translation)	3/24/2017	NS00091123	NS00091127	
PTX1248	Memorandum ██████████ ██████████ from Nippon Shinyaku Co., Ltd. to NS Pharma, Inc.	9/20/2019	NS00065822	NS00065826	
PTX1249	██████████ Spreadsheet (Japanese followed by certified English translation)	6/26/2020	NS00073811	NS00073823	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1250	[REDACTED] Spreadsheet (Japanese followed by certified English translation)	5/14/2021	NS00073824	NS00073830	
PTX1251	Forecast Model - Stretch		NS00140987	NS00140987	
PTX1252	"[REDACTED] Slide Deck		NS00140988	NS00140994	
PTX1253	Sales Spreadsheet		NS00140995	NS00140995	
PTX1254	First 10-year Sales Forecast for Viltolarsen (tentative) Spreadsheet	11/1/2019	NS00140997	NS00140997	
PTX1255	First 10-year Sales Forecast for Viltolarsen (tentative) Spreadsheet	1/21/2020	NS00140998	NS00140998	
PTX1256	First 10-year Sales Forecast for Viltolarsen (tentative) Spreadsheet	1/21/2020	NS00140999	NS00140999	
PTX1257	First 10-year Sales Forecast for Viltolarsen (tentative) Spreadsheet	1/21/2020	NS00141000	NS00141000	
PTX1258	First 10-year Sales Forecast for Viltolarsen (tentative) Spreadsheet		NS00141001	NS00141001	
PTX1259	"Patent Information Submitted with the Filing of an NDA, Amendment, or Supplement," NDA Number 211970, Sarepta Therapeutics, Inc., golodirsen injection, U.S. Patent No. 9,994,851, Form FDA 3542a	7/31/2018	SRPT-VYDS-0007000	SRPT-VYDS-0007003	
PTX1260	NS Pharma, Inc. [REDACTED] [REDACTED] Spreadsheet	12/31/2020	NS00036986	NS00036986	
PTX1261	VYONDYS 53 Sales Spreadsheet for 2022 Quarter 1		SRPT-VYDS-0213329	SRPT-VYDS-0213329	
PTX1262	"[REDACTED] Deck Slide	1/1/2020	SRPT-VYDS-0209765	SRPT-VYDS-0209765	
PTX1263	COGS Estimates Spreadsheet		SRPT-VYDS-0210699	SRPT-VYDS-0210699	
PTX1264	COGS Estimates Spreadsheet		SRPT-VYDS-0210700	SRPT-VYDS-0210700	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1265	Sarepta Therapeutics, "[REDACTED] [REDACTED] Slide Deck	11/23/2020	SRPT-VYDS-0210701	SRPT-VYDS-0210725	
PTX1266	COGS Estimates Spreadsheet		SRPT-VYDS-0210726	SRPT-VYDS-0210726	
PTX1267	COGS Estimates Spreadsheet		SRPT-VYDS-0210799	SRPT-VYDS-0210799	
PTX1268	COGS Estimates Spreadsheet		SRPT-VYDS-0210800	SRPT-VYDS-0210800	
PTX1269	COGS Estimates Spreadsheet		SRPT-VYDS-0210801	SRPT-VYDS-0210801	
PTX1270	Sarepta Therapeutics, "[REDACTED] [REDACTED] Slide Deck	6/21/2021	SRPT-VYDS-0210802	SRPT-VYDS-0210836	
PTX1271	Sarepta Therapeutics, "[REDACTED] [REDACTED] Slide Deck	6/20/2022	SRPT-VYDS-0227788	SRPT-VYDS-0227825	
PTX1272	Sarepta Therapeutics, "Q3 2022 Customer QBR" Slide Deck	10/19/2022	SRPT-VYDS-0227481	SRPT-VYDS-0227529	
PTX1273	Sarepta Therapeutics, "Integrated Customer Insights, October 2022, Data Presented as of End of August 2022" Slide Deck	9/1/2022	SRPT-VYDS-0227530	SRPT-VYDS-0227559	
PTX1274	Sarepta Therapeutics, "Integrated Customer Insights, October 2022, Data Presented as of End of September 2022" Slide Deck	9/30/2022	SRPT-VYDS-0227560	SRPT-VYDS-0227585	
PTX1275	Sarepta Therapeutics, "Integrated Customer Insights, August 2022, Data Presented as of End of July 2022" Slide Deck	8/1/2022	SRPT-VYDS-0227586	SRPT-VYDS-0227615	
PTX1276	Sarepta Therapeutics, "Integrated Customer Insights, November 2022, Data Presented as of End of October 2022" Slide Deck	10/31/2022	SRPT-VYDS-0227616	SRPT-VYDS-0227642	
PTX1277	Sarepta Therapeutics, "Integrated Customer Insights, December 2022" Slide Deck	12/1/2022	SRPT-VYDS-0227643	SRPT-VYDS-0227669	
PTX1278	Sarepta Therapeutics, "Integrated Customer Insights, July 2022" Slide Deck		SRPT-VYDS-0227670	SRPT-VYDS-0227701	
PTX1279	Sarepta Therapeutics, "Integrated Customer Insights, Published January 2023, Covering Q4 2022" Slide Deck	1/1/2023	SRPT-VYDS-0227702	SRPT-VYDS-0227728	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1280	Sarepta Therapeutics, "Integrated Customer Insights, Published April 2023, Covering Q4 2022" Slide Deck	4/1/2023	SRPT-VYDS-0227729	SRPT-VYDS-0227748	
PTX1281	Sarepta Therapeutics, "Integrated Customer Insights, Published March 2023, Covering Q4 2022" Slide Deck	3/1/2023	SRPT-VYDS-0227749	SRPT-VYDS-0227766	
PTX1282	Master Services Agreement between [REDACTED] and [REDACTED]	11/2/2022	SRPT-VYDS-0219945	SRPT-VYDS-0219962	
PTX1283	Master Development and Supply Agreement between [REDACTED] and [REDACTED]	10/22/2021	SRPT-VYDS-0219892	SRPT-VYDS-0219932	
PTX1284	Product Addendum to October 22, 2021 Master Development and Supply Agreement between [REDACTED] and [REDACTED]	6/30/2022	SRPT-VYDS-0219939	SRPT-VYDS-0219944	
PTX1285	Commercial Packaging Agreement between [REDACTED] and [REDACTED]	1/8/2016	SRPT-VYDS-0219826	SRPT-VYDS-0219873	
PTX1286	Distribution Services Agreement between [REDACTED] and [REDACTED]	12/4/2015	SRPT-VYDS-0213458	SRPT-VYDS-0213507	
PTX1287	First Amendment to Distribution Services Agreement between [REDACTED] and [REDACTED]	5/1/2019	SRPT-VYDS-0213451	SRPT-VYDS-0213457	
PTX1288	[REDACTED] Agreement between Nippon Shinyaku Co., Ltd. and [REDACTED]	8/20/2014	NS00091066; NS00073467	NS00091090 NS00073478	
PTX1289	[REDACTED] Agreement between Nippon Shinyaku Co., Ltd. and [REDACTED]	7/17/2019	NS00065881	NS00065910	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1290	Agreement between Nippon Shinyaku Co., Ltd. and (Japanese followed by certified English translation)	1/25/2021	NS00065911; NS00090914	NS00065916; NS00090926	
PTX1291	Agreement for the between Nippon Shinyaku Co., Ltd. and (Japanese followed by certified English translation)	7/6/2012	NS00073402; NS00090927	NS00073408; NS00090941	
PTX1292	Agreement between Nippon Shinyaku Co., Ltd. and (Japanese followed by certified English translation)	9/9/2019	NS00073409; NS00090942	NS00073418; NS00090962	
PTX1293	Agreement for the between Nippon Shinyaku Co., Ltd. and (Japanese followed by certified English translation)	10/6/2014	NS00073419; NS00090963	NS00073425; NS00090977	
PTX1294	Viltepso Supply Chain in U.S. Chart (Japanese followed by certified English translation)		NS00073426; NS00090978	NS00073426; NS00090980	
PTX1295	Agreement P between Nippon Shinyaku Co., Ltd., (Japanese followed by certified English translation)	8/30/2019	NS00073428; NS00090984	NS00073441; NS00091012	
PTX1296	Agreement P between Nippon Shinyaku Co., Ltd., (Japanese followed by certified English translation)	8/30/2019	NS00073428; NS00090984	NS00073441; NS00091012	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1297	Agreement between Nippon Shinyaku Co., Ltd. and [REDACTED] (Japanese followed by certified English translation)	10/19/2018	NS00073442; NS00091013	NS00073450; NS00091031	
PTX1298	Agreement between Nippon Shinyaku Co., Ltd. and [REDACTED] (Japanese followed by certified English translation)	7/12/2018	NS00073451; NS00091032	NS00073459; NS00091050	
PTX1299	Agreement between Nippon Shinyaku Co., Ltd. and [REDACTED] (Japanese followed by certified English translation)	2/13/2017	NS00073460; NS00091051	NS00073466; NS00091065	
PTX1300	Materials for [REDACTED] Committee (Japanese followed by certified English translation)	10/15/2009	NS00091091	NS00091105	
PTX1301	Memorandum of [REDACTED] between Nippon Shinyaku Co., Ltd. and [REDACTED] (Japanese)	9/2/2022	NS00091106	NS00091112	
PTX1302	[REDACTED]	4/16/2021	NS00074932	NS00074932	
PTX1303	Notice of T [REDACTED] Agreement between NS Pharma, Inc., including its parent company, Nippon Shinyaku Co., Ltd., [REDACTED]	11/6/2020	NS00074986	NS00074986	
PTX1304	[REDACTED]	4/16/2021	NS00075033	NS00075033	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1305	First Amendment to the [REDACTED] Agreement between [REDACTED] and NS Pharma, Inc.	1/28/2021	NS00075076	NS00075078	
PTX1306	First Amendment to the [REDACTED] Agreement between NS Pharma and [REDACTED] (effective as of April 26, 2021)	4/26/2021	NS00075121	NS00075121	
PTX1307	First Amendment to the [REDACTED] Agreement between NS Pharma, Inc. and [REDACTED] (effective as of April 26, 2021)	4/26/2021	NS00075162	NS00075162	
PTX1308	Second Amendment to the [REDACTED] Agreement between NS Pharma, Inc. and [REDACTED] (effective as of December 1, 2021)	12/1/2021	NS00075163	NS00075164	
PTX1309	[REDACTED] License, Collaboration, and Option Agreement by and between Sarepta Therapeutics Three, LLC and F. Hoffmann-LaRoche Ltd	8/4/2021	SRPT-VYDS-0205743	SRPT-VYDS-0205756	
PTX1310	Exhibit 10.1 to License, Collaboration, and Option Agreement by and between Sarepta Therapeutics Three, LLC and F. Hoffmann-LaRoche Ltd	8/4/2021	SRPT-VYDS-0203136	SRPT-VYDS-0203140	
PTX1311	[REDACTED] License, Collaboration, and Option Agreement by and between Sarepta Therapeutics Three, LLC and F. Hoffmann-LaRoche Ltd	8/4/2021	SRPT-VYDS-0203691	SRPT-VYDS-0203700	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1312	Seventh Framework Programme, Theme [Health.2012.1.4.-4] [Targeted nucleic acid delivery as an innovative therapeutic or prophylactic approach]	11/10/2014	SRPT-VYDS-0206934	SRPT-VYDS-0207063	
PTX1313	Additional Agreement #1 to the [REDACTED] (English and Moscow)	3/24/2023	NS00090749	NS00090750	
PTX1314	FDA filing, "Application to Market a New or Abbreviated new Drug or Biologic for Human use," Sarepta Therapeutics, Inc., NDA 211970, golodirsen (INN approved, USAN under review)	8/28/2018	SRPT-VYDS-0006991	SRPT-VYDS-0006996	
PTX1315	FDA filing regarding 2.3.S. Drug Substance [Golodirsen, [REDACTED]], 1. General Information [Golodirsen, [REDACTED]] (metadata date modified 8/27/2018)	8/27/2018	SRPT-VYDS-0007018	SRPT-VYDS-0007019	
PTX1316	FDA filing regarding 2.3.S. Drug Substance [Golodirsen, [REDACTED]], Table of Contents" - 2. Manufacture (metadata date modified 8/27/2018)	8/27/2018	SRPT-VYDS-0007020	SRPT-VYDS-0007040	
PTX1317	REMOVED DOCUMENT FROM LIST (DUPLICATE)	12/16/2020	SRPT-VYDS-0007051	SRPT-VYDS-0007088	
PTX1318	U.S. Patent Application Publication No. US 2019/0225964 A1, Judith C. Van Deutekom et al., "Modulation of Exon Recognition in Pre-mRNA By Interfering With The Secondary RNA Structure," Pub. date July 25, 2019	7/25/2019	NS00036367	NS00036398	
PTX1319	Application No. 15/705,172, Wilton et al., "Amendment and Response to Non-Final Office Action Under 37 C.F.R. § 1.111," date filed January 5, 2018	1/5/2018	SRPT-VYDS-0000832	SRPT-VYDS-0000850	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1320	Excerpts from the Prosecution History of U.S. Patent No. 9,994,851, Application No. 15/705,172, "Amendment in Response to Non-Final Office Action Under 37 C.F.R. § 1.111" Wilton et al. for "Antisense Oligonucleotides for Inducing Exon Skipping and Methods of use Thereof" dated January 5, 2018	1/5/2018	SRPT-VYDS-0004781	SRPT-VYDS-0004799	
PTX1321	Peter Sazani et al., "Safety Pharmacology and Genotoxicity Evaluation of AVI-4658," 29.2 Intl J. of Toxicology 143-156 (Mar./Apr. 2010) ePublished date Jan. 28, 2010	1/28/2010	SRPT-VYDS-0008328	SRPT-VYDS-0008343	
PTX1322	Declaration of Fred Schnell Under 37 C.F.R. § 1.132, Application No. 14/776,533, Bestwick et al., "Exon Skipping Compositions for Treating Muscular Dystrophy," dated December 11, 2018	12/11/2018	SRPT-VYDS-0021518	SRPT-VYDS-0021521	
PTX1323	Handwritten Journal, "[REDACTED] [REDACTED] [REDACTED] 6/13/2005 - 9/27/2005 date ranges	9/27/2005	SRPT-VYDS-0155447	SRPT-VYDS-0155544	
PTX1324	Handwritten Journal, "[REDACTED] [REDACTED] cover and pages 1-118	7/22/2003	SRPT-VYDS-0155595	SRPT-VYDS-0155713	
PTX1325	Handwritten Journal, "[REDACTED] [REDACTED] covers and pages 1-106, 9/11/04 - 4/3/05 date ranges	3/4/2005	SRPT-VYDS-0156293	SRPT-VYDS-0156401	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1326	Handwritten Journal, "[REDACTED] [REDACTED] 27/6/05 - 19/9/05 date ranges	9/19/2005	SRPT-VYDS-0156402	SRPT-VYDS-0156510	
PTX1327	Handwritten Journal, "[REDACTED] [REDACTED] " cover and pages 1-117	4/14/2004	SRPT-VYDS-0156913	SRPT-VYDS-0157030	
PTX1328	Handwritten Journal, "[REDACTED] [REDACTED] " cover and pages 3 - 167, dated 20/2/02	2/20/2002	SRPT-VYDS-0157031	SRPT-VYDS-0157197	
PTX1329	Handwritten Journal, "[REDACTED] [REDACTED], Book Number 2, From 22/7/03 - 14/4/03" cover and pages 1-118	4/14/2003	SRPT-VYDS-0157534	SRPT-VYDS-0157652	
PTX1330	Handwritten Journal, "[REDACTED] [REDACTED] " covers and pages 1-167	10/5/2004	SRPT-VYDS-0157938	SRPT-VYDS-0158108	
PTX1331	Handwritten Journal, "[REDACTED] [REDACTED] " covers and pages 1-124, date ranges not redacted 9/2/04 to 28/5/04	5/28/2004	SRPT-VYDS-0158779	SRPT-VYDS-0158884	
PTX1332	Handwritten Journal, "[REDACTED] [REDACTED] " cover and pages 3 - 163, date ranges not redacted 6/3/07 to 2/7/07	7/2/2007	SRPT-VYDS-0159421	SRPT-VYDS-0159585	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1333	Handwritten Journal, "[REDACTED] [REDACTED] [REDACTED] " cover and pages 1 - 166, date ranges not redacted 19/10/09 to 15/4/10	4/15/2010	SRPT-VYDS-0159586	SRPT-VYDS-0159753	
PTX1334	Handwritten Journal, "[REDACTED] [REDACTED] [REDACTED] " covers and pages 1 - 167, date ranges not redacted 26/5/08 to 25/2/09	2/25/2009	SRPT-VYDS-0160001	SRPT-VYDS-0160170	
PTX1335	Handwritten Journal, "[REDACTED] [REDACTED] [REDACTED] date ranges not redacted 31/10/05 to 21/March 2006	3/21/2006	SRPT-VYDS-0160171	SRPT-VYDS-0160340	
PTX1336	Handwritten Journal, "[REDACTED] [REDACTED] " cover and pages 1 - 166 (last entry not redacted is 11th May 07	5/11/2007	SRPT-VYDS-0160341	SRPT-VYDS-0160520	
PTX1337	Handwritten Journal, "[REDACTED] [REDACTED] [REDACTED] " covers and pages 1 - 167	9/1/2008	SRPT-VYDS-0160947	SRPT-VYDS-0161118	
PTX1338	Handwritten Journal, "[REDACTED] [REDACTED] [REDACTED] " covers and pages 1 - 33	3/18/2011	SRPT-VYDS-0161292	SRPT-VYDS-0161336	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1339	Handwritten Journal, "[REDACTED]" covers and pages 1 - 118	2/8/2011	SRPT-VYDS-0161827	SRPT-VYDS-0161956	
PTX1340	Handwritten Journal, "[REDACTED]" covers and pages 1 - 118	5/19/2010	SRPT-VYDS-0161957	SRPT-VYDS-0162088	
PTX1341	Handwritten Journal, "[REDACTED]" covers and pages 1 - 167, date ranges not redacted 15/5/09 to 21/6/11	6/21/2011	SRPT-VYDS-0162462	SRPT-VYDS-0162632	
PTX1342	Handwritten Journal, "[REDACTED]" cover and pages 1 - 118	11/12/2010	SRPT-VYDS-0162633	SRPT-VYDS-0162802	
PTX1343	Handwritten Journal, "[REDACTED]", cover and pages 12 - 167, date ranges 27/8/07 to 31/3/08	3/13/2008	SRPT-VYDS-0162803	SRPT-VYDS-0162959	
PTX1344	Handwritten Journal, "[REDACTED]" covers and pages 1 - 154, date ranges not redacted 28/2/08 to 02/05/08	5/2/2008	SRPT-VYDS-0163302	SRPT-VYDS-0163462	
PTX1345	Handwritten Journal, "[REDACTED]" continued from notebook no. 577, date 10/2012, cover and pages 1 - 134, date ranges not redacted 11/28/12 - 4/26/13	4/26/2013	SRPT-VYDS-0164137	SRPT-VYDS-0164360	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1346	Handwritten Journal, "[REDACTED]" covers and pages 1 - 118	10/1/2013	SRPT-VYDS-0201121	SRPT-VYDS-0201250	
PTX1347	"VYONDYS 53 Weekly Sales Summary 2019" with "Week Ending 12/20/19 and 12/27/19"	12/27/2019	SRPT-VYDS-0208201	SRPT-VYDS-0209126	
PTX1348	Handwritten Journal, "[REDACTED]" covers and pages 1 - 118	5/16/2012	SRPT-VYDS-0213544	SRPT-VYDS-0213678	
PTX1349	Handwritten Journal, "[REDACTED]" covers and pages 1 - 118	2/8/2011	SRPT-VYDS-0213679	SRPT-VYDS-0213811	
PTX1350	REMOVED DOCUMENT FROM LIST (DUPLICATE)	8/13/2010	WILTON0017528	WIL TON0017530	
PTX1351	Email thread between Steve Wilton and Neera Gulati (Suneel's mother), sent April 26 and July 16, 2009	7/16/2009	WILTON0017510	WILTON0017512	
PTX1352	Email thread between Steve Wilton and Neera Gulati (Suneel's mother), sent July 24, 2010 and August 13, 2010	8/13/2010	WILTON0017531	WILTON0017534	
PTX1353	Email thread between Steve Wilton and J. George Dickson, sent February 4, 2011 and March 3, 2011	3/3/2011	WILTON0017550	WILTON0017553	
PTX1354	Email message from Linda to A.M. Aartsma-Rus, G. Dickson, C. Adkin, V. Arechavala, Steve Wilton, J. Morgan, F. Muntoni, and Sanger, sent December 3, 2009	12/3/2009	WILTON0017680	WILTON0017683	
PTX1355	REMOVED DOCUMENT FROM LIST (DUPLICATE)	7/15/2010	WILTON0017853	WILTON0017855	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1356	Email tread between Steve Wilton and Neera and Ken Manning, sent June 9, 2010 and July 15, 2010	7/15/2010	WILTON0017865	WILTON0017868	
PTX1357	Linda J. Popplewell et al., "Targeted Skipping of Exon 53 of the Human <i>DMD</i> Gene: Recommendation of an Antisense Oligonucleotide for Clinical Trial," draft with redline and comments (metadata date created 12/22/2008, date modified 12/31/2008)	12/31/2008	WILTON0021482	WILTON0021501	
PTX1358	Letter to Professor Francesco Muntoni, Head, MDEX Consortium, Hammersmith Hospital, London from Professor Frank Mastaglia, Centre for Neuromuscular and Neurological Disorders, dated 21st November 2006	11/21/2006	WILTON0025146	WILTON0025146	
PTX1359	Email from J.C.T. van Deutekom to Steve Wilton, "RE: G'day from WA" sent 12/21/2004	12/21/2004	WILTON0026217	WILTON0026217	
PTX1360	Email thread between Steve Wilton and Francesco Muntoni "Re: Morpholino" sent April 19, 2005 and May 10, 2005	5/10/2005	WILTON0026253	WILTON0026255	
PTX1361	University of Western Australia v. Academisch Ziekenhuis Leiden, Interference No. 106,007, University of Western Australia Opposition 1 (Regarding Patentability Under 35 U.S.C. § 102/103), filed February 17, 2015	2/17/2015	NO BATES UWA Opp 1 02-17-2015	NO BATES UWA Opp 1 02-17-2015	
PTX1362	WIPO International Publication Number WO 2004/083446 A2, International Application No. PCT/NL2004/000196, Van Ommeren et al., "Modulation of Exon Recognition in Pre-mRNA By Interfering with the Secondary RNA Structure," International Publication Date September 30, 2004	9/30/2004	NS00065185	NS00065301	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1363	File History EXCERPT, U.S. Patent No. 9,447,417, "Amendment in Response to Non-Final Office Action Under 37 C.F.R. 1.111" from U.S. Patent Application No. 14/858,416, Sazani et al., "Multiple Exon Skipping for Compositions for DMD," Response dated January 27, 2016	1/27/2016	SRPT-VYDS-0089082	SRPT-VYDS-0089096	
PTX1364	File History EXCERPT, U.S. Patent No. 8,871,918, "Amendment in Response to Non-Final Office Action Under 37 C.F.R. 1.111" from U.S. Patent Application No. 12/605,276, Sazani et al., "Multiple Exon Skipping for Compositions for DMD," Response dated April 18, 2016	4/18/2014	SRPT-VYDS-0088082	SRPT-VYDS-0088102	
PTX1365	File History EXCERPT, "Amendment After Final Office Action Submitted With A Request for Continued Examination (RCE)," from U.S. Patent Application No. 14/214,480, Bestwick et al., "Exon Skipping Compositions for Treating Muscular Dystrophy," dated February 18, 2016	2/18/2016	SRPT-VYDS-0012291	SRPT-VYDS-0012311	
PTX1366	File History EXCERPT, "Amendment in Response to Non-Final Office Action Under 37 C.F.R. § 1.111," from U.S. Patent Application No. 14/213,641, Bestwick et al., "Exon Skipping Compositions for Treating Muscular Dystrophy," dated September 29, 2015	9/29/2015	SRPT-VYDS-0011783	SRPT-VYDS-0011792	
PTX1367	File History EXCERPT, "Office communication," from U.S. Patent Application No. 14/213,641 Bestwick et al., "Exon Skipping Compositions for Treating Muscular Dystrophy," dated October 16, 2015	10/16/2015	SRPT-VYDS-0090385	SRPT-VYDS-0090393	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1368	U.S. Publication Number 2007/0265215, Application No. 11433308, Iversen, Patrick L. & Weller, Dwight D., "Antisense restenosis composition and method," Publication Date November 15, 2007	11/15/2007	SRPT-VYDS-0089597	SRPT-VYDS-0089614	
PTX1369	U.S. Publication Number 2003/0166588, Application No. 09848868, Iversen, Patrick L. & Hudziak, Robert, "Splice-region antisense composition and method," Publication Date September 4, 2003	9/4/2003	SRPT-VYDS-0226305	SRPT-VYDS-0226333	
PTX1370	U.S. SEC Form 8-K, date of report January 09, 2023, Sarepta Therapeutics, Inc., prepared by Douglas S. Ingram, President and Chief Executive Officer date January 9, 2023	1/9/2023	NO BATES SEC 8-K Sarepta Therapeutics filed 01- 09-2023	NO BATES SEC 8-K Sarepta Therapeutics filed 01- 09-2023	
PTX1371	American Medical Association, "Research Letter, Spending on Targeted Therapies for Duchenne Muscular Dystrophy," (JAMA Pub. Mar. 11, 2024)	3/11/2024	NONE	NONE	
PTX1372	[REDACTED] (metadata date created 7/3/2009, date modified 9/9/2009)	9/9/2009	NS00075442	NS00075442	
PTX1373	Nippon Shinyaku [REDACTED] (2009) (metadata date created 7/13/2007, date modified 2/11/2009)	2/11/2009	NS00059696	NS00059696	
PTX1374	Opening Expert Report of Christine C. Esau, Ph.D, Regarding Infringement of Certain NS Patents Exhibit 1 - Curriculum Vitae (served September 8, 2023)	9/8/2023	NONE	NONE	
PTX1375	Expert Report of Dr. Michelle L. Hastings Regarding invalidity of the UWA Patents Exhibit 2 (served September 8, 2023)	9/8/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1376	Reply Expert Report and Disclosure of Mark J. Hosfield, Submitted October 27, 2023 Exhibit 1	10/27/2023	NONE	NONE	
PTX1377	Expert Report of Scott E. Kamholz, Esq. Appendix B (served September 8, 2023)	9/8/2023	NONE	NONE	
PTX1378	Opening Expert Report of Nathan W. Luedtke, Ph.D Regarding Infringement of U.S. Patent No. 10,683,322 ("The '322 Patent") Exhibit 1 (served September 8, 2023)	9/8/2023	NONE	NONE	
PTX1379	Expert Report of Robert S. Maness, Ph.D. Appendix A (served September 8, 2023)	9/8/2023	NONE	NONE	
PTX1380	Rebuttal Technical Expert Report of Jonathan Strober, M.D. Exhibit 1 – Curriculum Vitae (served October 11, 2023)	10/11/2023	NONE	NONE	
PTX1381	Expert Report of Dr. Matthew J.A. Wood Exhibit 2 (served September 8, 2023)	9/8/2023	NONE	NONE	
PTX1382	Declaration of Marc D. Evans in Support of Defendant Sarepta Therapeutics, Inc.'s Motion to Exclude Dr. Matthew Wood as an Expert Witness (D.I. 299), executed August 3, 2023, and Exhibits 1-13 (D.I. 299-1)	8/3/2023	NONE	NONE	
PTX1383	"[REDACTED] (metadata date created 2/5/2013, date modified 2/5/2013)	2/5/2013	BESTWICK00000004	BESTWICK00000004	
PTX1384	Graphs and charts entitled: [REDACTED] (metadata date modified 12/4/2012)	12/4/2012	BESTWICK00000012	BESTWICK00000012	
PTX1385	"[REDACTED] chart (metadata date modified 1/29/2013)	1/29/2013	BESTWICK00000019	BESTWICK00000019	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1386	Email thread between Adrienne Ste. Mari, Ed Kaye, Chris Garabedian, Effie Toshav, Dwight Weller, Peter Sazani, Ryszard Kole, Diane Frank, Juliet Ellis, Subject: [REDACTED], sent September 26 and 27,	9/27/2011	FRANK00000026	FRANK00000027	
PTX1387	Email thread between Francesco Muntoni, Ed Kaye, Laine Cowan, Juliet Ellis, George Dickson, Peter Sazani, Diane Frank, Rick Bestwick, Subject: [REDACTED] sent March 4 and 5, 2012	3/5/2012	FRANK00000035	FRANK00000036	
PTX1388	Email thread between Diane Frank, Peter Linsley, Ed Kaye, Peter Sazani, Subject: cell culture screening for Exon 53, sent April 4,	4/4/2012	FRANK00000037	FRANK00000037	
PTX1389	Email thread between Stacey Bailey, Diane Frank, Jessica Stromme, Subject: Exon 53 samples, sent September 13, 2012	9/13/2012	FRANK00000146	FRANK00000148	
PTX1390	Email chain between Abbie Adams, Susan Fletcher, Diane Frank, Subject: Question on Exon 50 PMO and Subject: [REDACTED] sent July 5, 2012 and November 2, 2012	11/2/2012	FRANK00000298	FRANK00000298	
PTX1391	Email thread between Diane Frank, Steve Wilton, Susan Fletcher, Subject: updates, sent November 13, 2012	11/13/2012	FRANK00000416	FRANK00000417	
PTX1392	Email message from Emily Naughton to Diane Frank, Subject: Ex53 data, sent December 20, 2012	12/20/2012	FRANK00000722	FRANK00000722	
PTX1393	Email thread between Emily Naughton, Diane Frank, Brian Leppert, Subject: Myoblast Low Dose Nucleofection, sent January 22, 2013	1/22/2013	FRANK00000760	FRANK00000761	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1394	Diane Frank Notes, "DF-040, Exon 53 Screening: [REDACTED] [REDACTED] Date 1-22-13	1/22/2013	FRANK00001431	FRANK00001442	
PTX1395	Handwritten Journal, "[REDACTED] [REDACTED] covers and pages 1 - 45, date ranges 15/09/04 to 12/01/05	1/12/2005	SRPT-VYDS-0155545	SRPT-VYDS-0155594	
PTX1396	Handwritten Journal, "[REDACTED] [REDACTED]" covers and pages 1 - 167, date ranges 02/2/04 to 16/6/04	6/16/2004	SRPT-VYDS-0155833	SRPT-VYDS-0156009	
PTX1397	Handwritten Journal, "[REDACTED] [REDACTED] covers and pages 1 - 71, date ranges 06/6/01 to 16/11/01	11/16/2001	SRPT-VYDS-0156010	SRPT-VYDS-0156084	
PTX1398	Handwritten Journal, "[REDACTED] [REDACTED] covers and pages 1 - 167, date ranges 30/04/01 to 05/08/02	8/5/2002	SRPT-VYDS-0156511	SRPT-VYDS-0156678	
PTX1399	Handwritten Journal, "[REDACTED] [REDACTED]" covers and pages 1 - 51, date ranges 29.7.03 to 12.9.03	9/12/2003	SRPT-VYDS-0156679	SRPT-VYDS-0156739	
PTX1400	Handwritten Journal, "[REDACTED] [REDACTED] covers and pages 1 - 167, date ranges 24/1/05 to 13/4/2005	4/13/2005	SRPT-VYDS-0156740	SRPT-VYDS-0156912	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1401	Handwritten Journal, "[REDACTED]" covers and pages 1 - 125, date ranges 22/05/02 to 14/8/02	8/14/2002	SRPT-VYDS-0157198	SRPT-VYDS-0157329	
PTX1402	Handwritten Journal, "[REDACTED]" covers and pages 1 - 32, Experiment 67 to Experiment 75 (no dates)	2005	SRPT-VYDS-0157330	SRPT-VYDS-0157364	
PTX1403	Handwritten Journal, "[REDACTED]" covers and pages 1 - 167, date ranges 10.2.03 to 30.7.03	7/30/2003	SRPT-VYDS-0157365	SRPT-VYDS-0157533	
PTX1404	Handwritten Journal, "[REDACTED]" covers and pages 1 - 167, date ranges 16/6/04 to 14/09/04	6/16/2004	SRPT-VYDS-0157653	SRPT-VYDS-0157821	
PTX1405	Handwritten Journal, "A [REDACTED]" covers and pages 1 - 114, date ranges 26/07/02 to 09/04/03	4/9/2003	SRPT-VYDS-0157822	SRPT-VYDS-0157937	
PTX1406	Handwritten Journal, "[REDACTED]" covers and pages 1 - 167, date ranges 15.8.02 to 7.2.03	2/7/2003	SRPT-VYDS-0158436	SRPT-VYDS-0158607	
PTX1407	Handwritten Journal, "[REDACTED]" covers and pages 1 - 167, date ranges 10.2.03 to 30.7.03	7/30/2003	SRPT-VYDS-0158608	SRPT-VYDS-0158778	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1408	Handwritten Journal, "Laboratory Notebook I [REDACTED] covers and pages 1 - 118	3/29/2010	SRPT-VYDS-0159754	SRPT-VYDS-0159884	
PTX1409	Handwritten Journal, "[REDACTED]" covers and pages 1 - 121	5/10/2005	SRPT-VYDS-0160820	SRPT-VYDS-0160946	
PTX1410	Handwritten Journal, "[REDACTED]" covers and pages 1 - 118, date 30/05/12	5/30/2012	SRPT-VYDS-0162089	SRPT-VYDS-0162228	
PTX1411	Sarepta Therapeutics, Inc. Consulting Agreement between Sarepta Therapeutics, Inc. and [REDACTED], effective as of April 13, 2014	4/13/2014	SRPT-VYDS-0164600	SRPT-VYDS-0164607	
PTX1412	Email thread between Emily Naughton, Fred Schnell, Lisa Borland, Kathrin Kucharski, Subject: WB Question for Fred, sent December 19 and 20, 2019	12/20/2019	SRPT-VYDS-0183613	SRPT-VYDS-0183614	
PTX1413	Email message from Fred Schnell to Emily Naughton Subject: [REDACTED] sent 1/12/2015	1/12/2015	SRPT-VYDS-0185579	SRPT-VYDS-0185579	
PTX1414	GraphPad Prism file, date 2014-06-03, title "[REDACTED]"	6/3/2014	SRPT-VYDS-0185580	SRPT-VYDS-0185589	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1415	SRP-4053: Off-Target Sequence Analysis, Sponsor Study No. SR-18-066, Client: Sarepta Therapeutics, Subject of Evaluation: [REDACTED]	11/19/2018	SRPT-VYDS-0188663	SRPT-VYDS-0188679	
PTX1416	Email message from Parnian Zia-Amirhosseini to Paul Korner, Heidi Krenz, Lixin Han, Xiaodong Wang, Diane Frank, Josph Rutkowski, Geno Clemenzi, Vineet Sharma, Xin Wei, Shande Tang, Maria Uria-Nickelsen, Vinay Jayakumar, Ann Karen Henry, Saleh El Husayni (plus CCs), Subject: [REDACTED] sent 8/10/2018	8/10/2018	SRPT-VYDS-0189054	SRPT-VYDS-0189055	
PTX1417	[REDACTED]	8/10/2018	SRPT-VYDS-0189056	SRPT-VYDS-0189074	
PTX1418	[REDACTED]	12/12/2012	SRPT-VYDS-0217752	SRPT-VYDS-0217752	
PTX1419	[REDACTED]	8/10/2018	SRPT-VYDS-0189185	SRPT-VYDS-0189187	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1420	4053-101 Part 2 Week 48 Interim Dystrophin Report, December 5, 2017, [REDACTED] [REDACTED] [REDACTED] Study Director Diane Frank, PhD, Sponsor Sarepta Therapeutics, Inc.	12/15/2017	SRPT-VYDS-0195446	SRPT-VYDS-0195821	
PTX1421	Email from Diane Frank to Fred Schnell, Guriq Basi, Francesco Muntoni, Subject: ! Please review: final slide responses for dystrophin, sent 2/5/2018	2/5/2018	SRPT-VYDS-0197208	SRPT-VYDS-0197208	
PTX1422	[REDACTED] " presentation deck (metadata date modified 2/5/2018)	2/5/2018	SRPT-VYDS-0197209	SRPT-VYDS-0197211	
PTX1423	Question 2 (CONT.) presentation deck (metadata date modified 2/5/2018)	2/5/2018	SRPT-VYDS-0197212	SRPT-VYDS-0197217	
PTX1424	Email message from Ian Estepan to Dallan Murray, Ashish Dugar, Diane Frank, Johannes Dworzak, Fred Schnell, Todd Truesdale, Hemchand Sookdeo, Parnian Zia-Amirhosseini, Subject: [REDACTED] sent 6/28/2018	6/28/2018	SRPT-VYDS-0199660	SRPT-VYDS-0199660	
PTX1425	Email thread between Diane Frank, Guriq Basi, Fred Schnell, Subject: MM resolution for NDA, sent June 27, July 2, 3 and 5, 2018	7/5/2018	SRPT-VYDS-0200039	SRPT-VYDS-0200042	
PTX1426	Email message from Fred Schnell to Parid Sava sent 3/23/2021, "[REDACTED] [REDACTED]	3/23/2021	SRPT-VYDS-0200985	SRPT-VYDS-0200985	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1427	Handwritten Journal, "Laboratory Notebook I [REDACTED] covers and pages 1 - 117	2/8/2011	SRPT-VYDS-0200992	SRPT-VYDS-0201120	
PTX1428	Handwritten Journal, "[REDACTED] [REDACTED] covers and pages 1 - 132	7/1/2009	SRPT-VYDS-0201251	SRPT-VYDS-0201392	
PTX1429	Handwritten Journal, "Laboratory Notebook [REDACTED] [REDACTED] covers and pages 1 - 118	7/26/2010	SRPT-VYDS-0201393	SRPT-VYDS-0201523	
PTX1430	Email message from Diane Frank to Steve Wilton, Susan Fletcher Subject: Lab support for next exon screening programs, sent	9/8/2012	SRPT-VYDS-0213902	SRPT-VYDS-0213902	
PTX1431	Email message from Diane Frank to Susan Fletcher, Abbie Adams Subject: [REDACTED], sent 9/24/2012	9/24/2012	SRPT-VYDS-0213931	SRPT-VYDS-0213931	
PTX1432	Email chain from Diane Frank to Susan Fletcher, Abbie Adams Subject: Travel to Perth!, [REDACTED] sent August 28, September 24 and 25, 2012	9/25/2012	SRPT-VYDS-0213932	SRPT-VYDS-0213933	
PTX1433	Email message from Diane Frank to Abbie Adams, Susan Fletcher, Stephen Wilton Subject: proposal draft and links, sent 10/19/2012	10/19/2012	SRPT-VYDS-0213991	SRPT-VYDS-0213991	
PTX1434	Email thread between Diane Frank, Kate Haviland Subject: Wilton lab funding, sent 10/19/2012	10/19/2012	SRPT-VYDS-0213999	SRPT-VYDS-0214001	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1435	Email thread between Diane Frank, Stacey Bailey, Rick Bestwick Subject: Exon 53 aliquots, sent 10/29/2012	10/29/2012	SRPT-VYDS-0214029	SRPT-VYDS-0214030	
PTX1436	Email thread between Diane Frank, Rick Bestwick, Brian Leppert, Stacey Bailey, Subject: Blinding Identifier Workbook for DMD exon 53, sent 10/29/2012	10/29/2012	SRPT-VYDS-0214033	SRPT-VYDS-0214034	
PTX1437	Email thread between Stacey Bailey, Laine Cowan, Diane Frank, Rick Bestwick, Jessica Stromme, Subject: Exon 53 shipment, sent November 5 and 6, 2012	11/6/2012	SRPT-VYDS-0214273	SRPT-VYDS-0214273	
PTX1438	Email thread between Emily Naughton, Brian Leppert, Diane Frank, Rick Bestwick, Subject: Compounds Arrived, sent November 6, 2012	11/6/2012	SRPT-VYDS-0214274	SRPT-VYDS-0214274	
PTX1439	Email thread between Emily Naughton, Diane Frank, Brian Leppert, Subject: [REDACTED] sent November 6, 2012	11/6/2012	SRPT-VYDS-0214275	SRPT-VYDS-0214276	
PTX1440	Email thread between Diane Frank, Kate Haviland, Rick Bestwick Subject: Exon numbers, sent 11/8/2012	11/8/2012	SRPT-VYDS-0214292	SRPT-VYDS-0214292	
PTX1441	Annemieke Aartsma-Rus et al., Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations, for Peer Review, submitted by author 20 Aug 2008	8/20/2008	SRPT-VYDS-0214293	SRPT-VYDS-0214317	
PTX1442	Email message from Diane Frank to Peter Sazani, Ed Kaye, Laine Cowan, Subject: Ex53 updates, sent 11/8/2012	11/8/2012	SRPT-VYDS-0214318	SRPT-VYDS-0214318	
PTX1443	Email message from Diane Frank to Ryszard Kole, Brian Leppert, Emily Naughton, Subject: PCR problems, sent 11/13/2012	11/13/2012	SRPT-VYDS-0214354	SRPT-VYDS-0214354	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1444	Email thread between Laine Cowan, Francesco Muntoni, Juliet Ellis, Penelope Smith, George Dickson, Linda Popplewell, Diane Frank, Karen Anthony, Ed Kaye, Jenny Morgan, Chris Garabedian, Jessica Stromme, Peter Sazani, Rick Bestwick Subject: [REDACTED] [REDACTED] sent November 28 and 29, 2012	11/29/2012	SRPT-VYDS-0214526	SRPT-VYDS-0214527	
PTX1445	Email thread between Abbie Adams, Diane Frank Subject: SOP for nucleofection, sent November 29, 2012	11/29/2012	SRPT-VYDS-0214530	SRPT-VYDS-0214530	
PTX1446	Email message from Diane Frank to Rick Bestwick, Subject: Ex53 data, sent 12/4/2012	12/4/2012	SRPT-VYDS-0214552	SRPT-VYDS-0214552	
PTX1447	GraphPad Prism file, date 2012-12-03, title "Project info 1	12/3/2012	SRPT-VYDS-0214553	SRPT-VYDS-0214588	
PTX1448	Chart, Project info 1	12/3/2012	SRPT-VYDS-0214589	SRPT-VYDS-0214589	
PTX1449	Email chain from Laine Cowan to Francesco Muntoni, Juliet Ellis, Kate Haviland, Catherine Edlin, Rick Bestwick, George Dickson, Penelope Smith, Linda Popplewell Subject: [REDACTED] [REDACTED] sent between November 6, 2012 and January 7, 2013	1/7/2013	SRPT-VYDS-0214661	SRPT-VYDS-0214669	
PTX1450	SKIP-NMD Work-package 1, Teleconference #2 of 17th Dec 2012 - Aide-Memoire	12/17/2012	SRPT-VYDS-0214670	SRPT-VYDS-0214670	

Plaintiffs' Trial Exhibit List

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1456	Linda Popplewell, Anita Le-Heron, SKIP-NMD WP1 Interim Report, 11th January 2013, Royal Holloway - University of London	1/11/2013	SRPT-VYDS-0214765	SRPT-VYDS-0214784	
PTX1457	Email message from Diane Frank to Stacey Bailey, Rick Bestwick, Laine Cowan, Ed Kaye, Peter Sazani, Chris Garabedian, Subject: EUSKIP Exon 53 update, sent 1/14/2013	1/14/2013	SRPT-VYDS-0214796	SRPT-VYDS-0214796	
PTX1458	Email chain between Juliet Ellis, Chris Garabedian, Ed Kaye, Laine Cowan, Volker Straub, Kate Bushby, Thomas Voit, EUMERCURI, George Dickson, Laurent Servais, Raymond Gilles, Filippo E. Leone, C. Gaultier, Aleona Blinova, Eric Dorveaux, Joanna Cox, Ruth Murray, Raymond Georges, Mark Isaac, Louise Wrigley, Larue Sinigre, Uta Binnie, Becky Davis, Virginia Arechavala, Kanagasabai Ganeshaguru, Jenny Morgan, Karen Anthony, Peter Sazani, Penelope Smith, William Van Thoff, Francesco Muntoni, Martin Scott, Catherine Bellamy, W. Williams, Diane Frank Subjects: [REDACTED] [REDACTED] sent December 10, 2012, January 15, 27, 29, 2013	1/29/2013	SRPT-VYDS-0214994	SRPT-VYDS-0214999	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1459	Grant agreement no 305370, SKIP-NMD, A phase I/IIa clinical trial in Duchenne muscular dystrophy using systemically delivered morpholino antisense oligomer to skip exon 53, Collaborative project, HEALTH.2012.1.4-4, Work Package 1: Choice of lead sequence, D1.1, Antisense oligonucleotide comparative analysis I, Author(s): George Dickson, Linda Popplewell (RHUL), Reviewer(s): Juliet Ellis, Karen Anthony, Jenny Morgan, Francesco Muntoni (UCL), Diane Frank (SRPT), Date of Delivery to the EC 31/1/2013	1/31/2013	SRPT-VYDS-0215000	SRPT-VYDS-0215009	
PTX1460	Email message from Diane Frank to George Dickson, Francesco Muntoni, Subject: Updates on my lab, sent 2/4/2013	2/4/2013	SRPT-VYDS-0215125	SRPT-VYDS-0215125	
PTX1461	Email chain between Penelope Smith, Linda Popplewell, Diane Frank, Karen Anthony, Juliet Ellis, Laine Cowan, Peter Sazani, Francesco Muntoni, Anita Le-Heron, Virginia Arechavala, Ed Kaye, Jenny Morgan, George Dickson, Subjects: SKIP-NMD WP1 Teleconference: February meeting and SKIP-NMD WP1 Teleconference: February 7th rescheduled and Sarepta- callin in: SKIP-NMD WP1 Teleconference: February 7th rescheduled, sent between January 15, 16, 17, 2013, February 3,	2/7/2013	SRPT-VYDS-0215206	SRPT-VYDS-0215212	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1462	Email chain between Penelope Smith, Linda Popplewell, Diane Frank, Karen Anthony, Juliet Ellis, Laine Cowan, Peter Sazani, Francesco Muntoni, Anita Le-Heron, Virginia Arechavala, Ed Kaye, Jenny Morgan, George Dickson Subjects: SKIP-NMD WP1 Teleconference: February meeting and SKIP-NMD WP1 Teleconference: February 7th rescheduled and SKIP-NMD WP1 second report-UCL & RHUL, sent between January 15, 16, 17,	2/18/2013	SRPT-VYDS-0215284	SRPT-VYDS-0215288	
PTX1463	SKIP-NMD WP1 Second Interim Report, 18th February 2013, Royal Holloway - University of London	2/18/2013	SRPT-VYDS-0215289	SRPT-VYDS-0215297	
PTX1464	Email chain between Penelope Smith, Linda Popplewell, Diane Frank, Karen Anthony, Juliet Ellis, Laine Cowan, Peter Sazani, Francesco Muntoni, Anita Le-Heron, Virginia Arechavala, Ed Kaye, Jenny Morgan, George Dickson Subjects: SKIP-NMD WP1 Teleconference: February meeting and SKIP-NMD WP1 Teleconference: February 7th rescheduled and SKIP-NMD WP1 second report-UCL & RHUL, sent between January 15, 16, 17,	2/19/2013	SRPT-VYDS-0215317	SRPT-VYDS-0215321	
PTX1465	EUSKIP Exon 53 cell culture data report, Feb 18, 2013, Results from partner SRPT: Diane Frank, Director and Brian Leppert, Scientist	2/18/2013	SRPT-VYDS-0215322	SRPT-VYDS-0215328	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1466	Email thread between Jessica Stromme, Tom Holt, Jayant Aphale, Bao Cai, Lori Houle-Custer, Ankur Desai, Stacey Bailey, Laine Cowan, Diane Frank, Subject: Exon 53 sequence, sent March 5, 6, 2013	3/6/2013	SRPT-VYDS-0215455	SRPT-VYDS-0215456	
PTX1467	Email message from Emily Naughton to Rick Bestwick, Diane Frank, Subject: Exon 53 Data, sent 12/21/2012	12/21/2012	SRPT-VYDS-0217587	SRPT-VYDS-0217587	
PTX1468	Email thread between Emily Naughton and Diane Frank, Subject: Exon 53 Data, sent December 19, 20, 2012	12/20/2012	SRPT-VYDS-0217646	SRPT-VYDS-0217647	
PTX1469	Email message from Emily Naughton to Diane Frank, Subject: Exon 53 Data, sent 12/20/2012	12/20/2012	SRPT-VYDS-0217648	SRPT-VYDS-0217648	
PTX1470	Email message from Emily Naughton to Brian Leppert, Subject: [REDACTED] Data, sent 12/13/2012	12/13/2013	SRPT-VYDS-0217729	SRPT-VYDS-0217729	
PTX1471	[REDACTED] Exon Skipping Analysis Graph (metadata date created 12/13/2012, date modified 10/10/2022)	10/10/2022	SRPT-VYDS-0217750	SRPT-VYDS-0217750	
PTX1472	Email message from Emily Naughton to Diane Frank, Subject: Technical Issues, sent 12/12/2012	12/12/2012	SRPT-VYDS-0217751	SRPT-VYDS-0217751	
PTX1473	Email message from Emily Naughton to Diane Frank (cc Brian Leppert) Subject: Updates, sent 10/17/2012	10/17/2012	SRPT-VYDS-0218117	SRPT-VYDS-0218118	
PTX1474	Graph (metadata date created 5/19/2023, date modified 6/9/2009)	6/9/2009	SRPT-VYDS-0227321	SRPT-VYDS-0227321	
PTX1475	Graph (metadata date created 5/19/2023, date modified 7/29/2009)	7/29/2009	SRPT-VYDS-0227322	SRPT-VYDS-0227322	
PTX1476	Graph (metadata date created 5/19/2023, date modified 6/19/2009)	6/19/2009	SRPT-VYDS-0227323	SRPT-VYDS-0227323	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1477	Graph (metadata date created 5/19/2023, date modified 6/19/2009)	6/19/2009	SRPT-VYDS-0227324	SRPT-VYDS-0227324	
PTX1478	Graph (metadata date created 5/19/2023, date modified 6/9/2009)	6/9/2009	SRPT-VYDS-0227325	SRPT-VYDS-0227325	
PTX1479	Graph (metadata date created 5/19/2023, date modified 6/19/2009)	6/19/2009	SRPT-VYDS-0227326	SRPT-VYDS-0227326	
PTX1480	Graph (metadata date created 5/19/2023, date modified 6/9/2009)	6/9/2009	SRPT-VYDS-0227327	SRPT-VYDS-0227327	
PTX1481	Graph (metadata date created 5/19/2023, date modified 6/19/2009)	6/19/2009	SRPT-VYDS-0227328	SRPT-VYDS-0227328	
PTX1482	Graph (metadata date created 5/19/2023, date modified 7/29/2009)	7/29/2009	SRPT-VYDS-0227329	SRPT-VYDS-0227329	
PTX1483	Graph (metadata date created 5/19/2023, date modified 8/12/2009)	8/12/2009	SRPT-VYDS-0227330	SRPT-VYDS-0227330	
PTX1484	Graph (metadata date created 5/19/2023, date modified 8/12/2009)	8/12/2009	SRPT-VYDS-0227331	SRPT-VYDS-0227331	
PTX1485	Graph (metadata date created 5/19/2023, date modified 8/7/2009)	8/7/2009	SRPT-VYDS-0227332	SRPT-VYDS-0227332	
PTX1486	Graph (metadata date created 5/19/2023, date modified 8/11/2009)	8/11/2009	SRPT-VYDS-0227333	SRPT-VYDS-0227333	
PTX1487	Graph (metadata date created 5/19/2023, date modified 8/12/2009)	8/12/2009	SRPT-VYDS-0227334	SRPT-VYDS-0227334	
PTX1488	Graph (metadata date created 5/19/2023, date modified 8/12/2009)	8/12/2009	SRPT-VYDS-0227335	SRPT-VYDS-0227335	
PTX1489	Graph (metadata date created 5/19/2023, date modified 8/12/2009)	8/12/2009	SRPT-VYDS-0227336	SRPT-VYDS-0227336	
PTX1490	Graph (metadata date created 5/19/2023, date modified 8/12/2009)	8/12/2009	SRPT-VYDS-0227337	SRPT-VYDS-0227337	
PTX1491	Graph (metadata date created 5/19/2023, date modified 8/7/2009)	8/7/2009	SRPT-VYDS-0227338	SRPT-VYDS-0227338	
PTX1492	Graph (metadata date created 5/19/2023, date modified 8/13/2009)	8/13/2009	SRPT-VYDS-0227339	SRPT-VYDS-0227339	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1493	Graph (metadata date created 5/19/2023, date modified 8/7/2009)	8/7/2009	SRPT-VYDS-0227340	SRPT-VYDS-0227340	
PTX1494	Graph (metadata date created 5/19/2023, date modified 8/12/2009)	8/12/2009	SRPT-VYDS-0227341	SRPT-VYDS-0227341	
PTX1495	Graph (metadata date created 5/19/2023, date modified 8/12/2009)	8/12/2009	SRPT-VYDS-0227342	SRPT-VYDS-0227342	
PTX1496	Graph (metadata date created 5/19/2023, date modified 8/13/2009)	8/13/2009	SRPT-VYDS-0227343	SRPT-VYDS-0227343	
PTX1497	Graph (metadata date created 5/19/2023, date modified 8/12/2009)	8/12/2009	SRPT-VYDS-0227344	SRPT-VYDS-0227344	
PTX1498	Graph (metadata date created 5/19/2023, date modified 8/7/2009)	8/7/2009	SRPT-VYDS-0227345	SRPT-VYDS-0227345	
PTX1499	Graph (metadata date created 5/19/2023, date modified 8/13/2009)	8/13/2009	SRPT-VYDS-0227346	SRPT-VYDS-0227346	
PTX1500	Graph (metadata date created 5/19/2023, date modified 8/7/2009)	8/7/2009	SRPT-VYDS-0227347	SRPT-VYDS-0227347	
PTX1501	Graph (metadata date created 5/19/2023, date modified 6/9/2009)	6/9/2009	SRPT-VYDS-0227348	SRPT-VYDS-0227348	
PTX1502	Graph (metadata date created 5/19/2023, date modified 6/19/2009)	6/19/2009	SRPT-VYDS-0227349	SRPT-VYDS-0227349	
PTX1503	Graph (metadata date created 5/19/2023, date modified 8/2/2009)	8/2/2009	SRPT-VYDS-0227350	SRPT-VYDS-0227350	
PTX1504	Graph (metadata date created 5/19/2023, date modified 8/2/2009)	8/2/2009	SRPT-VYDS-0227351	SRPT-VYDS-0227351	
PTX1505	Graph (metadata date created 5/19/2023, date modified 8/2/2009)	8/2/2009	SRPT-VYDS-0227352	SRPT-VYDS-0227352	
PTX1506	Graph (metadata date created 5/19/2023, date modified 8/2/2009)	8/2/2009	SRPT-VYDS-0227353	SRPT-VYDS-0227353	
PTX1507	Graph (metadata date created 5/19/2023, date modified 6/19/2009)	6/19/2009	SRPT-VYDS-0227354	SRPT-VYDS-0227354	
PTX1508	Graph (metadata date created 5/19/2023, date modified 6/19/2009)	6/19/2009	SRPT-VYDS-0227355	SRPT-VYDS-0227355	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1509	Worksheet entitled "PPMO" (metadata date created 9/16/2006, date modified 11/2/2009)	11/2/2009	SRPT-VYDS-0227369	SRPT-VYDS-0227369	
PTX1510	Amended and Restated Exclusive License Agreement between The University of Western Australia, Sarepta Therapeutics, and Sarepta International CV, restated as of April 10, 2013	4/10/2013	UWA0000051	UWA0000077	
PTX1511	REMOVED DOCUMENT FROM LIST (DUPLICATE)	3/27/2008	WILTON0001724	WILTON0001724	
PTX1512	REMOVED DOCUMENT FROM LIST (DUPLICATE)	3/27/2008	WILTON0001725	WILTON0001725	
PTX1513	REMOVED DOCUMENT FROM LIST (DUPLICATE)	4/24/2008	WILTON0002167	WILTON0002167	
PTX1514	REMOVED DOCUMENT FROM LIST (DUPLICATE)	4/24/2008	WILTON0002168	WILTON0002168	
PTX1515	Judith C. T. van Deutekom and Gert-Jan B. van Ommen, "Advances in Duchenne Muscular Dystrophy Gene Therapy," Nature Reviews, Genetics, Vol.4, October 2003 (metadata date created 9/8/2003)	9/8/2003	WILTON0002169	WIL TON0002178	
PTX1516	REMOVED DOCUMENT FROM LIST (DUPLICATE)	6/13/2008	WILTON0002432	WILTON0002432	
PTX1517	REMOVED DOCUMENT FROM LIST (DUPLICATE)	6/13/2008	WILTON0002433	WILTON0002433	
PTX1518	REMOVED DOCUMENT FROM LIST (DUPLICATE)	6/13/2008	WILTON0002434	WILTON0002434	
PTX1519	REMOVED DOCUMENT FROM LIST (DUPLICATE)	6/13/2008	WILTON0002435	WILTON0002435	
PTX1520	Email from A. Adams to S. Wilton Subject: Images, sent 6/27/2008	6/27/2008	WILTON0002678	WILTON0002678	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1521	Images: C57 Mouse 4 Weeks Treatment measuring Zenon Alexa Fluor 488, Picro Mallory Trichrome stain, Hematoxylin and eosin stain	6/27/2008	WILTON0002679	WILTON0002679	
PTX1522	Images: C57 Mouse 10 Weeks Treatment	6/27/2008	WILTON0002680	WILTON0002680	
PTX1523	Images: 10 mg/kg/week x 10 Treated mdx and mdx Control	6/27/2008	WILTON0002681	WILTON0002681	
PTX1524	Email from A. Adams to S. Wilton Subject: Progress report Charles Fund, sent 8/28/2008	8/28/2008	WILTON0003170	WILTON0003170	
PTX1525	Test results of varying AO combinations during Charlie experiments	8/28/2008	WILTON0003171	WILTON0003177	
PTX1526	50-53 Cocktail	8/28/2008	WILTON0003178	WILTON0003178	
PTX1527	Email from A. Adams to S. Wilton Subject: AOs for AVI, sent 9/4/2008	9/4/2008	WILTON0003179	WILTON0003179	
PTX1528	Table: Requests for sequences with varying umole amounts	9/4/2008	WILTON0003180	WILTON0003181	
PTX1529	Email from A. Adams to S. Wilton Subject: exon 52 53 23 controls, sent 2/24/2009	2/24/2009	WILTON0004816	WILTON0004816	
PTX1530	Images: Results Treated vs Control	2/24/2009	WILTON0004817	WILTON0004817	
PTX1531	Email from A. Adams to S. Wilton Subject: Charleys Report, sent 4/22/2009	4/22/2009	WILTON0004953	WILTON0004953	
PTX1532	Diagram representing AO positions for the optimization of exons 50-53	4/22/2009	WILTON0004954	WILTON0004956	
PTX1533	Email from S. Fletcher to S. Wilton and A. Adams Subject: Brevia Paper, sent 7/9/2009	7/9/2009	WILTON0005598	WILTON0005598	
PTX1534	Sue Fletcher et al., "Specific isoform induction by antisense mediated alternative splicing"	7/9/2009	WILTON0005599	WIL TON0005612	
PTX1535	Email from P. Meloni to S. Fletcher, cc S. Wilton Subject: FW: Eid report, sent 8/11/2009	8/11/2009	WILTON0005836	WILTON0005836	
PTX1536	Figure 1 (Eid06-2570) 8 - 21 del fibroblasts culture-1350	8/11/2009	WILTON0005837	WILTON0005837	
PTX1537	Table, "List of all Aos made for exon 51"	8/11/2009	WILTON0005897	WIL TON0005899	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1538	Email from A. Fall to S. Wilton Subject: Re: Exon 51 and 53, sent 11/23/2005	11/23/2005	WILTON0012315	WILTON0012315	
PTX1539	REMOVED DOCUMENT FROM LIST (DUPLICATE)	12/6/2005	WILTON0012317	WIL TON0012326	
PTX1540	REMOVED DOCUMENT FROM LIST (DUPLICATE)	12/7/2005	WILTON0012329	WILTON0012329	
PTX1541	Email from McClorey to S. Wilton, cc S. Fletcher and A. Fall Subject: Human explant paper, sent 12/7/2005	12/7/2005	WILTON0012330	WIL TON0012332	
PTX1542	Email from S. Wilton to A. Fall Subject: Paper, sent 12/9/2005	12/9/2005	WILTON0012355	WIL TON0012363	
PTX1543	Email from S. Wilton to A. Adams and P. Meloni re: 12 AOS list cited, sent on 4/24/2008	4/24/2008	WILTON0014790	WILTON0014790	
PTX1544	BMC Molecular Biology Research Article "Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries"	7/2/2007	WILTON0014824	WIL TON0014831	
PTX1545	Email from S. Wilton to P. Meloni Subject: PCT Final, sent 7/24/2008	7/24/2008	WILTON0015531	WILTON0015531	
PTX1546	REMOVED DOCUMENT FROM LIST (DUPLICATE)	7/24/2008	WILTON0015532	WILTON0015619	
PTX1547	Email from S. Wilton to P. Meloni et. All Subject: MT Submission, sent 9/1/2008	9/1/2008	WILTON0016003	WILTON0016003	
PTX1548	Editorial Manager(tm) for Molecular Therapy Manuscript Draft	8/28/2008	WILTON0016004	WILTON0016033	
PTX1549	Email from S. Wilton to P. Meloni Subject: RevisedMDA, sent 9/4/2008	9/4/2008	WILTON0016082	WILTON0016082	
PTX1550	"Research Plan," Wilton, Stephen D.	9/4/2008	WILTON0016083	WIL TON0016125	
PTX1551	REMOVED DOCUMENT FROM LIST (DUPLICATE)	9/4/2008	WILTON0016126	WIL TON0016162	
PTX1552	Email from S. Wilton to A. Adams Subject: AOS for AVI, sent 9/5/2008	9/5/2008	WILTON0016163	WILTON0016163	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1553	REMOVED DOCUMENT FROM LIST (DUPLICATE)	9/5/2008	WILTON0016164	WILTON0016166	
PTX1554	Email from Abbie Adams to Steve Wilton, Subject: Results, sent 6/28/2010	6/28/2010	WILTON0017528	WIL TON0017530	
PTX1555	REMOVED DOCUMENT FROM LIST (DUPLICATE)	12/23/2008	WILTON0017692	WIL TON0017695	
PTX1556	Email from S. Wilton to A. Adams Subject: FW: exon 53 paper, sent 12/23/2008	12/23/2008	WILTON0017701	WIL TON0017704	
PTX1557	Email from A. Adams to S. Wilton Subject: MOEs for exon 53 have arrived	6/21/2011	WILTON0017725	WIL TON0017727	
PTX1558	REMOVED DOCUMENT FROM LIST (DUPLICATE)	6/7/2011	WILTON0017728	WIL TON0017732	
PTX1559	Email from S. Jordan to S. Wilton et. All Subject: Calling Now, sent 6/7/2011	6/7/2011	WILTON0017733	WIL TON0017738	
PTX1560	Email from A. Adams to S. Wilton Subject: Calling Now, sent 6/7/2011	6/7/2011	WILTON0017739	WIL TON0017744	
PTX1561	Email from S. Wilton to F. Bennett Subject: Calling Now, sent 6/8/2011	6/8/2011	WILTON0017749	WIL TON0017753	
PTX1562	Email thread between Steve Wilton, Frank Bennett, Frank Rigo, Sue Fletcher, Abbie Adams, Stacy Jordan, Subject: in vitro data, sent 6/1/2011	6/1/2011	WILTON0017754	WIL TON0017757	
PTX1563	REMOVED DOCUMENT FROM LIST (DUPLICATE)	6/1/2011	WILTON0017758	WIL TON0017761	
PTX1564	Email from S. Wilton to F. Bennett et. All Subject: human exon 53 ASOs	6/14/2011	WILTON0017762	WIL TON0017764	
PTX1565	Email from S. Wilton to S. Jordan et. All Subject: Calling Scheduling, sent 6/2/2011	6/2/2011	WILTON0017765	WIL TON0017769	
PTX1566	REMOVED DOCUMENT FROM LIST (DUPLICATE)	6/1/2011	WILTON0017773	WIL TON0017775	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1567	Email thread between Steve Wilton, Frank Bennett, Frank Rigo, Sue Fletcher, Abbie Adams, Stacy Jordan, sent June 1 and 2, 2011	6/2/2011	WILTON0017776	WILTON0017780	
PTX1568	Email thread between Abbie Adams, Steve Wilton, George Vella, sent May 8, 9, 14, 16, 2008	5/16/2008	WILTON0017808	WILTON0017818	
PTX1569	Email message from Abbie Adams to Steve Wilton, June 23, 2010	6/23/2010	WILTON0017853	WILTON0017855	
PTX1570	REMOVED DOCUMENT FROM LIST (DUPLICATE)	6/28/2010	WILTON0017861	WILTON0017864	
PTX1571	Email thread between Abbie Adams, Steve Wilton, Sue Fletcher sent 23/06/10	6/23/2010	WILTON0017883	WILTON0017885	
PTX1572	Email thread between Steve Wilton and Abbie Adams, sent 23 September 2009	9/23/2009	WILTON0017969	WILTON0017971	
PTX1573	Email message from Penny Meloni to Steve Wilton and Sue Fletcher, sent 2009-01-11	8/11/2009	WILTON0017972	WILTON0017975	
PTX1574	Email thread between Abbie Adams, Steve Wilton, George Vella, sent May 8, 9, 14, 16, 2008	5/16/2008	WILTON0018032	WILTON0018037	
PTX1575	Email message from Abbie Adams to Steve Wilton, sent 6/11/2009	6/11/2009	WILTON0018059	WILTON0018062	
PTX1576	Email message from Abbie Adams to Steve Wilton, sent 3/26/2010	3/26/2010	WILTON0018351	WILTON0018353	
PTX1577	Email message from Linda Popplewell to George Dickson, Carl Adkin, Virginia Arechavala, Steve Wilton, Jenny Morgan, Francesco Muntoni, Annemieke Aartsma-Rus Aartsma-Rus, Subject: proofs of exon 53 paper, sent 25 Nov 2009	11/25/2009	WILTON0018407	WILTON0018409	
PTX1578	Email message from Abbie Adams to Steve Wilton, sent 3/25/2011	3/25/2011	WILTON0018464	WILTON0018466	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1579	Email message from Frank Rigo to Steve Wilton and Abbie Adams, sent 6/13/2011	6/13/2011	WILTON0018564	WILTON0018566	
PTX1580	Abbie M. Fall et al., "Induction of revertant fibres in the mdx mouse using antisense oligonucleotides, Genetic Vaccines and Therapy 2006 4:3 (published 24 May 2006)	5/24/2006	WILTON0021884	WILTON0021895	
PTX1581	Email message from Abbie Fall to Steve Wilton, sent 2/1/2005	2/1/2005	WILTON0026220	WILTON0026220	
PTX1582	Email message from Abbie Fall to Steve Wilton, Subject: Protocol, sent 9/9/2005	9/9/2005	WILTON0026285	WILTON0026285	
PTX1583	Email message from Abbie Fall to Steve Wilton, sent 1/13/2006	1/13/2006	WILTON0026324	WILTON0026324	
PTX1584	Email message from Abbie Fall to Steve Wilton, sent 1/19/2006	1/19/2006	WILTON0026327	WILTON0026327	
PTX1585	Email message from Abbie Fall to Steve Wilton, Subject: Changes, sent 3/7/2006	3/7/2006	WILTON0026381	WILTON0026381	
PTX1586	Email thread between Abbie Fall, Jenny Morgan, Steve Wilton, Subject: PMO sent, sent June 6, 7, 12, 2006	6/12/2006	WILTON0026408	WILTON0026409	
PTX1587	Email thread between Neera Gulati and Steve Wilton, sent 9/1/2008	9/1/2008	WILTON0017501	WILTON0017504	
PTX1588	REMOVED DOCUMENT FROM LIST (DUPLICATE)	11/23/2005	WILTON0012315	WILTON0012315	
PTX1589	Email message from Neera Gulati to Steve Wilton	9/6/2008	WILTON0018439	WILTON0018441	
PTX1590	Email message from Neera Gulati to Steve Wilton	9/6/2008	WILTON0018674	WILTON0018675	
PTX1591	Email thread between Neera Gulati and Steve Wilton, sent 6/9/08	6/9/2008	WILTON0017912	WILTON0017915	
PTX1592	Email thread between Neera Gulati and Steve Wilton, sent 24/07/10	7/24/2010	WILTON0017520	WILTON0017523	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1593	U.S. Appl. No. 14/776,533 Final Office Action dated 11/16/2017	11/16/2017	SRPT-VYDS-0090004	SRPT-VYDS-0090027	
PTX1594	Fletcher et al., Evaluation of a short interspersed nucleotide element in the 3' untranslated region of the defective dystrophin gene of dogs with muscular dystrophy, Am. J. Vet. Res. 62, 164-68 (2000) (accepted Dec 22, 2000, pub. December 2011)	12/22/2000	NONE	NONE	
PTX1595	Gebski et al., Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle, Hum. Mol. Gen. 12, 1801-11 (2003) (accepted May 28, 2003, pub. 2003)	5/28/2003	NONE	NONE	
PTX1596	U.S. Appl. No. 14/776,533 non-Final Office Action dated 2/28/2017	2/28/2017	NONE	NONE	
PTX1597	U.S. Appl. No. 14/776,533 Preliminary Amendment dated 2/29/2016	2/29/2016	NONE	NONE	
PTX1598	U.S. Appl. No. 14/776,533 Response to Restriction Requirement and Amendment dated 2/3/2017	2/3/2017	NONE	NONE	
PTX1599	U.S. Provisional Appl. No. 61/108,416, October 24, 2008	10/24/2008	NONE	NONE	
PTX1600	GraphPad Prism file, date 2012-12-20, title "Project info 1" (metadata date created 12/21/2012, date modified 10/10/2022)	12/21/2012	SRPT-VYDS-0217588	SRPT-VYDS-0217644	
PTX1601	GraphPad Prism file, date 2012-12-20, title "Project info 1" (metadata date created 12/20/2012, date modified 10/10/2022)	12/20/2012	SRPT-VYDS-0217649	SRPT-VYDS-0217689	
PTX1602	GraphPad Prism file, date 2012-12-20, title "Project info 1" (metadata date created 12/13/2012, date modified 10/10/2022)	12/13/2013	SRPT-VYDS-0217730	SRPT-VYDS-0217749	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1603	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	8/24/2023	NS00156734	NS00156766	
PTX1604	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	9/15/2023	NS00156767	NS00156807	
PTX1605	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	10/30/2023	NS00156808	NS00156829	
PTX1606	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	11/29/2023	NS00156830	NS00156853	
PTX1607	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	12/26/2023	NS00156854	NS00156873	
PTX1608	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	1/17/2024	NS00156874	NS00156888	
PTX1609	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	2/22/2024	NS00156889	NS00156909	
PTX1610	Morgan Lewis Invoice for Nippon Shinyaku Co., Ltd.	3/8/2024	NS00156910	NS00156925	
PTX1611	Abe, Ikubo & Katayama Summary of Attorney Fees for Nippon Shinyaku - US IP Litigation	None	NS00156926	NS00156926	
PTX1612	Abe, Ikubo & Katayama Invoice No. 23100765 (Japanese and Certified English Translation)	10/6/2023	NS00156927	NS00156928	
PTX1613	Abe, Ikubo & Katayama Invoice No. 23110701 (Japanese and Certified English Translation)	11/8/2023	NS00156929	NS00156930	
PTX1614	Abe, Ikubo & Katayama Invoice No. 23120742 (Japanese and Certified English Translation)	12/7/2023	NS00156931	NS00156932	
PTX1615	Abe, Ikubo & Katayama Invoice No. 24010845 (Japanese and Certified English Translation)	1/12/2024	NS00156933	NS00156934	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1616	Abe, Ikubo & Katayama Invoice No. 24020855 (Japanese and Certified English Translation)	2/7/2024	NS00156935	NS00156936	
PTX1617	Abe, Ikubo & Katayama Invoice No. 24030834 (Japanese and Certified English Translation)	3/7/2024	NS00156937	NS00156938	
PTX1618	Spreadsheet of financials (Japanese and Certified English Translation)	None	NS00156939	NS00156940	
PTX1619	NS Pharma Final [REDACTED] of Viltepso for Calendar Year 20203	2/14/2024	NS00156941	NS00156941	
PTX1620	Spreadsheet of financials - shipments [REDACTED]	None	NS00156942	NS00156942	
PTX1621	Invoice to NS Pharma for Viltolarsen	2/26/2024	NS00156943	NS00156943	
PTX1622	Spreadsheet - Updated financials	None	NS00156944	NS00156944	
PTX1623	Wire Transaction - NS Pharma	2/27/2024	NS00156945	NS00156945	
PTX1624	Sarepta Updated Financial Production	4/2/2024	SRPT-VYDS-0246333	SRPT-VYDS-0246333	
PTX1625	Email message from Steve Wilton to Abbie Fall, Subject: Exon 51 and 53	11/23/2005	WILTON0012314	WILTON0012314	
PTX1626	Email message from Abbie Fall to Pat Iversen and Steve Wilton, Subject: Exon 51 and 53	11/24/2005	WILTON0012316	WILTON0012316	
PTX1627	Email message from Steve Wilton to Abbie Adams, Penny Meloni attaching "Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy," sent April 24, 2008	4/24/2008	WILTON0014782	WILTON0014789	
PTX1628	Email message from Abbie Adams to Steve Wilton attaching "exon 53 copy.jpg," sent January 28, 2009	1/28/2009	WILTON0004483	WILTON0004484	
PTX1629	Email message from Abbie Adams to Steve Wilton, sent June 11, 2009	6/11/2009	WILTON0005298	WILTON0005298	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1630	Email thread between Linda Popplewell, A. Aartsma-Rus, G. Dickson, C. Adkin, V. Arechavala, Steve Wilton, J. Morgan, F. Muntoni, and ig2@sanger.co.uk, Subject: Exon 53 paper	10/28/2009	WILTON0010161	WILTON0010161	
PTX1631	Email message from Abbie Adams to Steve Wilton (regarding sequences of the requested exons)	9/23/2009	WILTON0006355	WILTON0006355	
PTX1632	Email message from Sue Fletcher to Steve Wilton, Subject: Grant your copy, attaching Track Record and Publications	2/19/2008	WILTON0001293	WILTON0001297	
PTX1633	Email message from Steve Wilton to Sue Fletcher attaching "Lay summary of progress," sent May 6, 2008	5/6/2008	WILTON0014818	WILTON0014822	
PTX1634	Email message from Sue Fletcher to Steve Wilton, Subject: Charles final, attaching "[REDACTED]," sent October 17, 2008	10/17/2008	WILTON0003508	WILTON0003516	
PTX1635	Exon 43, 44, 45, 46, 50, 52, 53 charts (metadata date created 5/26/2010, date modified 6/9/2010)	6/9/2010	WILTON0010363	WILTON0010370	
PTX1636	Email from S. Handford to A. Bates and G. Campen Subject: RE: antisense patent, Sent 11/10/2008	11/10/2008	UWA0001170	UWA0001171	
PTX1637	Email from S. Handford to L. Portilla Subject: Confirmation of license with AVI BioPharma Inc sent 4/12/2012	4/12/2012	UWA0001135	UWA0001136	
PTX1638	Email from S. Handford to S. Wilton et. all Subject: Emailing: Emerging drugs for Duchenne muscular dystrophy sent 5/30/2012	5/30/2012	UWA0001145	UWA0001145	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1639	Email from I. Heystek to Sarepta Accounts Team Subject: FW: Golodirsén milestone sent 1/14/2020	1/14/2020	UWA0001005	UWA0001008	
PTX1640	Email thread from M. Hurley to S. Handford Subject: RE: Q3 statement sent 11/9/2020	11/9/2020	UWA0001023	UWA0001025	
PTX1641	Letter from L. DeLacour to P. Curtis Subject: Sarepta 2013 DMD1 Licence Fee Payment Disbursement [REDACTED] sent 5/16/2013	5/16/2013	UWA0000997	UWA0000997	
PTX1642	Email from K. Andrews to S. Handford Subject: Viltolarsén sent 8/13/2020	8/13/2020	UWA0001009	UWA0001022	
PTX1643	Declaration (37 CFR 1.63) for Utility or Design Application Using an Application Data Sheet (37 CFR 1.76) and Application Data Sheet 37 CFR 1.76 filed September 14, 2017	9/14/2017	SRPT-VYDS-0002988	SRPT-VYDS-0002999	
PTX1644	Excerpts from Application No. 15/703,172: "Preliminary Amendment Under 37 C.F.R. § 1.115"	9/15/2017	SRPT-VYDS-0003099	SRPT-VYDS-0003102	
PTX1645	Excerpts from Application No. 15/703,172: Office Action	10/5/2017	SRPT-VYDS-0004606	SRPT-VYDS-0004615	
PTX1646	Excerpts from Application No. 15/705,172: "Examiner-Initiated Interview Summary," date of interview 27 March 2018	3/27/2018	SRPT-VYDS-0004952	SRPT-VYDS-0004952	
PTX1647	Excerpts from Application No. 15/705,172: "Office Action Summary," mail date	4/4/2018	SRPT-VYDS-0004945	SRPT-VYDS-0004951	
PTX1648	Excerpts from Application No. 15/705,172: Notice of Allowance and Fee(s) Due, OMB Clearance and PRA Burden Statement for PTOL-85 Part B, Notice of Allowability, mail date 04/09/2018	4/9/2018	SRPT-VYDS-0004959	SRPT-VYDS-0004967	
PTX1649	Updated Financial Spreadsheet - H.15 Selected Interest Rates for Apr 03, 2024	4/3/2024	SRPT-VYDS-0246334	SRPT-VYDS-0246334	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1650	Sarepta Therapeutics, Inc. Form 10-Q for period ended March 31, 2023	5/2/2023	SRPT-VYDS-0246335	SRPT-VYDS-0246408	
PTX1651	Sarepta Therapeutics, Inc. Form 10-Q for period ended June 30, 2023	8/2/2023	SRPT-VYDS-0246409	SRPT-VYDS-0246626	
PTX1652	Sarepta Therapeutics, Inc. Form 10-Q for period ended September 30, 2023	11/1/2023	SRPT-VYDS-0246627	SRPT-VYDS-0246709	
PTX1653	Sarepta Therapeutics, Inc. Form 10-K for the fiscal year ended December 31, 2023	2/28/2024	SRPT-VYDS-0246710	SRPT-VYDS-0246877	
PTX1654	Mark Hosfield Curriculum Vitae attached to the Supplemental Expert Report of Mark	4/15/2024	None	None	
PTX1655	Opening Expert Report of Christine C. Esau, Ph.D, Regarding Infringement of Certain NS Patents Exhibit 2 – Materials Considered (served September 8, 2023)	9/8/2023	None	None	
PTX1656	Rebuttal Expert Report of Christine C. Esau, Ph.D, Regarding Non-Infringement of the UWA Patents Exhibit A – Materials Considered (served October 11, 2023)	10/11/2023	None	None	
PTX1657	Expert Report of Dr. Michelle L. Hastings Regarding invalidity of the UWA Patents Exhibit 1 – Materials Considered (served September 8, 2023)	9/8/2023	None	None	
PTX1658	Responsive Expert Report of Dr. Michelle L. Hastings Regarding Invalidity of the UWA Patents Exhibit 1 – Materials Considered (served October 11, 2023)	10/11/2023	None	None	
PTX1659	Reply Expert Report of Dr. Michelle L. Hastings Regarding The Invalidity of the UWA Patents Appendix – Materials Considered (served October 27, 2023)	10/27/2023	None	None	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1660	Expert Report and Disclosure of Mark J. Hosfield Appendix A (served September 8, 2023)	9/8/2023	None	None	
PTX1661	Expert Report and Disclosure of Mark J. Hosfield Appendix B (served September 8, 2023)	9/8/2023	None	None	
PTX1662	Expert Report and Disclosure of Mark J. Hosfield Exhibit 1 – Curriculum Vitae (served September 8, 2023)	9/8/2023	None	None	
PTX1663	Expert Report and Disclosure of Mark J. Hosfield Exhibit 2 (served September 8, 2023)	9/8/2023	None	None	
PTX1664	Expert Report and Disclosure of Mark J. Hosfield Exhibit 3A (served September 8, 2023)	9/8/2023	None	None	
PTX1665	Expert Report and Disclosure of Mark J. Hosfield Exhibit 3B (served September 8, 2023)	9/8/2023	None	None	
PTX1666	Expert Report and Disclosure of Mark J. Hosfield Exhibit 4 (served September 8, 2023)	9/8/2023	None	None	
PTX1667	Expert Report and Disclosure of Mark J. Hosfield Appendix 5 (served September 8, 2023)	9/8/2023	None	None	
PTX1668	Expert Report and Disclosure of Mark J. Hosfield Exhibit 6 (served September 8, 2023)	9/8/2023	None	None	
PTX1669	Expert Report and Disclosure of Mark J. Hosfield Exhibit 7 (served September 8, 2023)	9/8/2023	None	None	
PTX1670	Rebuttal Expert Report and Disclosure of Mark J. Hosfield Exhibit 1 – Curriculum Vitae (served October 11, 2023)	10/11/2023	None	None	
PTX1671	Rebuttal Expert Report and Disclosure of Mark J. Hosfield Exhibit 2 (served October 11, 2023)	10/11/2023	None	None	
PTX1672	Rebuttal Expert Report and Disclosure of Mark J. Hosfield Exhibit 3 (served October 11, 2023)	10/11/2023	None	None	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1673	Rebuttal Expert Report and Disclosure of Mark J. Hosfield Exhibit 4 (served October 11, 2023)	10/11/2023	None	None	
PTX1674	Rebuttal Expert Report and Disclosure of Mark J. Hosfield Exhibit 5 (served October 11, 2023)	10/11/2023	None	None	
PTX1675	Reply Expert Report and Disclosure of Mark J. Hosfield Exhibit 2 (served October 27, 2023)	10/27/2023	None	None	
PTX1676	Reply Expert Report and Disclosure of Mark J. Hosfield Exhibit 3A (served October 27, 2023)	10/27/2023	None	None	
PTX1677	Reply Expert Report and Disclosure of Mark J. Hosfield Exhibit 3B (served October 27, 2023)	10/27/2023	None	None	
PTX1678	Reply Expert Report and Disclosure of Mark J. Hosfield Exhibit 3C (served October 27, 2023)	10/27/2023	None	None	
PTX1679	Reply Expert Report and Disclosure of Mark J. Hosfield Exhibit 4 (served October 27, 2023)	10/27/2023	None	None	
PTX1680	Reply Expert Report and Disclosure of Mark J. Hosfield Exhibit 5 (served October 27, 2023)	10/27/2023	None	None	
PTX1681	Reply Expert Report and Disclosure of Mark J. Hosfield Exhibit 6 (served October 27, 2023)	10/27/2023	None	None	
PTX1682	Reply Expert Report and Disclosure of Mark J. Hosfield Exhibit 7 (served October 27, 2023)	10/27/2023	None	None	
PTX1683	Reply Expert Report and Disclosure of Mark J. Hosfield Exhibit 8 (served October 27, 2023)	10/27/2023	None	None	
PTX1684	Reply Expert Report and Disclosure of Mark J. Hosfield Appendix A (served October 27, 2023)	10/27/2023	None	None	
PTX1685	Reply Expert Report and Disclosure of Mark J. Hosfield Appendix B (served October 27, 2023)	10/27/2023	None	None	
PTX1686	Supplemental Expert Report and Disclosure of Mark J. Hosfield Exhibit 2 (served April 12, 2024)	4/12/2024	None	None	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1687	Supplemental Expert Report and Disclosure of Mark J. Hosfield Exhibit 3A (served April 12, 2024)	4/12/2024	None	None	
PTX1688	Supplemental Expert Report and Disclosure of Mark J. Hosfield Exhibit 3B (served April 12, 2024)	4/12/2024	None	None	
PTX1689	Supplemental Expert Report and Disclosure of Mark J. Hosfield Exhibit 3C (served April 12, 2024)	4/12/2024	None	None	
PTX1690	Supplemental Expert Report and Disclosure of Mark J. Hosfield Exhibit 4 (served April 12, 2024)	4/12/2024	None	None	
PTX1691	Supplemental Expert Report and Disclosure of Mark J. Hosfield Exhibit 5 (served April 12, 2024)	4/12/2024	None	None	
PTX1692	Supplemental Expert Report and Disclosure of Mark J. Hosfield Exhibit 6 (served April 12, 2024)	4/12/2024	None	None	
PTX1693	Supplemental Expert Report and Disclosure of Mark J. Hosfield Exhibit 7 (served April 12, 2024)	4/12/2024	None	None	
PTX1694	Supplemental Expert Report and Disclosure of Mark J. Hosfield Exhibit 8 (served April 12, 2024)	4/12/2024	None	None	
PTX1695	Supplemental Expert Report and Disclosure of Mark J. Hosfield Appendix A (served April 12, 2024)	4/12/2024	None	None	
PTX1696	Supplemental Expert Report and Disclosure of Mark J. Hosfield Appendix B (served April 12, 2024)	4/12/2024	None	None	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1697	Supplemental Rebuttal Expert Report and Disclosure of Mark J. Hosfield Exhibit 1 – Curriculum Vitae (served April 19, 2024)	4/19/2024	None	None	
PTX1698	Supplemental Rebuttal Expert Report and Disclosure of Mark J. Hosfield Exhibit 2 (served April 19, 2024)	4/19/2024	None	None	
PTX1699	Supplemental Rebuttal Expert Report and Disclosure of Mark J. Hosfield Exhibit 3 (served April 19, 2024)	4/19/2024	None	None	
PTX1700	Supplemental Rebuttal Expert Report and Disclosure of Mark J. Hosfield Exhibit 4 (served April 19, 2024)	4/19/2024	None	None	
PTX1701	Supplemental Rebuttal Expert Report and Disclosure of Mark J. Hosfield Exhibit 5 (served April 19, 2024)	4/19/2024	None	None	
PTX1702	Expert Report of Scott E. Kamholz, Esq. Appendix A (served September 8, 2023)	9/8/2023	None	None	
PTX1703	Responsive Expert Report of Scott E. Kamholz, Esq. Exhibit 1 (served October 11, 2023)	10/11/2023	None	None	
PTX1704	Reply Expert Report of Scott E. Kamholz, Esq. Appendix (served October 27, 2023)	10/27/2023	None	None	
PTX1705	Reply Expert Report of Scott E. Kamholz, Esq. Exhibit 1 (served October 27, 2023)	10/27/2023	None	None	
PTX1706	Opening Expert Report of Nathan W. Luedtke, Ph.D Regarding Infringement of U.S. Patent No. 10,683,322 ("The '322 Patent") Exhibit 2 (served September 8, 2023)	9/8/2023	None	None	
PTX1707	Technical Expert Report of Jonathan Strober, M.D. Exhibit 1 (served September 8, 2023)	9/8/2023	None	None	
PTX1708	Technical Expert Report of Jonathan Strober, M.D. Exhibit 2 – Curriculum Vitae (served September 8, 2023)	9/8/2023	None	None	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1709	Rebuttal Technical Expert Report of Jonathan Strober, M.D. Exhibit 2 (served October 11, 2023)	10/11/2023	None	None	
PTX1710	Expert Report of Dr. Matthew J.A. Wood Exhibit 1 (served September 8, 2023)	9/8/2023	None	None	
PTX1711	Expert Rebuttal Report of Dr. Matthew J.A. Wood Exhibit 1 (served October 11, 2023)	10/11/2023	None	None	
PTX1712	Expert Reply Report of Dr. Matthew J.A. Wood Exhibit 1 (served October 27, 2023)	10/27/2023	None	None	
PTX1713	Expert Report of Robert S. Maness, Ph.D. Appendix B (served September 8, 2023)	9/8/2023	None	None	
PTX1714	Expert Report of Robert S. Maness, Ph.D. Appendix C (served October 4, 2023)	10/4/2023	None	None	
PTX1715	Expert Reply Report of Robert S. Maness, Ph.D. Exhibit 1 (served October 27, 2023)	10/27/2023	None	None	
PTX1716	Expert Reply Report of Robert S. Maness, Ph.D. Exhibit 2 (served October 27, 2023)	10/27/2023	None	None	
PTX1717	Expert Reply Report of Robert S. Maness, Ph.D. Appendix A (served October 27, 2023)	10/27/2023	None	None	
PTX1718	Supplemental Report of Robert S. Maness, Ph.D. Exhibit 1 (served April 12, 2024)	4/12/2024	None	None	
PTX1719	Supplemental Report of Robert S. Maness, Ph.D. Exhibit 2 (served April 12, 2024)	4/12/2024	None	None	
PTX1720	Supplemental Report of Robert S. Maness, Ph.D. Exhibit 3 (served April 12, 2024)	4/12/2024	None	None	
PTX1721	Supplemental Report of Robert S. Maness, Ph.D. Appendix A (served April 12, 2024)	4/12/2024	None	None	
PTX1722	International Publication Number WO 2007/028065 A2, C. Brank Bennett, et al., "Chimeric Oligomeric Compounds for Modulation of Splicing," Int'l pub. date March 8, 2007	3/8/2007	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1723	Utility Patent Application 17/805,402, Richard K. Bestwick, "Exon Skipping Compositions for Treating Muscular Dystrophy," sent June 3, 2022	6/3/2022	NONE	NONE	
PTX1724	Patent Application Publication No. US 2022/0364093 A1, Richard K. Bestwick and Diane Elizabeth Frank, "Exon Skipping Compositions for Treating Muscular Dystrophy," Pub. date November 17, 2022	11/17/2022	NONE	NONE	
PTX1725	Email from Pat Furlong to Steve Wilton (cc C. Donovan), Subject: [REDACTED] " sent May 7,	5/7/2007	WILTON0012395	WILTON0012395	
PTX1726	Email thread between J. George Dickson, Steve Wilton, Mathew Wood, and Francesco Muntoni, Subject: "[REDACTED]" sent February 4, February 25 and March 2, 2011	3/2/2011	WILTON0017603	WILTON0017607	
PTX1727	Email thread between J. George Dickson, Steve Wilton, Mathew Wood, and Francesco Muntoni, Subject: "[REDACTED]" sent February 4, February 25 and February 26, 2011	2/26/2011	WILTON0017631	WILTON0017635	
PTX1728	Email thread between J. George Dickson, Steve Wilton, Mathew Wood, and Francesco Muntoni, Subject: "[REDACTED]" sent February 4, February 25 and March 2, 2011	3/2/2011	WILTON0017781	WILTON0017786	
PTX1729	Email thread between J. George Dickson, Steve Wilton, Mathew Wood, and Francesco Muntoni, Subject: "[REDACTED]" sent November 8, 9 and 10, 2010	11/10/2010	WILTON0018066	WILTON0018071	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1730	Email thread between Nimi Langer and Steve Wilton, Subject: "[REDACTED]" sent November 9, 21, and 22, 2011	11/22/2011	WILTON0018391	WILTON0018397	
PTX1731	Email thread between Francesco Muntoni and Steve Wilton, Subject: "[REDACTED]" sent April 22, 2004 and November 30, 2004	11/30/2004	WILTON0026200	WILTON0026202	
PTX1732	Email thread between Francesco Muntoni and Steve Wilton, Subject: "[REDACTED]" sent February 4, 6, 15 and 17, 2005	2/17/2005	WILTON0026222	WILTON0026223	
PTX1733	Email thread between Francesco Muntoni and Steve Wilton, Subject: "[REDACTED]" sent February 4, 6, 15 and 18, 2005	2/18/2005	WILTON0026224	WILTON0026226	
PTX1734	Email thread between Francesco Muntoni and Steve Wilton, Subject: "[REDACTED]" sent 04/20/2006	4/20/2006	WILTON0026387	WILTON0026388	
PTX1735	Email thread between Jenny Morgan and Steven Wilton, Subject: "[REDACTED]" sent 6/6/2006	6/6/2006	WILTON0026402	WILTON0026403	
PTX1736	Steve D. Wilton and Susan Fletcher, "Exon skipping and Duchenne muscular dystrophy: Hope, hype and how feasible?" 56 Neurology India 254-262 (July-September 2008)	9/1/2008	NONE	NONE	
PTX1737	Zacharias Aloysius Dwi Pramono et al., "Induction of Exon Skipping of the Dystrophin Transcript in Lymphoblastoid Cells by Transfecting an Antisense Oligodeoxynucleotide Complementary to an Exon Recognition Sequence," 226 Biochem. & Biophysical Research Commn's 445-449 (Recv'd Aug. 8, 1996)	8/8/1996	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1738	European Patent Application EP 1 568 769 A1, Masafumi Matsuo et al., "ENA Nucleic Acid Drugs Modifying Splicing in mRNA Precursor," Int'l App. No. PCT/JP2003/014915, Pub. date August 31,	8/31/2005	NS00036470	NS00036878	
PTX1739	Advance Pricing Agreement between NS Pharma, Inc. and The Internal Revenue Service, effective March 27, 2024	3/27/2024	NS00156946	NS00156963	
PTX1740	Agreement on Mutual Consultation (Notice), dated December 1, 2023 (Japanese followed by certified English translation)	12/1/2023	NS00156964	NS00156972	
PTX1741	Opening Expert Report of Steven F. Dowdy, Ph.D., served September 8, 2023	9/8/2023	NONE	NONE	
PTX1742	Rebuttal Expert Report of Steven F. Dowdy, Ph.D., served October 11, 2023	10/11/2023	NONE	NONE	
PTX1743	CNBC, "These are the 10 highest-paid CEOs in the U.S.--some pull in over \$200 million a year," (Pub. July 5, 2023) at https://www.cnbc.com/2023/07/05/heres-how-much-the-10-highest-paid-us-ceos-earn.html	7/5/2023	NONE	NONE	
PTX1744	CEOWorld, "Here are the Highest-Paid Biopharmaceutical CEOs in the United States," (May 26, 2023) at https://ceoworld.biz/2023/05/27/here-are-the-highest-paid-biopharmaceutical-ceos-in-the-united-states/	5/26/2023	NONE	NONE	
PTX1745	Reply Expert Report of Steven F. Dowdy, Ph.D., served October 27, 2023	10/27/2023	NONE	NONE	
PTX1746	Expert Report of Andrew H. Hirshfeld, served September 8, 2023	9/8/2023	NONE	NONE	
PTX1747	Expert Rebuttal Report of Andrew H. Hirshfeld, served October 27, 2023	10/27/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1748	Opening Expert Report of John C. Jarosz, served September 8, 2023	9/8/2023	NONE	NONE	
PTX1749	Rebuttal Expert Report of John C. Jarosz, served October 11, 2023	10/11/2023	NONE	NONE	
PTX1750	Reply Expert Report of John C. Jarosz, served October 11, 2023	10/27/2023	NONE	NONE	
PTX1751	Supplemental Opening Expert Report of John C. Jarosz, served April 12, 2024	4/12/2024	NONE	NONE	
PTX1752	Supplemental Rebuttal Expert Report of John C. Jarosz, served April 19, 2024	4/19/2024	NONE	NONE	
PTX1753	Rebuttal Expert Report of Yao Lu, Ph.D., served October 11, 2023	10/11/2023	NONE	NONE	
PTX1754	Supplemental Rebuttal Report of Yao Lu, Ph.D., served April 19, 2024	4/19/2024	NONE	NONE	
PTX1755	Opening Expert Report of Stanley Nelson, M.D., served September 8, 2023	9/8/2023	NONE	NONE	
PTX1756	Rebuttal Expert Report of Stanley Nelson, M.D., served October 11, 2023	10/11/2023	NONE	NONE	
PTX1757	Reply Expert Report of Stanley Nelson, M.D., served October 27, 2023	10/27/2023	NONE	NONE	
PTX1758	Opening Expert Report of Bradley L. Pentelute, Ph.D., served September 8, 2023	9/8/2023	NONE	NONE	
PTX1759	Rebuttal Expert Report of Brandley L. Pentelute, Ph.D. Regarding Non-Infringement of U.S. Patent No. 10,683,322, served October 11, 2023	10/11/2023	NONE	NONE	
PTX1760	Milestones Become Stepping Stones, "Strategy Tools and Wins," 2023 NCM	1/1/2023	NS00156973	NS00156973	
PTX1761	United Healthcare Commercial, <i>Medical Benefit Drug Policy</i> , Effective Date August 1, 2023	8/1/2023	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1762	Supplemental Financial Document: Native Excel Workbook, four worksheets: "Commerical_20, Commerical_21, Commercial_22, Commercial_23, and Commercial_24"	8/1/2024	NS00157824	NS00157824	
PTX1763	Supplemental Financial Document: Viltesso_Record of Costs of Shipping to the US (2020 -2024) (<i>Japanese with certified English translation</i>)	None	NS00157825	NS00157825	
PTX1764	Supplemental Financial Document: Printout of Native Workbook with heading "Ship to Clinigen"	None	NS00157826_Replacement	NS00157826_Replacement	
PTX1765	Supplemental Financial Document: Sarepta's updated financial production - Native spreadsheet with tabs: (1) Vyondys Summary; and (2) Commercial Spend Detail	None	SRPT-VYDS-0247660	SRPT-VYDS-0247660	
PTX1766	CERI's Outline available at https://www.cerij.or.jp/ceri_en/gaiyou/gaiyou_menu.html	8/22/2024	NONE	NONE	
PTX1767	CERI'S Chemicals Assessment and Research Center available at https://www.cerij.or.jp/ceri_en/gyoumu/hyouka ken_menu.html	8/22/2024	NONE	NONE	
PTX1768	U.S. Patent No. 6,683,173 (Dempsy et al.)	1/27/2004	NS00156974	NS00157040	
PTX1769	U.S. Patent Publication No. 2006/0147952 A1 (van Ommen et al.)	7/6/2006	NS00157041	NS00157071	
PTX1770	Asseline et al., "Oligodeoxynucleotides covalently linked to intercalating dyes as base sequence-specific ligands. Influence of dye attachment site," The EMBO J., 3:795-800 (1984)	1/16/1984	NS00157072	NS00157077	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1771	Le et al., "Thiomorpholino oligonucleotides as a robust class of next generation platforms for alternate mRNA splicing," PNAS 119(36) (2022)	8/29/2022	NS00157078	NS00157085	
PTX1772	Lebleu et al., "Cell penetrating peptide conjugates of steric block oligonucleotides," Advanced Drug Delivery Reviews 60:517-529 (2008)	10/22/2007	NS00157086	NS00157098	
PTX1773	Li et al., "Fully automated fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers," Nature Comm'ns (2021)	7/20/2021	NS00157099	NS00157106	
PTX1774	Neuman et al., "Antisense Morpholino-Oligomers Directed against the 5' End of the Genome Inhibit Coronavirus Proliferation and Growth," J. Virology, 78:5891-5899 (2004)	6/1/2004	NS00157107	NS00157115	
PTX1775	Neuman et al., "Inhibition, Escape, and Attenuated Growth of Severe Acute Respiratory Syndrome Coronavirus Treated with Antisense Morpholino Oligomers," J. Virology, 79:9665-9676 (2005)	8/1/2005	NS00157116	NS00157127	
PTX1776	Paul & Caruthers, "Synthesis of Backbone-Modified Morpholino Oligonucleotides Using Phosphoramidite Chemistry," Molecules, 28:5380 (2023)	7/13/2023	NS00157128	NS00157139	
PTX1777	Swenson et al., "Chemical Modifications of Antisense Morpholino Oligomers Enhance Their Efficacy against Ebola Virus Infection," Antimicrobial Agents & Chemotherapy, 53:2089-2099 (2009)	5/1/2009	NS00157140	NS00157150	
PTX1778	Zhang et al., "Synthesis and properties of morpholino chimeric oligonucleotides." Tetrahedron Letters 49:3570-3573 (2008)	4/9/2008	NS00157151	NS00157154	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1779	Excel workbook: Exon53	7/3/2009	NS00062121	NS00062121	
PTX1780	Sazani et al., "Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs," Nucleic Acid Res, 29(19):3965-3975 (2001)	8/6/2001	NS00062630	NS00062639	
PTX1781	McClore et al., "Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD," Gene Ther, 13:1373-1381 (2006)	5/25/2006	NS00123770	NS00123778	
PTX1782	Excel workbook: exon53 skipping	6/18/2009	NS00138319	NS00138319	
PTX1783	Aartsma-Rus et al., "Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells," Gene Ther, 11:1391-98 (2004)	7/1/2004	NS00157155	NS00157162	
PTX1784	Aartsma-Rus, "Antisense-mediated modulation of splicing: Therapeutic implications for Duchenne muscular dystrophy," RNA Biology, 7(4): 453-461 (2010)	7/1/2010	NS00157163	NS00157172	
PTX1785	Adams et al., "Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries," BMC Mol Biol, 8:57 (2007)	7/2/2007	NS00157173	NS00157180	
PTX1786	Aung-Htut et al., "In Vitro Validation of Phosphorodiamidate Morpholino Oligomers," Molecules, 24:2922-33 (2019)	8/12/2019	NS00157181	NS00157191	
PTX1787	Ding et al., "Visualizing RNA conformational and architectural heterogeneity in solution," Nat Commun, 14(1):714 (2023)	2/9/2023	NS00157192	NS00157202	
PTX1788	Egli and Manoharan, "Chemistry, structure and function of approved oligonucleotide therapeutics," Nucleic Acids Res, 51(6):2529-73 (2023)	3/7/2023	NS00157203	NS00157247	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1789	Fletcher et al., "Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide," J Gene Med, 8:207-16 (2006)	11/14/2005	NS00157248	NS00157257	
PTX1790	Fletcher et al., "Morpholino Oligomer-Medicated Exon Skipping Averts the Onset of Dystrophic Pathology in the mdx Mouse," Mol Ther, 15(9):1587-1592 (2007)	6/19/2007	NS00157258	NS00157263	
PTX1791	Ghosh and Iverson, "Intracellular Delivery Strategies for Antisense Phosphorodiamidate Morpholino Oligomers," Antisense & Nucleic Acid Drug Dev, 10:263-274 (2000)	4/25/2000	NS00157264	NS00157275	
PTX1792	Jankowsky & Harris, "Specificity and non-specificity in RNA-protein interactions," Nat. Rev. Mol. Cell Biol., 16(9):533-544 (2016)	2/7/2016	NS00157276	NS00157301	
PTX1793	Li et al., "Fully automater fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers," Nature Communications, 12:4396 (2021)	7/20/2021	NS00157302	NS00157309	
PTX1794	Lu et al., "The Status of Exon Skipping as a Therapeutic Approach to Duchenne Muscular Dystrophy," Mol Ther, 19(1):9-15 (2011)	10/26/2010	NS00157310	NS00157316	
PTX1795	Manoharan, "Oligonucleotide Conjugates as Potential Antisense Drugs with Improved Uptake, Biodistribution, Targeted Delivery, and Mechanism of Action," Antisense & Nucleic Acid Drug Dev, 12:103-128 (2002)	8/31/2001	NS00157317	NS00157342	
PTX1796	Morcos PA, "Achieving Efficient Delivery of Morpholino Oligos in Cultured Cells," Genesis, 30:94-102 (2001)	5/10/2001	NS00157343	NS00157351	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1797	Moulton, JD & Yan, "Using Morpholinos to Control Gene Expression," Curr. Protoc. Mol. Biol., 83:26.8.1-29 (2008)	7/1/2008	NS00157352	NS00157380	
PTX1798	HM Moulton & JD Moulton (eds.), Morpholino Oligomers: Methods and Protocols, Methods in Molecular Biology vol. 1565 (2017)	1/1/2017	NS00157381	NS00157663	
PTX1799	Partridge et al., "A Simple Method for Delivering Morpholino Antisense Oligos into the Cytoplasm of Cells," Antisense Nucleic Acid Drug Dev, 6:169-175 (1996)	5/13/1996	NS00157664	NS00157670	
PTX1800	Saito et al., "Antisense PMO Found in Dystrophic Dog Model Was Effective in Cells from Exon 7-Deleted DMD Patient," PLoS ONE, 5(8):e12239 (2010)	8/18/2010	NS00157671	NS00157678	
PTX1801	Sazani et al., "Systemically delivered antisense oligomers upregulate gene expression in mouse tissues," Nature Biotechnol., 20:1228-1233 (2002)	11/11/2002	NS00157679	NS00157684	
PTX1802	Stirchak et al., "Uncharged stereoregular nucleic acid analogs," Nucleic Acid Res, 17(15):6129-41 (1989)	6/29/1989	NS00157685	NS00157697	
PTX1803	Summerton, "Endo-Porter: A Novel Reagent For Safe, Effective Delivery of Substances Into Cells," Ann. N.Y. Acad. Sci., 1068:62-75 (2005)	11/1/2005	NS00157698	NS00157708	
PTX1804	Gene Tools website: https://www.gene-tools.com/	7/8/2024	NS00157709	NS00157711	
PTX1805	Gene Tools web archives (80/Node/23): https://web.archive.org/web/20051222184949/http://www.gene-tools.com:80/node/23	7/8/2024	NS00157712	NS00157714	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1806	Gene Tools web archives (80/Node/36): https://web.archive.org/web/20070630114759/http://www.gene-tools.com:80/node/36	7/8/2024	NS00157715	NS00157716	
PTX1807	Gene Tools web archives (Node/15): https://web.archive.org/web/20110526180010/http://www.gene-tools.com/node/15	7/8/2024	NS00157717	NS00157717	
PTX1808	Gene Tools web archives (Node/23): https://web.archive.org/web/20051222184949/http://www.gene-tools.com:80/node/23	7/8/2024	NS00157718	NS00157721	
PTX1809	Gene Tools web archives (Node/5): https://web.archive.org/web/20051220181301/http://www.gene-tools.com/node/5	7/8/2024	NS00157722	NS00157725	
PTX1810	Gene Tools web archives (Node/9): https://web.archive.org/web/20051220171348/http://www.gene-tools.com/node/9	7/8/2024	NS00157726	NS00157727	
PTX1811	Gene Tools web archives (Price List): https://web.archive.org/web/20060326093256/http://www.gene-tools.com/files/price_list.pdf	8/2/2004	NS00157728	NS00157728	
PTX1812	Second Declaration of Matthew J.A. Wood, M.D., D. Phil., University of Western Australia v. Acadmisch Ziekenhuis Leiden, PTAB (UWA Exhibit 2116)	2/17/2015	NONE	NONE	
PTX1813	CLINICALTRIALS.GOV, Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy (Record History), https://clinicaltrials.gov/study/NCT00159250?term=morpholino%20OR%20PMO&sort=StudyFirstPostDate&page=2&rank=45&tab=history&a=1#version-content-panel	9/4/2024	NS00157768	NS00157782	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1814	CLINICALTRIALS.GOV, Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy (Study Details), https://clinicaltrials.gov/study/NCT00159250?term=morpholino%20OR%20PMO&sort=StudyF	9/4/2024	NS00157783	NS00157796	
PTX1815	CLINICALTRIALS.GOV (Search Results), https://clinicaltrials.gov/search?term=morpholino%20OR%20PMO&sort=StudyFirstPostDate&page=2	9/4/2024	NS00157797	NS00157800	
PTX1816	Sarepta Therapeutics Announces First Patient Dosed in European Phase I/II Study of SRP-4053 in Duchenne Muscular Dystrophy Patients, https://investorrelations.sarepta.com/static-files/502dbadd-5ac0-410d-bf09-779ba3198731	1/14/2015	NS00157801	NS00157803	
PTX1817	Gene Tools Web Archive (Node 15), https://web.archive.org/web/20060619224633/http://www.gene-tools.com:80/node/15	9/4/2024	NS00157804	NS00157804	
PTX1818	Gene Tools Web Archive (Node 23), https://web.archive.org/web/20051222184949/http://www.gene-tools.com/node/23	9/4/2024	NS00157805	NS00157808	
PTX1819	Freier, et al., The ups and downs of nucleic acid duplex: structure-stability studies on chemically-modified DNA:RNA duplexes, Nucleic Acids Research, Vol. 25, No. 22, 4429-	10/1/1997	NS00157809	NS00157823	
PTX1820	Aartsma-Rus et al., Exonic Sequences Provide Better Targets for Antisense Oligonucleotides Than Splice Site Sequences in the Modulation of Duchenne Muscular Dystrophy Splicing, Oligonucleotides, 20(2) (2010)	12/9/2009	NS00157729	NS00157738	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1821	Kundu et al., Synthesis of Phosphorodiamidate Morpholino Oligonucleotides Using Trityl and Fmoc Chemistry in an Automated Oligo Synthesizer, J. Org. Chem., 87:9466-9478 (2022)	7/15/2022	NS00157739	NS00157751	
PTX1822	Mitropant et al., By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping, J. Gene Med., 11:46-56 (2009)	11/12/2008	NS00157752	NS00157762	
PTX1823	Pramano et al., Induction of Exon Skipping of the Dystrophin Transcript in Lymphoblastoid Cells by Transfecting an Antisense Oligodeoxynucleotide Complementary to an Exon Recognition Sequence, Biochem Biophys Res Commun, 226:445-449 (1996)	8/8/1996	NS00157763	NS00157767	
PTX1824	Email thread between M. Wood, G. Dickson, and F. Muntoni regarding Exon 53 deep screening	3/24/2011	WILTON0017612	WILTON0017617	
PTX1825	Email thread between M. Wood, G. Dickson, and F. Muntoni regarding Exon 53 deep screening	4/5/2011	WILTON0018478	WILTON0018485	
PTX1826	Email thread between M. Wood, G. Dickson, and F. Muntoni regarding Exon 53 deep screening	3/12/2011	WILTON0018486	WILTON0018491	
PTX1827	Email correspondence between M. Wood, Dr. Wilton and Professor George Dickson	3/8/2011	WILTON0018492	WILTON0018500	
PTX1828	Heasman, Janet, Morpholino Oligos: Making Sense of Antisense?, Developmental Biology 243, 209-214 (2002)	1/22/2002	SRPT-VYDS-0247376	SRPT-VYDS-0247381	
PTX1829	Expert Report of Dr. Michelle L. Hastings Regarding Invalidity of the UWA Patents	7/3/2024	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1830	Supplemental Expert Report of Dr. Matthew J.A. Wood	7/3/2024	NONE	NONE	
PTX1831	Supplemental Rebuttal Expert Report of Steven F. Dowdy, Ph.D.	8/14/2024	NONE	NONE	
PTX1832	Supplemental Rebuttal Expert Report of Steven F. Dowdy, Ph.D. <i>with handwritten notes</i> (Dowdy Supplemental Dep. Ex. 14)	8/14/2024	NONE	NONE	
PTX1833	Supplemental Reply Expert Report of Dr. Michelle L. Hastings Regarding the Invalidity of the UWA Patents	9/4/2024	NONE	NONE	
PTX1834	Supplemental Reply Expert Report of Dr. Matthew J.A. Wood	9/4/2024	NONE	NONE	
PTX1835	Harper et al., "Safety and efficacy of viltolarsen in ambulatory and nonambulatory males with Duchenne muscular dystrophy," Scientific Reports 14:23488 (2024)	10/8/2024	NONE	NONE	
PTX1836	Expert Report of Dr. Michelle L. Hastings Regarding Invalidity of the UWA Patents (with Ex. 1-2)	9/8/2023	NONE	NONE	
PTX1837	Responsive Expert Report of Dr. Michelle L. Hastings Regarding the Validity of the NS Patents (with Ex. 1)	10/11/2023	NONE	NONE	
PTX1838	Expert Report and Disclosure of Mark J. Hosfield	9/8/2023	NONE	NONE	
PTX1839	Rebuttal Expert Report and Disclosure of Mark J. Hosfield	10/11/2023	NONE	NONE	
PTX1840	Reply Expert Report and Disclosure of Mark J. Hosfield	10/27/2023	NONE	NONE	
PTX1841	Supplemental Expert Report and Disclosure of Mark J. Hosfield	4/12/2024	NONE	NONE	
PTX1842	Supplemental Rebuttal Expert Report and Disclosure of Mark J. Hosfield	4/19/2024	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1843	Expert Report of Scott E. Kamholz, Esq.	9/8/2023	NONE	NONE	
PTX1844	Reply Expert Report of Scott E. Kamholz, Esq. (with Ex. 1)	10/27/2023	NONE	NONE	
PTX1845	Technical Expert Report of Jonathan Strober, M.D. (with Ex. 1-2)	9/8/2023	NONE	NONE	
PTX1846	Rebuttal Technical Expert Report of Jonathan Strober, M.D. (with Ex. 1-2)	10/11/2023	NONE	NONE	
PTX1847	Reply Technical Expert Report of Jonathan Strober, M.D.	10/27/2023	NONE	NONE	
PTX1848	Expert Report of Dr. Matthew J.A. Wood (with Ex. 1-2)	9/8/2023	NONE	NONE	
PTX1849	Expert Rebuttal Report of Dr. Matthew J.A. Wood (with Ex. 1)	10/11/2023	NONE	NONE	
PTX1850	Expert Reply Report of Dr. Matthew J.A. Wood (with Ex. 1)	10/27/2023	NONE	NONE	
PTX1851	Second Supplemental Expert Report of Mark J. Hosfield	11/5/2024	NONE	NONE	
PTX1852	Second Supplemental Expert Report of Mark J. Hosfield Exhibit 1 - Curriculum Vitae	11/5/2024	NONE	NONE	
PTX1853	Second Supplemental Expert Report of Mark J. Hosfield Exhibit 2	11/5/2024	NONE	NONE	
PTX1854	Second Supplemental Expert Report of Mark J. Hosfield Exhibit 3A Schedule 1-4	11/5/2024	NONE	NONE	
PTX1855	Second Supplemental Expert Report of Mark J. Hosfield Exhibit 3B Schedule 1-4	11/5/2024	NONE	NONE	
PTX1856	Second Supplemental Expert Report of Mark J. Hosfield Exhibit 3C Schedule 1-4	11/5/2024	NONE	NONE	
PTX1857	Second Supplemental Expert Report of Mark J. Hosfield Exhibit 4	11/5/2024	NONE	NONE	
PTX1858	Second Supplemental Expert Report of Mark J. Hosfield Exhibit 5 Schedule 1-1.5	11/5/2024	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1859	Second Supplemental Expert Report of Mark J. Hosfield Exhibit 6 Schedule 1-2	11/5/2024	NONE	NONE	
PTX1860	Second Supplemental Expert Report of Mark J. Hosfield Exhibit 8	11/5/2024	NONE	NONE	
PTX1861	Second Supplemental Expert Report of Mark J. Hosfield Appendix A	11/5/2024	NONE	NONE	
PTX1862	Second Supplemental Expert Report of Mark J. Hosfield Appendix B Schedule 1A-1B	11/5/2024	NONE	NONE	
PTX1863	Second Supplemental Opening Expert Report of John C. Jarosz	11/5/2024	NONE	NONE	
PTX1864	Second Supplemental Rebuttal Expert Report of Mark J. Hosfield	11/12/2024	NONE	NONE	
PTX1865	Second Supplemental Rebuttal Expert Report of Mark J. Hosfield Exhibit 1 - Curriculum	11/12/2024	NONE	NONE	
PTX1866	Second Supplemental Rebuttal Expert Report of Mark J. Hosfield Exhibit 2	11/12/2024	NONE	NONE	
PTX1867	Second Supplemental Rebuttal Expert Report of Mark J. Hosfield Exhibit 3 Schedule 1-2	11/12/2024	NONE	NONE	
PTX1868	Second Supplemental Rebuttal Expert Report of Mark J. Hosfield Exhibit 4	11/12/2024	NONE	NONE	
PTX1869	Second Supplemental Rebuttal Expert Report of Mark J. Hosfield Exhibit 5 Schedule 1-2	11/12/2024	NONE	NONE	
PTX1870	Second Supplemental Rebuttal Expert Report of John C. Jarosz	11/12/2024	NONE	NONE	
PTX1871	Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments, https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-third-quarter-2024-financial	11/6/2024	NONE	NONE	

PTX NO.	DESCRIPTION	DOC DATE	BEGBATES	ENDBATES	DEFENDANTS' OBJECTIONS
PTX1872	Hannah Green, "FDA's Sarepta decision could represent 'new way of thinking' for agency" Boston Business Journal	6/23/2024	NONE	NONE	
PTX1873	Tyler Patchen, "After Full Approval, Sarepta Lays Out Its Next Moves" BioSpace	6/26/2024	NONE	NONE	
PTX1874	Adam Feuerstein, "Sarepta demanded Duchenne patient advocacy group censor video critical of the company" STAT+	7/29/2024	NONE	NONE	
PTX1875	VIDEO MP4 FILE from article, Adam Feuerstein, "Sarepta demanded Duchenne patient advocacy group censor video critical of the company" STAT+	7/9/2024	NONE	NONE	
PTX1876	Mendell et al., "AAV gene therapy for Duchene muscular dystrophy: the EMBARK phase 3 randomized trial," Nature Medicine	10/9/2024	NONE	NONE	
PTX1877	"Delandistrogene Moxeparvovec Fails to Meet Primary End Point in Phase 3 Study" AJMC	11/15/2024	NONE	NONE	